



**Suicide-related events in young people following
prescription of SSRIs and other antidepressants: a self-
controlled case series analysis**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003247
Article Type:	Research
Date Submitted by the Author:	17-May-2013
Complete List of Authors:	Wijlaars, Linda; UCL, Primary Care and Population Health Nazareth, Irwin; UCL, Primary Care and Population Health Whitaker, Heather; Open University, Department of Mathematics and Statistics Evans, Stephen; LSHTM, Medical Statistics Unit Petersen, Irene; UCL, Primary Care and Population Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	General practice / Family practice, Mental health, Paediatrics, Public health
Keywords:	EPIDEMIOLOGY, MENTAL HEALTH, Suicide & self-harm < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY, Child & adolescent psychiatry < PSYCHIATRY

SCHOLARONE™
Manuscripts

Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis

Linda PMM Wijlaars¹, doctoral student,
Irwin Nazareth¹, professor of Primary Care and Population Science,
Heather J Whitaker², lecturer in statistics,
Stephen JW Evans³, professor of pharmacoepidemiology,
Irene Petersen¹, senior lecturer in epidemiology and medical statistics

1. Department of Primary Care and Population Health
University College London Medical School
Royal Free Campus
Rowland Hill Street
London
NW3 2PF
2. Department of Mathematics and Statistics
The Faculty of Mathematics, Computing and Technology
The Open University
Walton Hall
Milton Keynes
Buckinghamshire
MK7 6AA
3. Department of Medical Statistics
London School of Hygiene and Tropical Medicine
Keppel Street
London
WC1E 7HT

Correspondence to: Linda PMM Wijlaars (linda.wijlaars.10@ucl.ac.uk), contact address as above

Abstract

Objectives: We aimed to examine the temporal association between SSRI and tricyclic antidepressant (TCA) prescriptions and suicidal behaviour in children.

Design: Self-controlled case series.

Setting: Electronic health records were used from 479 general practices in The Health Improvement Network (THIN) UK primary care database from 1995 to 2009.

Participants: 81 young people aged 10-18 years with a record of completed suicide, 1,496 who attempted suicide, 1,178 with suicidal ideation and 2,361 with intentional self-harm.

Main outcome measures: Incidence Rate Ratios (IRRs) for completed and attempted suicide, suicidal ideation and intentional self-harm.

Results: For non-fatal suicide-related behaviour, IRRs were similar for the time the person was prescribed either SSRIs or TCAs: IRRs increased during pre-exposure, peaked on prescription day, were stable up to the fourth prescription-week, and decreased after prescriptions stopped. For both types of antidepressants, IRRs were lower or similar to pre-exposure levels during the period of prescription. For SSRIs, there was an increase in the IRR for completed suicide on the day of prescription (N=5; IRR=42.5, 95% CI: 4.5 to 403.4), and during the fourth week of SSRI prescription (N=2; IRR=11.3, 95% CI: 1.1 to 115.6).

Conclusions: Overall, there are no systematic differences between the association of TCAs and SSRIs with incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm, and apart from the day of prescription, rates did not exceed pre-exposure levels. The pattern of death from suicide for SSRIs was similar to that found in non-fatal suicide-related behaviour. Our results warrant a re-evaluation of the current prescribing of SSRIs in young people. We recommend the creation of a pragmatic registry for active pharmacovigilance.

Article summary

Article focus

- There has been concern that selective serotonin reuptake inhibitors (SSRIs) might be associated with an increased risk of suicidal thinking and behaviour in young people.
- We assess the temporal association between the risk of completed suicide, attempted suicide, suicidal ideation, intentional self-harm and antidepressant prescribing in adolescents using a large UK primary care database

Key messages

- There are no systematic differences between the association of TCAs and SSRIs with incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm
- We recommend the creation of a pragmatic registry that will allow for active pharmacovigilance at low cost and with no additional burden on clinician, health service or patient time, and which will facilitate long term, anonymous, unobtrusive follow-up for major clinical outcomes.

Strengths and limitations of this study

- The self-controlled case series method inherently controls for time-independent variables such as genetics, location and socio-economic status
- Changes in depression severity are poorly recorded over time, which is a limitation.

Introduction

Between 1-6% of adolescents in the community suffer from major depressive disorder¹. In addition, suicide is the third leading cause of death in 15-19 year olds at 6.9 per 100,000 population, and fourth for 10-14 year olds at 0.9 per 100,000 population². This calls for safe and effective depression treatments in this age group. As tricyclic antidepressants (TCAs) appear to lack efficacy for depression treatment in this age group, and have a poor side effect profile³, selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed pharmacological treatment for children and adolescents⁴.

However, there has been concern that SSRIs might be associated with an increased risk of suicidal behaviour in paediatric patients. Results from clinical trials led the Expert Working Group of the Committee on Safety of Medicines (CSM) to advise against initiation of treatment with selective serotonin inhibitors (SSRIs) for childhood depression in the UK in December 2003⁵. Fluoxetine, the only drug which is licensed to treat depression in young people in the UK, was exempted from this advice following review that concluded there was a favourable balance of benefits and risk⁶. The US Food and Drug Administration (FDA) issued similar advice in 2004⁷.

There is inconsistent evidence of an increased rate of suicidal behaviour and intentional self-harm associated with SSRIs⁸. Data from randomized controlled trials in adolescents and young adults report an increased risk of suicidal behaviour⁹. Part of this difference appears to depend on the methodology used. If suicidal behaviour was ascertained using the method of “adverse events” there was a small but significant increase in suicidal ideation. However, if the studies used rating scales to assess suicidal behaviours, most studies showed an improvement in suicidal behaviours.

1
2
3 The results from these trials should be interpreted with caution as they were not primarily
4 designed to measure suicidal behaviour and it would be unethical to do so using placebo as a
5 control^{10;11}. Moreover, none of these trials on SSRIs recruited from a general population
6 setting and completed suicides have not occurred in any studies⁹.

7
8
9
10
11
12 Observational studies in young people have found mixed results: some indicate that SSRIs
13 protect from suicidal behaviour¹²; others find no effect^{13;14}; or an increase in risk of suicidal
14 behaviour^{15;16}. These studies, however, have methodological limitations including small
15 numbers, high attrition rates and, most importantly, confounding by severity. Given the risk
16 of death in overdose, the lack of efficacy in children, and the side effects associated with
17 them, a prescriber would be less likely to prescribe tricyclic antidepressants (TCA) in
18 preference to SSRIs for a person at risk of suicidal behaviour¹⁷.

19
20
21
22
23
24
25
26
27
28
29
30 We have previously shown rates for SSRI prescriptions in children increased between 2005-
31 2009⁴. Neither TCAs nor SSRIs are considered appropriate first line treatment by the
32 National Institute for Clinical Excellence (NICE) for depression in children and adolescents.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Only when children are not responding to psychological treatment should treatment with
SSRIs be considered⁶. It is therefore important to reassess the risks of existing clinical data to
inform future practice. We aimed to assess the temporal association between the risk of
completed suicide, attempted suicide, suicidal thoughts, intentional self-harm and
antidepressant prescribing in adolescents, correcting for age and sex, using a large UK
primary care database.

Methods

Data Source

We used data from The Health Improvement Network (THIN) primary care database, including information from UK primary care data prospectively recorded between 1 January 1995 and 31 December 2009. THIN includes anonymised general practice records on more than 9 million patients from 479 practices in the United Kingdom and is one of the largest primary care databases available internationally. It is broadly representative of the UK general practice population in terms of demographics and consultation behaviour¹⁸. Data on diagnoses, interventions, symptoms, and referrals to secondary care are electronically recorded as Read Codes, a hierarchical coding system used in UK primary care¹⁹. All prescriptions are also electronically recorded. Clinical diagnoses recorded using Read codes have recently been shown to be accurate compared with other reliable sources²⁰.

Study population

This study included a cohort of young people and adolescents, aged 10-18 years who had a recorded suicidal or self-harm event. Patients were included if they were registered with a practice for at least six months between January 1995 and December 2009. Patients were followed up from the latest of the date they registered at the GP, 1 January 1995, or their 10th birthday, until (1) 31 December 2009, (2) their 19th birthday, (3) the date of death, or (4) the date they left the practice.

Measurements

Outcome - We identified completed suicides using relevant Read codes that were confirmed by a date of death within two weeks of the suicide event date. We searched a cause of death if available. The list of codes was an updated version of a published suicide code

1
2
3 list²¹. To make sure we did not miss any suicides, we extracted medical records on all young
4
5 people who died between the ages of 10 and 18 and examined the free text if there was no
6
7 clear cause of death (e.g. childhood cancer or a traffic accident) for possible suicides. We
8
9 excluded cases where there was doubt whether the death was due to suicide (i.e. 12 deaths
10
11 which received an open verdict by the coroner). Of these potential suicides, 1 patient had
12
13 records of TCA prescriptions, while 4 had records of SSRI prescriptions in the last year.
14
15 Suicide attempt, suicidal ideation and self-harm were identified using a Read code list that
16
17 was developed in line with published methods and reviewed by a general practitioner (IN)²².
18
19
20
21
22

23 *Exposure* - We used British National Formulary (BNF) codes representing antidepressants²³.
24
25 We classified antidepressants as TCAs, SSRIs and other antidepressants according to the
26
27 BNF. We excluded TCAs that were prescribed for nocturnal enuresis or neuropathic pain.
28
29 Comparing prescription data in THIN to dispensing data from NHS Prescription Services
30
31 showed that the mean practice redemption rate (the percentage of recorded prescriptions
32
33 which were dispensed) was as high as 96.7% for antidepressants²⁴.
34
35
36
37
38

39 We then identified the separate episodes of antidepressant prescription for each individual.
40
41 To constitute a new episode of antidepressant prescriptions, there had to be a preceding gap
42
43 of at least 3 months of no prescriptions. We choose 3 months as a prescription supply of
44
45 antidepressants is typically 1 month or less, and therefore a gap of at least 3 months between
46
47 prescriptions would likely represent a new episode of antidepressant prescriptions (although
48
49 not necessarily a new episode of depression). If a person switched from one drug to another
50
51 within 3 months, this did not constitute a new episode.
52
53
54
55
56
57
58
59
60

1
2
3 *Covariates* – We extracted information on sex, age and social deprivation score (Townsend
4 quintiles). Patients who were prescribed TCAs for nocturnal enuresis (as confirmed by Read
5 codes) were excluded. Finally, we considered consultation behaviour as a confounder.
6
7 Patients who consult infrequently with their GP, e.g. only when their prescription has run out,
8 might not have correctly timed records of all of their events. To correct for this we conducted
9 a sensitivity analysis where we only included patients who consulted at least once a week
10 during the month after their first antidepressant prescription.
11
12
13
14
15
16
17
18
19

20 **Statistical analysis**

21
22 *The Self-Controlled Case Series (SCCS) method* - We calculated incidence rate ratios (IRRs –
23 calculated by dividing the incidence rate in the exposed period by the incidence rate in the
24 control period) for completed suicide and suicidal behaviour using the self-controlled case
25 series (SCCS) method²⁵. The SCCS method was developed to investigate associations
26 between acute outcomes and transient exposures, using only data on cases. Since each case
27 served as his/her own control, the case-series method inherently accounts for confounding
28 factors that do not change over the observation period (such as variables related to genetics,
29 socio-economic status and gender). Using a Poisson model, IRRs can be calculated for any
30 number of pre-defined risk periods associated with the exposure, using the time outside of
31 these risk periods (the time when a subject is unexposed) as reference. A major advantage of
32 the SCCS is that it can have high efficiency relative to the retrospective cohort method from
33 which it is derived. As suicidal behaviour is rare, even in depressed persons, the SCCS
34 method is particularly suited for assessing its association with antidepressants as it requires a
35 much smaller number of persons to be included. Moreover, in using a self-controlled design
36 we circumvent the problem of selecting appropriate controls that cohort or case-control
37 designs encounter. In the case of suicidal behaviour and antidepressants this has proven
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 crucial as patients who are diagnosed as depressed but don't receive antidepressants might
4 differ from patients who are receiving antidepressants in severity of depression, a major
5 confounder in the studied association.
6
7

8
9 The SCCS method is limited in that it only works for non-recurrent events when the event
10 risk is small over the observation period, which is the case for completed suicide. Also, it
11 requires variability in the age at the time of event: if all events were to happen at exactly the
12 same age (which is not the case in our study), then the method would fail. Finally, the method
13 only produces estimates of relative incidence, rather than absolute incidence.
14
15
16
17
18
19
20
21
22

23 *Suicide attempts, suicidal ideation and self-harm* – For the analyses on suicide attempts,
24 suicidal ideation and self-harm we used an adapted version of the standard SCCS method,
25 allowing for repeated exposures and events and correcting by 1-year age groups^{25;26}. By
26 including a pre-exposure period, we corrected our estimates for event-dependent exposure. If
27 the probability of exposure to antidepressants is changed from baseline after an event, it
28 follows that the probability of the occurrence of an event is also changed in the immediate
29 pre-exposure period. Including a pre-exposure period removes this time from the baseline and
30 corrects the estimates accordingly.
31
32
33
34
35
36
37
38
39

40 Subjects who went on to commit suicide were excluded from these analyses. Using the SCCS
41 method, the incidence rate ratio for the three outcomes was estimated during 14 different risk
42 periods (Figure 1): baseline (or unexposed to antidepressants); four 1-month pre-exposure
43 periods, the last of which is the reference; the day of prescription; four 1-week early exposure
44 periods; a period of variable length to cover the remainder of the period of exposure to the
45 antidepressant for that episode; and three 1-month periods of washout after the end of the
46 antidepressant episode. We included the separate 1-week periods at the start of prescription as
47 it is known that antidepressants (especially SSRIs) take this amount of time to have an
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 effect²⁷. We also compared the effects of individual antidepressants on the IRR of the three
4
5 suicidal behaviour outcomes.
6
7

8
9
10 *Suicide* - We used an adapted method (SCCS for censored post-event exposures) to assess the
11 effects of antidepressants on childhood suicide as the original approach cannot deal with
12 deaths²⁸. This method takes account of the early cessation of the observation period due to
13
14 deaths and accordingly corrects the IRR estimates. We corrected for age by creating four age
15
16 groups: 10-12, 13-14, 15-16 and 17-18 year olds. We estimated IRRs for the same risk
17
18 periods as for the other outcomes, without the four pre-exposure risk periods and used
19
20 baseline (time unexposed to antidepressants) as reference.
21
22

23
24 All analyses were conducted with the use of Stata software, version 12.1 (Stata Corp, College
25
26 Station, Texas). The scheme for THIN to obtain and provide anonymous patient data to
27
28 researchers was approved by the National Health Service South-East Multicenter Research
29
30 Ethics Committee (MREC) in 2002 and scientific approval for this study was obtained from
31
32 CMD Medical Research's Scientific Review Committee in May 2011.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

There was a total follow-up time of 4,190,410 person-years of 10-18-year olds in THIN. In total, 81 young people were identified with a record of a completed suicide, 1,496 young people with a record of attempted suicide, 1,178 young people with a record of suicidal ideation, and 2,361 with a record of intentional self-harm. Of young people with completed suicides, 30% were female, compared to 60%, 73% and 74% of young people with a record of attempted suicide, suicidal ideation, or self-harm, respectively (Table 1). There was no significant difference in age of first event between the different outcomes. The data were complete for all variables except Townsend scores, which were missing for 92 (2%) persons.

Attempted suicide, suicidal ideation and self-harm

For attempted suicide, suicidal ideation and self-harm, there were similar patterns between young people that were prescribed SSRIs and TCAs (Table 2 & Figures 2A, B & C): there was an upwards trend in the IRR during pre-exposure; a peak on the day of prescription; a stable or slightly increased rate ratio during the first weeks of prescription; and during the washout period levels decreased again. The increase on prescription day was highest for young people with a record of suicidal ideation (SSRIs: IRR=33.4, 95%CI: 23.6 to 47.4; TCAs: IRR=14.0, 95%CI: 6.8 to 28.8). There were no significant differences between IRRs for any of the behaviour types for any risk periods. Patterns were similar between individual SSRIs (fluoxetine, citalopram, sertraline and paroxetine, results in appendix).

The IRR for each type of behaviour has a strong relation with age. When compared to 15-16 year olds, 17-18 year olds are twice as likely to attempt suicide (IRR=1.90, 95%CI: 1.6 to 2.3 and IRR=2.1, 95%CI: 1.7 to 2.5 for SSRIs and TCAs, respectively) but those between 10-12

1
2
3 years old are less likely to attempt suicide (IRR=0.3, 95%CI: 0.2 to 0.4 and IRR=0.2, 95%CI:
4
5 0.1 to 0.2 for SSRIs and TCAs, respectively). Patterns were similar for the other outcomes.
6
7

8
9
10 There were no statistically significant differences between boys and girls for either SSRIs or
11 TCAs (results not shown). Finally, restricting the analyses to regular consulters (those who
12 consulted at least five times during the first four weeks of prescription) did not alter effect
13 estimates. Of the young people with a record of attempted suicide or intentional self-harm,
14 33% were regular consulters, compared to 49% of young people with a record of suicidal
15 ideation.
16
17
18
19
20
21

22 23 24 25 **Suicide**

26
27 Using an expected suicide rate of 3.28 (95%CI: 3.12 to 3.43) per 100,000 person-years in the
28 UK population of 10-18-year olds ²⁹, we would expect 137 (95%CI: 131 to 144) completed
29 suicides in our study population. However, 41% of suicides registered by the Office of
30 National Statistics (ONS) were of undetermined intent, leaving 59% or 81 (95%CI: 77 to 85)
31 expected suicides that received a verdict by a coroner. This estimate corresponds to the
32 number of 81 completed suicides we identified between 1995 and 2009 within the THIN
33 database. Of the 81 young people with a completed suicide, 21 (26%) had a prior record of a
34 depression diagnosis or depression symptoms. Nineteen young people (23%) were taking
35 antidepressants in the year before their suicide, and 11 (14%) were still taking them at the
36 time of, or shortly before their suicide. There was also a high proportion of young people
37 with (a history of) behaviour disorders 16 (20%), history of self-harm 8 (10%), a psychiatric
38 referral 19 (23%), a hyperkinetic disorder 5 (6%) or eating disorder 3 (4%).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 There were no completed suicides within the risk periods for antidepressants other than
4 SSRI (Table 3). Eleven (14%) completed suicides were within the risk periods. Similar to
5
6 the results from the data on suicidal behaviour, the IRR was highest on the day of
7
8 prescription (IRR=42.5, 95%CI: 4.5 to 403.4). There were no events in the first two weeks of
9
10 the SSRI episode, but there was an increased rate ratio in week three (IRR=8.0, 95%CI: 0.8
11
12 to 76.7, based on a single case) and a statistically significant increase in week 4 (IRR=11.3,
13
14 95%CI: 1.1 to 115.6, though based on two cases). After the fourth week of the SSRI episode,
15
16 the IRR decreased and returned to baseline levels during wash-out. There were no significant
17
18 differences between age groups.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Overall, there are no systematic differences between TCAs and SSRIs in incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm, and apart from an increase common to both TCAs and SSRIs on the day of prescription, rates were not statistically significantly different from pre-exposure levels. The pattern of incidence risk ratios for completed suicides for the 11 people prescribed SSRIs was similar to that found in attempted suicide, suicidal ideation and self-harm. However, concerns regarding antidepressants need to be weighed against the risk of untreated depression.

Pre-exposure IRRs for attempted suicide, suicidal ideation and self-harm appeared to be marginally higher, though not statistically significant, for SSRIs compared to TCAs. This could be because young people who are deemed to be more at risk of suicidal behaviour could preferentially be prescribed SSRIs over TCAs, given TCAs' toxicity in overdose¹⁷.

The high IRRs on the day of antidepressant prescription for all three non-fatal outcomes could be an artefact of GP recording behaviour. Rather than the antidepressant causing the self-harming behaviour, the self-harming behaviour is an indication for the GP to prescribe the drug and to record depression in the electronic records on the same day.

Up to the fourth week of prescription, the IRRs for attempted suicide, suicidal ideation and self-harm remained around the levels experienced during the pre-exposure period.

Considering that suicidal behaviour is common in young depressed people, some suicidal and self-harm events would be expected irrespective of whether SSRIs are prescribed or not³⁰.

The suicidal behaviour decreased when the prescriptions were stopped. Given the nature of the data, it is difficult to know whether the SSRIs were causing suicidal behaviour and these behaviours improved when the SSRIs were discontinued, or if the SSRIs were discontinued when the child's depression (and as a consequence the suicidal behaviour) improved.

1
2
3 There are three possible explanations for the slightly increased IRRs during the first month of
4 prescription. One is that SSRIs fail to relieve the suicidal behaviour associated with
5 depression because of a lag in antidepressant effect, an incomplete response, or a treatment-
6 resistant depression. It is known that SSRIs take a couple of weeks to reach their full
7 antidepressant effects and hence reduce the risk of suicidal behaviour²⁷.

8
9
10
11
12
13
14 A second possibility is that the SSRIs generate a novel set of suicidal emotions or behaviours.
15
16 Early improvements in clinical depression can lead to a person acting on existing suicidal
17 feelings. This activation syndrome has been described for both TCAs and SSRIs, and is
18 widely recognized by psychiatrists, as well as the FDA^{31;32}. While patients might be
19 demotivated and demoralized at the height of their depression, when they start treatment they
20 become more active during the first weeks of taking the drug. During this time the
21 antidepressant effect of the medication will not have reached its full effect resulting in
22 persistent depression but simultaneous increased activity. This could lead to a greater risk of
23 suicidal behaviour until the full effects of antidepressants are realized few weeks later³¹.

24
25
26
27
28
29
30
31
32
33
34 Several studies and systematic reviews have shown an age effect in the risk of suicidal
35 behaviour with the use of SSRIs. In adults and the elderly the risk is neutral or SSRIs show a
36 protective effect, while in adolescents and young adults there appears to be an increased risk
37 of suicidal behaviour^{9;15;33}.

38
39
40
41
42
43 Although we did not find a statistically significant sustained increase in suicidal
44 behaviour with either SSRIs or TCAs, negative outcomes did not appear to be decreased
45 either – although our study was not designed to assess this. This is in line with Cochrane
46 reviews on both drug groups: the review on tricyclic antidepressants concludes that these
47 drugs are not useful in treating depression in pre-pubertal children, and that there is only
48 marginal evidence to support the use of TCAs in adolescents, although the magnitude of the
49 effect is likely to be moderate at best³⁴. Similarly, it is unclear what the effect is of SSRIs on
50
51
52
53
54
55
56
57
58
59
60

1
2
3 suicide completion. Although evidence from clinical trials implies an increased risk of
4
5 suicide-related outcomes (but not completed suicide), the evidence for this association is of
6
7 low quality³⁵.
8
9

10 11 **Comparison to other studies**

12
13
14 Our results build on the findings of Schneeweis et al.¹³. They found no statistically significant
15
16 differences in relative risk for attempted and completed suicide between different types of
17
18 antidepressants (fluoxetine, citalopram, fluvoxamine, paroxetine, sertraline and TCAs) when
19
20 examining 266 attempted and 3 completed suicides. Moreover, an ecological study found no
21
22 change in rates of completed suicides or hospital admissions for self-harm following the
23
24 CSM advice³⁶, suggesting there is no, or only a weak, relationship with antidepressant
25
26 prescriptions. Our findings are also similar to those of Simon et al.³⁷ who used computerised
27
28 health plan records and report the highest rates for attempted suicide in the month before
29
30 prescription, rather than after start of the prescription. Finally, a meta-analysis³⁸ found that, of
31
32 27 paediatric RCTs on antidepressants prescribed for major depressive disorder (MDD),
33
34 obsessive compulsive disorder (OCD) and non-OCD anxiety disorders, the risk of suicidal
35
36 ideation or attempt among patients on placebo was greater in trials assessing MDD. Although
37
38 this difference in baseline risk for suicidal thinking and behaviour was not statistically
39
40 significant, it could indicate part of the association between antidepressants and suicidal
41
42 thinking and behaviour can be explained by the underlying disease, rather than the drug.
43
44 Importantly, the authors concluded that relative to placebo, the benefits (though only modest
45
46 in MDD) outweigh the risks from suicidal ideation/suicide attempts.
47
48
49
50
51

52 53 **Main strength and limitations**

1
2
3 The main strength of this study is its sample size that enables examination of outcomes
4 separately by completed and attempted suicide, suicidal ideation and self-harm, and by
5 individual antidepressants. However, even in using a database as large as THIN, we could
6 identify only a small number of completed suicides, leading to limited power in that analysis.
7 Similarly, power was limited for analysing individual antidepressants, which are presented in
8 the appendix. Nevertheless, the use of the SCCS method allows us to control for time-
9 independent confounders, making our estimations more robust.

10
11
12 A limitation to our study is that the THIN database only provides data on antidepressant
13 prescriptions. We do not know whether prescriptions were dispensed, or whether patients
14 adhered to prescription. However, though it is known that adherence levels are around 50%
15 for young people taking SSRIs, and even lower for TCAs³⁹, our data does represent a real-life
16 situation. Moreover, by assessing episodes of antidepressant prescription, we take account of
17 multiple prescriptions per patient, which increases the likelihood of adherence as we expect
18 patients who are not taking their medication would not come back for a new prescription.

19
20
21 Moreover, it is known that suicidal behaviour is often missed in clinical assessment⁴⁰.
22
23 However, it is likely that the most severe forms (attempted suicides and severe suicidal
24 ideation) are most likely to be recorded by clinicians. Also, in using a self-controlled design,
25 we decrease the chance of misclassifying controls. There is some suggestion that
26 antidepressants might specifically increase suicidal thinking and behaviour in patients who
27 did not experience these behaviours prior to starting antidepressant treatment. Due to
28 variation in clinicians' assessment and recording of (the absence of) suicidal thinking and
29 behaviour, we could not examine this hypothesis using this database. Finally, we were not
30 able to account for changes in depression severity over time as this is poorly recorded.

31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 **Conclusion** 57 58 59 60

1
2
3 Our study shows that there are similar incidence rate ratio patterns for attempted suicide,
4 suicidal ideation and self-harm for SSRIs and TCAs. Also, the pattern for completed suicides
5 associated with SSRI prescriptions is similar, though there are no records of completed
6 suicides within our pre-defined risk periods for TCAs. Although the CSM's warning was a
7 sensible cautionary recommendation at the time, it appears that the current line of evidence
8 suggests a reverse causality: it is the underlying depression that leads to suicidal behaviour
9 and the prescribing of antidepressants, although a causal effect of SSRIs, or no effect at all
10 cannot be ruled out. Moreover, even if antidepressant drugs would temporarily increase the
11 risk of suicidal behaviour in young persons, the risk untreated depression poses is far greater.
12 In conclusion, our results indicate that the association of suicidal behaviour associated with
13 antidepressants occurs primarily around the day of prescription, suggesting depression
14 severity and GP recording behaviour as the culprit rather than antidepressants, and thus
15 warrant a re-evaluation of the current guidelines regarding the prescription of SSRIs in
16 primary care.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 34 35 36 **Recommendation**

37
38 Our results are not definitive, and due to the rare nature of the outcome and the intricacies of
39 the problem studied, it is difficult to think of a single study or study design that will be able to
40 provide a satisfying answer to the problem at hand. It is possible that the creation of a
41 pragmatic registry, similar to that proposed by van Staa and colleagues in their pragmatic
42 randomised trial⁴¹, will allow for active pharmacovigilance. Such a system would at low cost
43 and with no additional burden on clinician, health service or patient time, facilitate long term,
44 anonymous, unobtrusive follow-up for major clinical outcomes. As such, clinicians would be
45 prompted to monitor and record (the absence of) suicidal behaviour and ideation more
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

regularly and closely, using similar outcome measurements as those used in clinical trials, as well as (changes in) depression severity.

For peer review only

Acknowledgements

We would like to thank the general practitioners who contributed data to THIN.

Contributors All authors were responsible for study conception and design. LPW was responsible for data analysis. LPW authors drafted the manuscript. All authors participated in the interpretation of data, critical revision and final approval of the manuscript.

Funding statement: The work was supported by a PhD studentship from the National Institute of Health Research English National School for Primary Care Research. The funding organisation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; and preparation, review or approval of the manuscript.

Competing interests statement: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: LPMMW had financial support in the form of a studentship from the National Institute of Health Research English National School for Primary Care Research for the submitted work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data sharing: Examples of statistical code used for the self-controlled case series method (including the adapted method for dealing with censored data) are available from the [Open University website](#). Statistical code is available from the corresponding author.

References

- 1
2
3
4
5 (1) Kessler RC, Avenevoli S, Ries Merikangas K. Mood disorders in children and
6 adolescents: an epidemiologic perspective. *Biological Psychiatry* 2001; 49(12):1002-
7 1014.
- 8
9
10 (2) Heron M. Deaths: leading causes for 2007. *National vital statistics reports* 2011;
11 59(8):1-95.
- 12
13 (3) Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drug for depression in
14 children and adolescents. *Cochrane Database Syst Rev* 2002;(4).
- 15
16 (4) Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant
17 prescribing in children and adolescents: A cohort study in The Health Improvement
18 Network (THIN). *PLoS One* 2012.
- 19
20 (5) Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and
21 suicide in adults: meta-analysis of drug company data from placebo controlled,
22 randomised controlled trials submitted to the MHRA's safety review. *BMJ* 2005;
23 330(7488):385.
- 24
25 (6) National Institute for Health and Clinical Excellence. CG28 Depression in children
26 and young people: NICE guideline. 2005. London, National Institute for Health and
27 Clinical Excellence.
- 28
29 (7) FDA. Suicidality in Children and Adolescents Being Treated With Antidepressant
30 Medications. US Food and Drug Administration [2004 [cited 2011 June 29];
31 Available from: URL:
32 [http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsa
33 ndProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisorie
34 s/ucm161679.htm](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679.htm)
- 35
36 (8) Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E.
37 Selective serotonin reuptake inhibitors in childhood depression: systematic review of
38 published versus unpublished data. *The Lancet* 2004; 363(9418):1341-1345.
- 39
40 (9) Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with
41 antidepressant drugs. *Arch Gen Psychiatry* 2006; 63(3):332-339.
- 42
43 (10) Rothman KJ, Michels KB. The continuing unethical use of placebo controls. *N Engl J*
44 *Med* 1994; 331(6):394-398.
- 45
46 (11) Grosso A, Douglas I, MacAllister R, Petersen I, Smeeth L, Hingorani AD. Use of the
47 self-controlled case series method in drug safety assessment. *Expert Opin Drug Saf*
48 2011; 10(3):337-340.
- 49
50 (12) Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA et al. Early
51 evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and
52 suicide in children and adolescents. *Am J Psychiatry* 2007; 164(9):1356-1363.
- 53
54
55
56
57
58
59
60

- 1
2
3 (13) Schneeweiss S, Patrick AR, Solomon DH, Dormuth CR, Miller M, Mehta J et al.
4 Comparative safety of antidepressant agents for children and adolescents regarding
5 suicidal acts. *Pediatrics* 2010; 125(5):876-888.
6
- 7 (14) Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. *JAMA*
8 2004; 292(3):338-343.
9
- 10 (15) Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely
11 depressed children and adults - A case-control study. *Arch Gen Psychiatry* 2006;
12 63(8):865-872.
13
- 14 (16) Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal Thoughts and Behavior
15 With Antidepressant Treatment: Reanalysis of the Randomized Placebo-Controlled
16 Studies of Fluoxetine and Venlafaxine. *Arch Gen Psychiatry* 2012;archgenpsychiatry.
17
- 18 (17) Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following
19 prescription of SSRIs and other antidepressants: confounding by indication. *Br J Clin*
20 *Pharmacol* 2005; 60(5):519-525.
21
- 22 (18) Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a
23 quality-evaluated database of primary care data. *Inform Prim Care* 2004; 12(3):171-
24 177.
25
- 26 (19) Booth N. What are the Read Codes? *Health Libr Rev* 1994; 11(3):177-182.
27
- 28 (20) Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General
29 Practice Research Database: a systematic review. *Br J Gen Pract* 2010; 60(572):e128-
30 e136.
31
- 32 (21) Arana A, Wentworth CE, yuso-Mateos JL, Arellano FM. Suicide-related events in
33 patients treated with antiepileptic drugs. *N Engl J Med* 2010; 363(6):542-551.
34
- 35 (22) Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary
36 care databases. *Pharmacoepidemiology and drug safety* 2009; 18(8):704-707.
37
- 38 (23) British National Formulary. 60 ed. London: BMJ group; RPS Publishing; 2010.
39
- 40 (24) The NHS Information Centre PaPCS. Prescription compliance: a review of the
41 proportion of prescriptions dispensed. 7-9-2011.
42
- 43 (25) Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the
44 self-controlled case series method. *Stat Med* 2006; 25(10):1768-1797.
45
- 46 (26) Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case
47 series studies. *Stat Methods Med Res* 2009; 18(1):7-26.
48
- 49 (27) Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective
50 serotonin reuptake inhibitor antidepressant action: systematic review and meta-
51 analysis. *Arch Gen Psychiatry* 2006; 63(11):1217-1223.
52
- 53 (28) Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored,
54 perturbed, or curtailed post-event exposures. *Biostatistics* 2009; 10(1):3-16.
55
56
57
58
59
60

- 1
2
3 (29) Windfuhr K, While D, Hunt I, Turnbull P, Lowe R, Burns J et al. Suicide in juveniles
4 and adolescents in the United Kingdom. *J Child Psychol Psychiatry* 2008;
5 49(11):1155-1165.
6
7 (30) Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. *J*
8 *Child Psychol Psychiatry* 2006; 47(3-4):372-394.
9
10 (31) Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A et al.
11 Antidepressant-induced jitteriness/anxiety syndrome: systematic review. *Br J*
12 *Psychiatry* 2009; 194(6):483-490.
13
14 (32) Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL.
15 Suicidality as a possible side effect of antidepressant treatment. *J Clin Psychiatry*
16 2004; 65(6):742-749.
17
18 (33) Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of
19 suicide: a systematic review of observational studies. *CMAJ* 2009; 180(3):291-297.
20
21 (34) Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drug for depression in
22 children and adolescents. *Cochrane Database Syst Rev* 2010;(4).
23
24 (35) Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation
25 antidepressants for depressive disorders in children and adolescents. *Cochrane*
26 *Database of Systematic Reviews* 2012.
27
28 (36) Wheeler BW, Gunnell D, Metcalfe C, Stephens P, Martin RM. The population impact
29 on incidence of suicide and non-fatal self harm of regulatory action against the use of
30 selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological
31 study. *BMJ* 2008; 336(7643):542-545.
32
33 (37) Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant
34 treatment. *Am J Psychiatry* 2006; 163(1):41-47.
35
36 (38) Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA et al. Clinical
37 response and risk for reported suicidal ideation and suicide attempts in pediatric
38 antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA* 2007;
39 297(15):1683-1696.
40
41 (39) Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP et al.
42 Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic
43 antidepressants: comparison of drug adherence. *Cochrane Database Syst Rev*
44 2000;(4):CD002791.
45
46 (40) Fitzpatrick C, Abayomi NN, Kehoe A, Devlin N, Glackin S, Power L et al. Do we
47 miss depressive disorders and suicidal behaviours in clinical practice? *Clinical Child*
48 *Psychology and Psychiatry* 2012; 17(3):449-458.
49
50 (41) van Staa T, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A et al.
51 Pragmatic randomised trials using routine electronic health records: putting them to
52 the test. *BMJ* 2012; 344.
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1: Risk periods included in self-controlled case series analysis for attempted suicide, suicidal ideation and self-harm and suicide. 1 = baseline; 2-5 = 1-month pre-exposure periods; 6 = prescription day; 7-10 = four 1-week exposure periods; 11 = remainder of antidepressant exposure; 12-14= three 1-month washout periods

Figure 2A, B, C: IRR for A) attempted suicide, B) suicidal ideation and C) self-harm for tricyclic antidepressants (TCAs) and selective serotonin inhibitors (SSRIs). The month before a prescription was issued (pre-exposure 4) was used as the reference.

TABLES

Table 1: Demographics by category of suicidal or self-harming behaviour

	Completed suicide 81	Attempted suicide 1496	Suicidal ideation 1178	Self-harm 2361	General population 952892
Girls (%)	24 (29.6)	1089 (72.8)	708 (60.1)	1752 (74.2)	461610 (48.4)
# taking ADs (%)	19 (23.1)	527 (36.6)	578 (52.8)	128 (5.7)	27632 (2.9)
# depressed (%)	21 (25.9)	728 (48.7)	819 (69.5)	173 (7.3)	41101 (4.3)
# Townsend score (%)					
1 (most affluent)	20 (24.7)	266 (17.8)	193 (16.4)	442 (18.7)	227178 (23.8)
2	5 (6.2)	240 (16.0)	202 (17.2)	405 (17.2)	198686 (20.9)
3	13 (16.1)	286 (19.1)	236 (20.0)	452 (19.1)	184934 (19.4)
4	25 (30.9)	364 (24.3)	283 (24.0)	571 (24.2)	169792 (17.8)
5 (most deprived)	16 (19.8)	316 (21.1)	241 (20.5)	446 (18.9)	120116 (12.6)
Median age in years at (first) event (5%-95% percentiles)	16.8 (12.0-18.8)	16.5 (12.9 - 18.7)	16.7 (12.0 - 18.7)	15.9 (12.6 - 18.7)	-
Median time in study in years (5%-95% percentiles)	3.5 (0.2 - 8.4)	5.5 (1.4 - 9.0)	5.9 (1.5 - 9.0)	5.9 (1.5 - 9.0)	-

Table 2: Incidence Rate Ratios (IRRs) for different types of suicidal or self-harming behaviour by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs			TCAs		
	Suicide attempt 423 events† IRR (95% CI)	Suicidal ideation 458 events† IRR (95% CI)	Self-harm 654 events† IRR (95% CI)	Suicide attempt 79 events† IRR (95% CI)	Suicidal ideation 81 events† IRR (95% CI)	Self-harm 118 events† IRR (95% CI)
Unexposed	0.09 (0.07 - 0.13)	0.07 (0.05 - 0.10)	0.12 (0.09 - 0.17)	0.20 (0.09 - 0.46)	0.09 (0.05 - 0.18)	0.15 (0.08 - 0.30)
Pre-exposure 1 (- 4 months)	0.19 (0.10 - 0.38)	0.29 (0.15 - 0.54)	0.37 (0.22 - 0.61)	0.61 (0.18 - 2.10)	0.15 (0.03 - 0.68)	0.29 (0.08 - 1.03)
Pre-exposure 2 (- 3 months)	0.31 (0.17 - 0.53)	0.45 (0.26 - 0.77)	0.59 (0.38 - 0.90)	0.29 (0.06 - 1.39)	0.30 (0.10 - 0.90)	0.09 (0.01 - 0.71)
Pre-exposure 3 (-2 months)	0.62 (0.40 - 0.96)	0.76 (0.48 - 1.19)	0.65 (0.43 - 0.98)	0.14 (0.02 - 1.16)	0.21 (0.06 - 0.74)	0.46 (0.16 - 1.33)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	4.17 (2.44 - 7.12)	33.41 (23.56 - 47.39)	11.48 (7.93 - 16.62)	8.82 (2.79 - 27.82)	14.00 (6.81 - 28.75)	3.47 (0.97 - 12.45)
Week 1	0.79 (0.40 - 1.55)	0.38 (0.13 - 1.05)	0.69 (0.35 - 1.35)	1.18 (0.24 - 5.68)	0.59 (0.13 - 2.59)	0.77 (0.17 - 3.50)
Week 2	0.74 (0.39 - 1.42)	0.57 (0.26 - 1.27)	0.96 (0.55 - 1.68)	1.02 (0.21 - 4.91)	0.25 (0.03 - 1.91)	0.33 (0.04 - 2.57)
Week 3	1.07 (0.61 - 1.86)	1.56 (0.91 - 2.68)	1.33 (0.82 - 2.19)	0.53 (0.06 - 4.29)	1.03 (0.34 - 3.13)	1.01 (0.28 - 3.61)
Week 4	0.52 (0.24 - 1.15)	0.98 (0.51 - 1.91)	1.23 (0.73 - 2.07)	0.57 (0.07 - 4.67)	0.84 (0.24 - 2.94)	0.37 (0.05 - 2.90)
Rest of AD episode	0.53 (0.36 - 0.78)	0.72 (0.49 - 1.08)	0.64 (0.45 - 0.90)	0.38 (0.11 - 1.33)	0.52 (0.20 - 1.35)	0.48 (0.18 - 1.25)
Wash-out 1 (+ 1 month)	0.42 (0.25 - 0.69)	0.40 (0.23 - 0.70)	0.28 (0.16 - 0.48)	0.66 (0.21 - 2.09)	0.43 (0.16 - 1.11)	0.09 (0.01 - 0.69)
Wash-out 2 (+ 2 months)	0.17 (0.09 - 0.35)	0.12 (0.06 - 0.29)	0.32 (0.19 - 0.55)	0.28 (0.06 - 1.33)	0.27 (0.09 - 0.83)	0.43 (0.15 - 1.25)
Wash-out 3 (+ 3 months)	0.15 (0.09 - 0.25)	0.20 (0.12 - 0.33)	0.19 (0.12 - 0.31)	0.41 (0.16 - 1.03)	0.13 (0.06 - 0.27)	0.35 (0.17 - 0.73)

† Number of events in young people taking antidepressants



Table 3: Incidence Rate Ratios (IRRs) for completed suicide by risk period and age



Risk period	Censoring model IRR (95% CI)	# deaths†
Prescription day	42.52 (4.48 – 403.43)	5
Week 1		
Week 2	No events	0
Week 3	8.00 (0.84 – 76.71)	1
Week 4	11.25 (1.09 – 115.58)	2
Rest of AD episode	5.42 (0.57 – 51.94)	1
Wash-out 1	2.27 (0.24 – 21.76)	1
Wash-out2	2.08 (0.22 – 19.69)	1
Age Groups		# total deaths‡
10-12	0.61 (0.21 – 1.77)	8
13-14	1.14 (0.45 – 2.90)	15
15-16	Reference	21
17-18	0.41 (0.12 – 1.39)	37

† Number of suicides during risk periods (only includes youths who were taking antidepressants at the time of suicide, or those who had recently stopped)

‡ Number of suicides by age category

FIGURES





Supplementary Tables

eTable 1: Incidence Rate Ratios (IRRs) for attempted suicide for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 423 events† IRR (95% CI)	fluoxetine 198 events† IRR (95% CI)	citalopram 111 events† IRR (95% CI)	sertraline 39 events† IRR (95% CI)	paroxetine 61 events† IRR (95% CI)	TCAs 79 events IRR (95% CI)
Unexposed	0.09 (0.07 - 0.13)	0.10 (0.06 - 0.16)	0.08 (0.05 - 0.14)	0.11 (0.04 - 0.31)	0.07 (0.03 - 0.14)	0.20 (0.09 - 0.46)
Pre-exposure 1 (- 4 months)	0.19 (0.10 - 0.38)	0.18 (0.06 - 0.53)	0.26 (0.10 - 0.67)	0.20 (0.02 - 1.71)	0.21 (0.05 - 0.97)	0.61 (0.18 - 2.10)
Pre-exposure 2 (- 3 months)	0.31 (0.17 - 0.53)	0.41 (0.19 - 0.89)	0.20 (0.07 - 0.59)	0.20 (0.02 - 1.70)	0.21 (0.05 - 0.96)	0.29 (0.06 - 1.39)
Pre-exposure 3 (-2 months)	0.62 (0.40 - 0.96)	0.72 (0.38 - 1.37)	0.35 (0.15 - 0.83)	1.19 (0.36 - 3.88)	0.41 (0.13 - 1.30)	0.14 (0.02 - 1.16)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	4.17 (2.44 - 7.12)	5.84 (2.76 - 12.34)	2.02 (0.60 - 6.79)	5.31 (1.03 - 27.37)	3.96 (1.09 - 14.39)	8.82 (2.79 - 27.82)
Week 1	0.79 (0.40 - 1.55)	0.98 (0.37 - 2.59)	0.45 (0.10 - 1.92)	2.64 (0.63 - 11.06)	0.44 (0.06 - 3.45)	1.18 (0.24 - 5.68)
Week 2	0.74 (0.39 - 1.42)	0.50 (0.15 - 1.68)	1.16 (0.47 - 2.90)	0.76 (0.09 - 6.48)	0.38 (0.05 - 2.98)	1.02 (0.21 - 4.91)
Week 3	1.07 (0.61 - 1.86)	1.51 (0.70 - 3.28)	0.57 (0.17 - 1.92)	0.74 (0.09 - 6.33)	1.14 (0.31 - 4.14)	0.53 (0.06 - 4.29)
Week 4	0.52 (0.24 - 1.15)	1.13 (0.46 - 2.79)	0.21 (0.03 - 1.58)	1.65 (0.32 - 8.56)	No events	0.57 (0.07 - 4.67)
Rest of AD episode	0.53 (0.36 - 0.78)	0.65 (0.37 - 1.14)	0.50 (0.25 - 0.98)	1.02 (0.33 - 3.11)	0.30 (0.11 - 0.80)	0.38 (0.11 - 1.33)
Wash-out 1 (+ 1 month)	0.42 (0.25 - 0.69)	0.54 (0.27 - 1.10)	0.43 (0.19 - 0.98)	No events	0.40 (0.13 - 1.30)	0.66 (0.21 - 2.09)
Wash-out 2 (+ 2 months)	0.17 (0.09 - 0.35)	0.18 (0.06 - 0.53)	0.22 (0.07 - 0.63)	No events	0.19 (0.04 - 0.89)	0.28 (0.06 - 1.33)
Wash-out 3 (+ 3 months)	0.15 (0.09 - 0.25)	0.25 (0.13 - 0.46)	0.16 (0.09 - 0.29)	0.27 (0.10 - 0.77)	0.24 (0.10 - 0.57)	0.41 (0.16 - 1.03)

†Number of events in young people taking antidepressant

eTable 2: Incidence Rate Ratios (IRRs) for self-harm for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 654 events† IRR (95% CI)	fluoxetine 347 events† IRR (95% CI)	citalopram 151 events† IRR (95% CI)	sertraline 71 events† IRR (95% CI)	paroxetine 55 events† IRR (95% CI)	TCAs 118 events IRR (95% CI)
Unexposed	0.12 (0.09 - 0.17)	0.12 (0.08 - 0.17)	0.19 (0.10 - 0.35)	0.14 (0.06 - 0.31)	0.06 (0.03 - 0.15)	0.15 (0.08 - 0.30)
Pre-exposure 1 (- 4 months)	0.37 (0.22 - 0.61)	0.37 (0.19 - 0.72)	0.43 (0.15 - 1.22)	0.62 (0.20 - 1.91)	0.47 (0.12 - 1.82)	0.29 (0.08 - 1.03)
Pre-exposure 2 (- 3 months)	0.59 (0.38 - 0.90)	0.68 (0.40 - 1.15)	0.58 (0.23 - 1.48)	0.75 (0.26 - 2.18)	0.32 (0.07 - 1.52)	0.09 (0.01 - 0.71)
Pre-exposure 3 (-2 months)	0.65 (0.43 - 0.98)	0.57 (0.33 - 0.99)	0.67 (0.27 - 1.63)	0.88 (0.32 - 2.42)	0.77 (0.24 - 2.44)	0.46 (0.16 - 1.33)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	11.48 (7.93 - 16.62)	8.63 (5.13 - 14.52)	18.21 (8.69 - 38.16)	12.58 (4.72 - 33.53)	3.73 (0.77 - 17.97)	3.47 (0.97 - 12.45)
Week 1	0.69 (0.35 - 1.35)	0.60 (0.24 - 1.54)	1.41 (0.45 - 4.38)	0.57 (0.07 - 4.60)	No events	0.77 (0.17 - 3.50)
Week 2	0.96 (0.55 - 1.68)	0.63 (0.26 - 1.49)	1.53 (0.54 - 4.35)	0.91 (0.19 - 4.31)	1.02 (0.21 - 4.90)	0.33 (0.04 - 2.57)
Week 3	1.33 (0.82 - 2.19)	0.96 (0.46 - 1.99)	2.17 (0.85 - 5.51)	0.45 (0.06 - 3.63)	2.02 (0.59 - 6.93)	1.01 (0.28 - 3.61)
Week 4	1.23 (0.73 - 2.07)	0.88 (0.41 - 1.90)	1.36 (0.44 - 4.23)	0.97 (0.21 - 4.57)	1.63 (0.42 - 6.35)	0.37 (0.05 - 2.90)
Rest of AD episode	0.64 (0.45 - 0.90)	0.60 (0.38 - 0.93)	1.13 (0.56 - 2.27)	0.31 (0.12 - 0.81)	0.39 (0.12 - 1.24)	0.48 (0.18 - 1.25)
Wash-out 1 (+ 1 month)	0.28 (0.16 - 0.48)	0.39 (0.21 - 0.72)	0.47 (0.18 - 1.26)	0.13 (0.02 - 1.01)	0.27 (0.05 - 1.29)	0.09 (0.01 - 0.69)
Wash-out 2 (+ 2 months)	0.32 (0.19 - 0.55)	0.28 (0.14 - 0.56)	0.41 (0.14 - 1.17)	0.26 (0.05 - 1.21)	0.14 (0.02 - 1.13)	0.43 (0.15 - 1.25)
Wash-out 3 (+ 3 months)	0.19 (0.12 - 0.31)	0.18 (0.11 - 0.30)	0.41 (0.21 - 0.81)	0.35 (0.16 - 0.79)	0.23 (0.09 - 0.60)	0.35 (0.17 - 0.73)

†Number of events in young people taking antidepressant

eTable 3: Incidence Rate Ratios (IRRs) for suicidal ideation for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 458 events† IRR (95% CI)	fluoxetine 240 events† IRR (95% CI)	citalopram 108 events† IRR (95% CI)	sertraline 36 events† IRR (95% CI)	paroxetine 41 events† IRR (95% CI)	TCAs 81 events IRR (95% CI)
Unexposed	0.07 (0.05 - 0.10)	0.06 (0.04 - 0.09)	0.14 (0.06 - 0.32)	0.13 (0.05 - 0.34)	0.06 (0.02 - 0.18)	0.09 (0.05 - 0.18)
Pre-exposure 1 (- 4 months)	0.29 (0.15 - 0.54)	0.17 (0.07 - 0.44)	0.75 (0.24 - 2.35)	0.36 (0.07 - 1.79)	0.21 (0.02 - 1.77)	0.15 (0.03 - 0.68)
Pre-exposure 2 (- 3 months)	0.45 (0.26 - 0.77)	0.31 (0.15 - 0.65)	0.87 (0.29 - 2.59)	0.55 (0.14 - 2.20)	0.40 (0.08 - 2.09)	0.30 (0.10 - 0.90)
Pre-exposure 3 (-2 months)	0.76 (0.48 - 1.19)	0.56 (0.31 - 1.02)	1.27 (0.47 - 3.41)	1.07 (0.35 - 3.33)	0.98 (0.28 - 3.38)	0.21 (0.06 - 0.74)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	33.41 (23.56 - 47.39)	25.34 (16.34 - 39.31)	71.07 (31.77 - 159.01)	8.43 (2.37 - 29.93)	20.90 (6.83 - 64.01)	14.00 (6.81 - 28.75)
Week 1	0.38 (0.13 - 1.05)	0.43 (0.13 - 1.40)	0.61 (0.07 - 4.95)	No events	No events	0.59 (0.13 - 2.59)
Week 2	0.57 (0.26 - 1.27)	0.25 (0.06 - 1.03)	0.52 (0.06 - 4.23)	1.20 (0.24 - 5.96)	No events	0.25 (0.03 - 1.91)
Week 3	1.56 (0.91 - 2.68)	1.24 (0.60 - 2.53)	4.17 (1.51 - 11.51)	No events	1.49 (0.29 - 7.70)	1.03 (0.34 - 3.13)
Week 4	0.98 (0.51 - 1.91)	1.23 (0.58 - 2.59)	0.55 (0.07 - 4.50)	0.62 (0.07 - 5.16)	No events	0.84 (0.24 - 2.94)
Rest of AD episode	0.72 (0.49 - 1.08)	0.49 (0.29 - 0.82)	1.40 (0.58 - 3.37)	0.47 (0.16 - 1.35)	1.30 (0.43 - 3.90)	0.52 (0.20 - 1.35)
Wash-out 1 (+ 1 month)	0.40 (0.23 - 0.70)	0.38 (0.20 - 0.75)	0.27 (0.06 - 1.31)	0.33 (0.07 - 1.66)	0.20 (0.02 - 1.72)	0.43 (0.16 - 1.11)
Wash-out 2 (+ 2 months)	0.12 (0.06 - 0.29)	0.13 (0.04 - 0.36)	0.55 (0.16 - 1.88)	0.34 (0.07 - 1.73)	0.57 (0.14 - 2.42)	0.27 (0.09 - 0.83)
Wash-out 3 (+ 3 months)	0.20 (0.12 - 0.33)	0.15 (0.08 - 2.73)	0.50 (0.21 - 1.18)	0.07 (0.02 - 0.21)	0.08 (0.02 - 0.27)	0.13 (0.06 - 0.27)

†Number of events in young people taking antidepressant

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5-9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	n/a
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	7-9
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-9
		(b) Describe any methods used to examine subgroups and interactions	7-9
		(c) Explain how missing data were addressed	10
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	10-11

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	10
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-12
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



**Suicide-related events in young people following
prescription of SSRIs and other antidepressants: a self-
controlled case series analysis**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003247.R1
Article Type:	Research
Date Submitted by the Author:	10-Jul-2013
Complete List of Authors:	Wijlaars, Linda; UCL, Primary Care and Population Health Nazareth, Irwin; UCL, Primary Care and Population Health Whitaker, Heather; Open University, Department of Mathematics and Statistics Evans, Stephen; LSHTM, Medical Statistics Unit Petersen, Irene; UCL, Primary Care and Population Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	General practice / Family practice, Mental health, Paediatrics, Public health
Keywords:	EPIDEMIOLOGY, MENTAL HEALTH, Suicide & self-harm < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY, Child & adolescent psychiatry < PSYCHIATRY

SCHOLARONE™
Manuscripts

Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis

Linda PMM Wijlaars¹, doctoral student,
Irwin Nazareth¹, professor of Primary Care and Population Science,
Heather J Whitaker², lecturer in statistics,
Stephen JW Evans³, professor of pharmacoepidemiology,
Irene Petersen¹, senior lecturer in epidemiology and medical statistics

1. Department of Primary Care and Population Health
University College London Medical School
Royal Free Campus
Rowland Hill Street
London
NW3 2PF
2. Department of Mathematics and Statistics
The Faculty of Mathematics, Computing and Technology
The Open University
Walton Hall
Milton Keynes
Buckinghamshire
MK7 6AA
3. Department of Medical Statistics
London School of Hygiene and Tropical Medicine
Keppel Street
London
WC1E 7HT

Correspondence to: Linda PMM Wijlaars (linda.wijlaars.10@ucl.ac.uk), contact address as above

Abstract

Objectives: We aimed to examine the temporal association between SSRI and tricyclic antidepressant (TCA) prescriptions and suicide-related events in children and adolescents.

Design: Self-controlled case series.

Setting: Electronic health records were used from 479 general practices in The Health Improvement Network (THIN) UK primary care database from 1995 to 2009.

Participants: 81 young people aged 10-18 years with a record of completed suicide, 1,496 who attempted suicide, 1,178 with suicidal ideation and 2,361 with intentional self-harm.

Main outcome measures: Incidence Rate Ratios (IRRs) for completed and attempted suicide, suicidal ideation and intentional self-harm.

Results: For non-fatal suicide-related behaviour, IRRs were similar for the time the person was prescribed either SSRIs or TCAs: IRRs increased during pre-exposure, peaked on prescription day, were stable up to the fourth prescription-week, and decreased after prescriptions stopped. For both types of antidepressants, IRRs were lower or similar to pre-exposure levels during the period of prescription. For SSRIs, there was an increase in the IRR for completed suicide on the day of prescription (N=5; IRR=42.5, 95% CI: 4.5 to 403.4), and during the fourth week of SSRI prescription (N=2; IRR=11.3, 95% CI: 1.1 to 115.6).

Conclusions: Overall, there are no systematic differences between the association of TCAs and SSRIs with incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm, and apart from the day of prescription, rates did not exceed pre-exposure levels. The pattern of IRR for suicide for SSRIs was similar to that found in non-fatal suicide-related events. Our results warrant a re-evaluation of the current prescribing of SSRIs in young people. We recommend the creation of a pragmatic registry for active pharmacovigilance.

Article summary

Article focus

- There has been concern that selective serotonin reuptake inhibitors (SSRIs) might be associated with an increased risk of suicide-related events in young people.
- We assess the temporal association between the risk of completed suicide, attempted suicide, suicidal ideation, intentional self-harm and antidepressant prescribing, comparing SSRIs and tricyclic antidepressants (TCAs) in adolescents using a large UK primary care database.

Key messages

- There are no systematic differences between the association of TCAs and SSRIs with incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm
- Up to the fourth week of prescription, the IRRs for attempted suicide, suicidal ideation and self-harm remained around the levels experienced during the pre-exposure period, suggesting on-going close monitoring in the first month is important.

Strengths and limitations of this study

- The self-controlled case series method inherently controls for time-independent variables such as genetics, location and socio-economic status
- Changes in depression severity are poorly recorded over time, which is a limitation.

Introduction

Between 1-6% of adolescents in the community suffer from major depressive disorder¹. In addition, suicide is the third leading cause of death in 15-19 year olds at 6.9 per 100,000 population, and fourth for 10-14 year olds at 0.9 per 100,000 population². This calls for safe and effective depression treatments in this age group. As tricyclic antidepressants (TCAs) appear to lack efficacy for depression treatment in this age group, and have a poor side effect profile³, selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed pharmacological treatment for children and adolescents⁴.

However, there has been concern that SSRIs might be associated with an increased risk of suicide-related events in paediatric patients. Results from clinical trials led the Expert Working Group of the Committee on Safety of Medicines (CSM) to advise against initiation of treatment with selective serotonin inhibitors (SSRIs) for childhood depression in the UK in December 2003⁵. Fluoxetine, the only drug which is licensed to treat depression in young people in the UK, was exempted from this advice following review that concluded there was a favourable balance of benefits and risk⁶. The US Food and Drug Administration (FDA) issued similar advice in 2004⁷.

There is inconsistent evidence of an increased rate of suicide-related events and intentional self-harm associated with SSRIs⁸. Data from randomized controlled trials in adolescents and young adults report an increased risk of suicide-related events⁹. Part of this difference appears to depend on the methodology used. If suicide-related events were ascertained using the method of “adverse events” there was a small but significant increase in suicidal ideation. However, if the studies used rating scales to assess suicide-related events, most studies showed an improvement in suicide-related events.

1
2
3 The results from these trials should be interpreted with caution as they were not primarily
4 designed to measure suicide-related events and it would be unethical to do so using placebo
5 as a control^{10;11}. Moreover, none of these trials on SSRIs recruited from a general population
6 setting and completed suicides have not occurred in any studies⁹.

7
8
9
10
11 Observational studies in young people have found mixed results: some indicate that SSRIs
12 protect from suicide-related events¹²; others find no effect^{13;14}; or an increase in risk of
13 suicide-related events^{15;16}. These studies, however, have methodological limitations including
14 small numbers, high attrition rates and, most importantly, confounding by severity. Given the
15 risk of death in overdose, the lack of efficacy in children, and the side effects associated with
16 them, a prescriber would be less likely to prescribe tricyclic antidepressants (TCA) in
17 preference to SSRIs for a person at risk of suicide-related events¹⁷.

18
19
20
21
22
23
24
25
26
27
28
29
30 We have previously shown rates for SSRI prescriptions in children and adolescents increased
31 between 2005-2009⁴. Neither TCAs nor SSRIs are considered appropriate first line treatment
32 by the National Institute for Clinical Excellence (NICE) for depression in children and
33 adolescents. Only when children and adolescents are not responding to psychological
34 treatment should treatment with SSRIs be considered⁶. It is therefore important to reassess the
35 risks of existing clinical data to inform future practice. We aimed to assess the temporal
36 association between the risk of completed suicide, attempted suicide, suicidal thoughts,
37 intentional self-harm and antidepressant prescribing in adolescents, comparing SSRIs and
38 TCAs and correcting for age and sex, using a large UK primary care database.

Methods

Data Source

We used data from The Health Improvement Network (THIN) primary care database, including information from UK primary care data prospectively recorded between 1 January 1995 and 31 December 2009. THIN includes anonymised general practice records on more than 9 million patients from 479 practices in the United Kingdom and is one of the largest primary care databases available internationally. It is broadly representative of the UK general practice population in terms of demographics and consultation behaviour¹⁸. Data on diagnoses, interventions, symptoms, and referrals to secondary care are electronically recorded as Read Codes, a hierarchical coding system used in UK primary care¹⁹. All prescriptions are also electronically recorded. Clinical diagnoses recorded using Read codes have recently been shown to be accurate compared with other reliable sources²⁰.

Study population

This study included a cohort of young people and adolescents, aged 10-18 years who had a recorded suicidal or self-harm event. Patients were included if they were registered with a practice for at least six months between January 1995 and December 2009. Patients were followed up from the latest of the date they registered at the GP, 1 January 1995, or their 10th birthday, until (1) 31 December 2009, (2) their 19th birthday, (3) the date of death, or (4) the date they left the practice.

Measurements

Outcome - We identified completed suicides using relevant Read codes that were confirmed by a date of death within two weeks of the suicide event date. We searched a cause of death if available. The list of codes was an updated version of a published suicide code

1
2
3 list²¹. To make sure we did not miss any suicides, we extracted medical records on all young
4
5 people who died between the ages of 10 and 18 and examined the free text if there was no
6
7 clear cause of death (e.g. childhood cancer or a traffic accident) for possible suicides. We
8
9 excluded cases where there was doubt whether the death was due to suicide (i.e. 12 deaths
10
11 which received an open verdict by the coroner). Of these potential suicides, 1 patient had
12
13 records of TCA prescriptions, while 4 had records of SSRI prescriptions in the last year.
14
15 Suicide attempt, suicidal ideation and self-harm were identified using a Read code list that
16
17 was developed in line with published methods and reviewed by a general practitioner (IN)²².
18
19
20
21
22

23 *Exposure* - We used British National Formulary (BNF) codes representing antidepressants²³.
24
25 We classified antidepressants as TCAs, SSRIs and other antidepressants according to the
26
27 BNF. We excluded TCAs that were prescribed for nocturnal enuresis or neuropathic pain.
28
29 Comparing prescription data in THIN to dispensing data from NHS Prescription Services
30
31 showed that the mean practice redemption rate (the percentage of recorded prescriptions
32
33 which were dispensed) was as high as 96.7% for antidepressants²⁴.
34
35
36
37
38

39 We then identified the separate episodes of antidepressant prescription for each individual.
40
41 To constitute a new episode of antidepressant prescriptions, there had to be a preceding gap
42
43 of at least 3 months of no prescriptions. We choose 3 months as a prescription supply of
44
45 antidepressants is typically 1 month or less, and therefore a gap of at least 3 months between
46
47 prescriptions would likely represent a new episode of antidepressant prescriptions (although
48
49 not necessarily a new episode of depression). If a person switched from one drug to another
50
51 within 3 months, this did not constitute a new episode.
52
53
54
55
56
57
58
59
60

1
2
3 *Covariates* – We extracted information on sex, age and social deprivation score (Townsend
4 quintiles). Patients who were prescribed TCAs for nocturnal enuresis (as confirmed by Read
5 codes) were excluded. Finally, we considered consultation behaviour as a confounder.
6
7 Patients who consult infrequently with their GP, e.g. only when their prescription has run out,
8 might not have correctly timed records of all of their events. To correct for this we conducted
9 a sensitivity analysis where we only included patients who consulted at least once a week
10 during the month after their first antidepressant prescription.
11
12
13
14
15
16
17
18
19

20 **Statistical analysis**

21
22 *The Self-Controlled Case Series (SCCS) method* - We calculated incidence rate ratios (IRRs –
23 calculated by dividing the incidence rate in the exposed period by the incidence rate in the
24 control period) for completed suicide and suicide-related events using the self-controlled case
25 series (SCCS) method²⁵. The SCCS method was developed to investigate associations
26 between acute outcomes and transient exposures, using only data on cases. Since each case
27 served as his/her own control, the case-series method inherently accounts for confounding
28 factors that do not change over the observation period (such as variables related to genetics,
29 socio-economic status and gender). Using a Poisson model, IRRs can be calculated for any
30 number of pre-defined risk periods associated with the exposure, using the time outside of
31 these risk periods (the time when a subject is unexposed) as reference. A major advantage of
32 the SCCS is that it can have high efficiency relative to the retrospective cohort method from
33 which it is derived. As suicide-related events are rare, even in depressed persons, the SCCS
34 method is particularly suited for assessing its association with antidepressants as it requires a
35 much smaller number of persons to be included. Moreover, in using a self-controlled design
36 we circumvent the problem of selecting appropriate controls that cohort or case-control
37 designs encounter. In the case of suicide-related events and antidepressants this has proven
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 crucial as patients who are diagnosed as depressed but don't receive antidepressants might
4 differ from patients who are receiving antidepressants in severity of depression, a major
5 confounder in the studied association.
6
7

8
9 The SCCS method is limited in that it only works for non-recurrent events when the event
10 risk is small over the observation period, which is the case for completed suicide. Also, it
11 requires variability in the age at the time of event: if all events were to happen at exactly the
12 same age (which is not the case in our study), then the method would fail. Finally, the method
13 only produces estimates of relative incidence, rather than absolute incidence.
14
15
16
17
18
19
20
21
22

23 *Suicide attempts, suicidal ideation and self-harm* – For the analyses on suicide attempts,
24 suicidal ideation and self-harm we used an adapted version of the standard SCCS method,
25 allowing for repeated exposures and events and correcting by 1-year age groups^{25;26}. By
26 including a pre-exposure period, we corrected our estimates for event-dependent exposure. If
27 the probability of exposure to antidepressants is changed from baseline after an event, it
28 follows that the probability of the occurrence of an event is also changed in the immediate
29 pre-exposure period. Including a pre-exposure period removes this time from the baseline and
30 corrects the estimates accordingly.
31
32
33
34
35
36
37
38
39

40 Subjects who went on to commit suicide were excluded from these analyses. Using the SCCS
41 method, the incidence rate ratio for the three outcomes was estimated during 14 different risk
42 periods (Figure 1): baseline (or unexposed to antidepressants); four 1-month pre-exposure
43 periods, the last of which is the reference; the day of prescription; four 1-week early exposure
44 periods; a period of variable length to cover the remainder of the period of exposure to the
45 antidepressant for that episode; and three 1-month periods of washout after the end of the
46 antidepressant episode. We included the separate 1-week periods at the start of prescription as
47 it is known that antidepressants (especially SSRIs) take this amount of time to have an
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 effect²⁷. We also compared the effects of individual antidepressants on the IRR of the three
4
5 suicide-related event outcomes.
6
7

8
9
10 *Suicide* - We used an adapted method (SCCS for censored post-event exposures) to assess the
11 effects of antidepressants on childhood suicide as the original approach cannot deal with
12 deaths²⁸. This method takes account of the early cessation of the observation period due to
13 deaths and accordingly corrects the IRR estimates. We corrected for age by creating four age
14 groups: 10-12, 13-14, 15-16 and 17-18 year olds. We estimated IRRs for the same risk
15 periods as for the other outcomes, without the four pre-exposure risk periods and used
16 baseline (time unexposed to antidepressants) as reference.
17
18
19
20
21
22
23

24
25 All analyses were conducted with the use of Stata software, version 12.1 (Stata Corp, College
26 Station, Texas). The scheme for THIN to obtain and provide anonymous patient data to
27 researchers was approved by the National Health Service South-East Multicenter Research
28 Ethics Committee (MREC) in 2002 and scientific approval for this study was obtained from
29 CMD Medical Research's Scientific Review Committee in May 2011.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

There was a total follow-up time of 4,190,410 person-years of 10-18-year olds in THIN. In total, 81 young people were identified with a record of a completed suicide, 1,496 young people with a record of attempted suicide, 1,178 young people with a record of suicidal ideation, and 2,361 with a record of intentional self-harm. Of young people with completed suicides, 30% were female, compared to 60%, 73% and 74% of young people with a record of attempted suicide, suicidal ideation, or self-harm, respectively (Table 1). There was no significant difference in age of first event between the different outcomes. The data were complete for all variables except Townsend scores, which were missing for 92 (2%) persons. Due to small numbers, we were not able to analyse antidepressants other than SSRIs or TCAs.

Attempted suicide, suicidal ideation and self-harm

For attempted suicide, suicidal ideation and self-harm, there were similar patterns between young people that were prescribed SSRIs and TCAs (Table 2 & Figures 2A, B & C): there was an upwards trend in the IRR during pre-exposure; a peak on the day of prescription; a stable or slightly increased rate ratio during the first weeks of prescription; and during the washout period levels decreased again. The increase on prescription day was highest for young people with a record of suicidal ideation (SSRIs: IRR=33.4, 95%CI: 23.6 to 47.4; TCAs: IRR=14.0, 95%CI: 6.8 to 28.8). There were no significant differences between IRRs for any of the event types for any risk periods. Patterns were similar between individual SSRIs (fluoxetine, citalopram, sertraline and paroxetine, results in appendix).

The IRR for each type of event has a strong relation with age. When compared to 15-16 year olds, 17-18 year olds are twice as likely to attempt suicide (IRR=1.90, 95%CI: 1.6 to 2.3 and

1
2
3 IRR=2.1, 95%CI: 1.7 to 2.5 for SSRIs and TCAs, respectively) but those between 10-12
4
5 years old are less likely to attempt suicide (IRR=0.3, 95%CI: 0.2 to 0.4 and IRR=0.2, 95%CI:
6
7 0.1 to 0.2 for SSRIs and TCAs, respectively). Patterns were similar for the other outcomes.
8
9

10
11
12 There were no statistically significant differences between boys and girls for either SSRIs or
13
14 TCAs (results not shown). A small group of 25 patients had a prescription for an
15
16 antidepressant and a primary diagnosis other than depression (obsessive compulsive disorder
17
18 (OCD) or anxiety). Due to the small size of this group we did not perform a subgroup
19
20 analysis. Finally, restricting the analyses to regular consulters (those who consulted at least
21
22 five times during the first four weeks of prescription) did not alter effect estimates. Of the
23
24 young people with a record of attempted suicide or intentional self-harm, 33% were regular
25
26 consulters, compared to 49% of young people with a record of suicidal ideation.
27
28
29
30
31

32 **Suicide**

33
34 Using an expected suicide rate of 3.28 (95%CI: 3.12 to 3.43) per 100,000 person-years in the
35
36 UK population of 10-18-year olds ²⁹, we would expect 137 (95%CI: 131 to 144) completed
37
38 suicides in our study population. However, 41% of suicides registered by the Office of
39
40 National Statistics (ONS) were of undetermined intent, leaving 59% or 81 (95%CI: 77 to 85)
41
42 expected suicides that received a verdict by a coroner. This estimate corresponds to the
43
44 number of 81 completed suicides we identified between 1995 and 2009 within the THIN
45
46 database. Of the 81 young people with a completed suicide, 21 (26%) had a prior record of a
47
48 depression diagnosis or depression symptoms. Nineteen young people (23%) were taking
49
50 antidepressants in the year before their suicide, and 11 (14%) were still taking them at the
51
52 time of, or shortly before their suicide. There was also a high proportion of young people
53
54
55
56
57
58
59
60

1
2
3 with (a history of) behaviour disorders 16 (20%), history of self-harm 8 (10%), a psychiatric
4
5 referral 19 (23%), a hyperkinetic disorder 5 (6%) or eating disorder 3 (4%).
6
7

8
9
10 There were no completed suicides within the risk periods for antidepressants other than
11
12 SSRIs (Table 3). Eleven (14%) completed suicides were within the risk periods. Similar to
13
14 the results from the data on suicide-related events, the IRR was highest on the day of
15
16 prescription (IRR=42.5, 95%CI: 4.5 to 403.4). There were no events in the first two weeks of
17
18 the SSRI episode, but there was an increased rate ratio in week three (IRR=8.0, 95%CI: 0.8
19
20 to 76.7, based on a single case) and a statistically significant increase in week 4 (IRR=11.3,
21
22 95%CI: 1.1 to 115.6, though based on two cases). After the fourth week of the SSRI episode,
23
24 the IRR decreased and returned to baseline levels during wash-out. There were no significant
25
26 differences between age groups.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Overall, there are no systematic differences between TCAs and SSRIs in incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm, and apart from an increase common to both TCAs and SSRIs on the day of prescription, rates were not statistically significantly different from pre-exposure levels. The pattern of incidence risk ratios for completed suicides for the 11 people prescribed SSRIs was similar to that found in attempted suicide, suicidal ideation and self-harm. However, concerns regarding antidepressants need to be weighed against the risk of untreated depression.

Pre-exposure IRRs for attempted suicide, suicidal ideation and self-harm appeared to be marginally higher, though not statistically significant, for SSRIs compared to TCAs. This could be because young people who are deemed to be more at risk of suicide-related events could preferentially be prescribed SSRIs over TCAs, given TCAs' toxicity in overdose¹⁷.

The high IRRs on the day of antidepressant prescription for all three non-fatal outcomes could be an artefact of GP recording behaviour. Rather than the antidepressant causing the suicide-related events, the event is an indication for the GP to prescribe the drug and to record depression in the electronic records on the same day. As antidepressants should only be prescribed by child & adolescent psychiatrists (2005 NICE guidelines⁶), this artefact could also arise when GPs continue a prescription started in secondary care and record the initial indication when first prescribing this drug.

Up to the fourth week of prescription, the IRRs for attempted suicide, suicidal ideation and self-harm remained around the levels experienced during the pre-exposure period. Considering that suicide-related events are common in young depressed people, some suicidal and self-harm events would be expected irrespective of whether SSRIs are prescribed or not³⁰. The suicide-related events decreased when the prescriptions were stopped. Given the

1
2
3 nature of the data, it is difficult to know whether the SSRIs were causing suicide-related
4
5 events and these events improved when the SSRIs were discontinued, or if the SSRIs were
6
7 discontinued when the young person's depression (and as a consequence the risk of suicide-
8
9 related events) improved.

10
11 There are three possible explanations for the slightly increased IRRs during the first month of
12
13 prescription. One is that SSRIs fail to relieve the risk of suicide-related events associated with
14
15 depression because of a lag in antidepressant effect, an incomplete response, or a treatment-
16
17 resistant depression. It is known that SSRIs take a couple of weeks to reach their full
18
19 antidepressant effects and hence reduce the risk of suicide-related events²⁷.

20
21 A second possibility is that the SSRIs generate a novel set of suicidal emotions or behaviours.
22
23 Early improvements in clinical depression can lead to a person acting on existing suicidal
24
25 feelings. This activation syndrome has been described for both TCAs and SSRIs, and is
26
27 widely recognized by psychiatrists, as well as the FDA^{31;32}. While patients might be
28
29 demotivated and demoralized at the height of their depression, when they start treatment they
30
31 become more active during the first weeks of taking the drug. During this time the
32
33 antidepressant effect of the medication will not have reached its full effect resulting in
34
35 persistent depression but simultaneous increased activity. This could lead to a greater risk of
36
37 suicide-related events until the full effects of antidepressants are realized few weeks later³¹.

38
39 Several studies and systematic reviews have shown an age effect in the risk of
40
41 suicide-related events with the use of SSRIs. In adults and the elderly the risk is neutral or
42
43 SSRIs show a protective effect, while in adolescents and young adults there appears to be an
44
45 increased risk of suicide-related events^{9;15;33}.

46
47 Although we did not find a statistically significant sustained increase in suicide-
48
49 related events with either SSRIs or TCAs, negative outcomes did not appear to be decreased
50
51 either – although our study was not designed to assess this. This is in line with Cochrane
52
53
54
55
56
57
58
59
60

1
2
3 reviews on both drug groups: the review on tricyclic antidepressants concludes that these
4 drugs are not useful in treating depression in pre-pubertal children, and that there is only
5 marginal evidence to support the use of TCAs in adolescents, although the magnitude of the
6 effect is likely to be moderate at best³⁴. Similarly, it is unclear what the effect is of SSRIs on
7 suicide completion. Although evidence from clinical trials implies an increased risk of
8 suicide-related outcomes (but not completed suicide), the evidence for this association is of
9 low quality³⁵.

20 21 **Comparison to other studies**

22 Our results build on the findings of Schneeweis et al.¹³. They found no statistically significant
23 differences in relative risk for attempted and completed suicide between different types of
24 antidepressants (fluoxetine, citalopram, fluvoxamine, paroxetine, sertraline and TCAs) when
25 examining 266 attempted and 3 completed suicides. Moreover, an ecological study found no
26 change in rates of completed suicides or hospital admissions for self-harm following the
27 CSM advice³⁶, suggesting there is no, or only a weak, relationship with antidepressant
28 prescriptions. Our findings are also similar to those of Simon et al.³⁷ who used computerised
29 health plan records and report the highest rates for attempted suicide in the month before
30 prescription, rather than after start of the prescription. Finally, a meta-analysis³⁸ found that, of
31 27 paediatric RCTs on antidepressants prescribed for major depressive disorder (MDD),
32 OCD and non-OCD anxiety disorders, the risk of suicidal ideation or attempt among patients
33 on placebo was greater in trials assessing MDD. Although this difference in baseline risk for
34 suicide-related events was not statistically significant, it could indicate part of the association
35 between antidepressants and suicide-related events can be explained by the underlying
36 disease, rather than the drug. Importantly, the authors concluded that relative to placebo, the
37 benefits (though only modest in MDD) outweigh the risks from suicidal ideation/suicide
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 attempts. Due to small numbers of patients with primary diagnoses of OCD and anxiety
4 disorders, we could not repeat the meta-analysis' sub-group comparison.
5
6
7

8 9 10 **Main strength and limitations**

11 The main strength of this study is its sample size that enables examination of outcomes
12 separately by completed and attempted suicide, suicidal ideation and self-harm, and by
13 individual antidepressants. However, even in using a database as large as THIN, we could
14 identify only a small number of completed suicides, leading to limited power in that analysis.
15
16 Similarly, power was limited for analysing individual antidepressants, which are presented in
17 the appendix. Nevertheless, the use of the SCCS method allows us to control for time-
18 independent confounders, making our estimations more robust.
19
20

21 A limitation to our study is that the THIN database only provides data on antidepressant
22 prescriptions. We do not know whether prescriptions were dispensed, or whether patients
23 adhered to prescription. However, though it is known that adherence levels are around 50%
24 for young people taking SSRIs, and even lower for TCAs³⁹, our data does represent a real-life
25 situation. Moreover, by assessing episodes of antidepressant prescription, we take account of
26 multiple prescriptions per patient, which increases the likelihood of adherence as we expect
27 patients who are not taking their medication would not come back for a new prescription.
28
29

30 Moreover, it is known that suicide-related events are often missed in clinical assessment⁴⁰.
31
32 However, it is likely that the most severe forms (attempted suicides and severe suicidal
33 ideation) are most likely to be recorded by clinicians. Also, in using a self-controlled design,
34 we decrease the chance of misclassifying controls. There is some suggestion that
35 antidepressants might specifically increase suicide-related events in patients who did not
36 experience these events prior to starting antidepressant treatment. Due to variation in
37 clinicians' assessment and recording of (the absence of) suicide-related events, we could not
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 examine this hypothesis using this database. Finally, we were not able to account for changes
4
5 in depression severity over time as this is poorly recorded.
6
7

8 9 **Conclusion**

10 Our study shows that there are similar incidence rate ratio patterns for attempted suicide,
11
12 suicidal ideation and self-harm for SSRIs and TCAs. Also, the pattern for completed suicides
13
14 associated with SSRI prescriptions is similar, though there are no records of completed
15
16 suicides within our pre-defined risk periods for TCAs. Although the CSM's warning was a
17
18 sensible cautionary recommendation at the time, it appears that the current line of evidence
19
20 suggests a reverse causality: it is the underlying depression that leads to suicide-related
21
22 events and the prescribing of antidepressants, although a causal effect of SSRIs, or no effect
23
24 at all cannot be ruled out. Moreover, even if antidepressant drugs would temporarily increase
25
26 the risk of suicide-related events in young persons, the risk untreated depression poses is far
27
28 greater. In conclusion, our results indicate that the association of suicide-related events
29
30 associated with antidepressants occurs primarily around the day of prescription, suggesting
31
32 depression severity and GP recording behaviour as the culprit rather than antidepressants, and
33
34 thus warrant a re-evaluation of the current guidelines regarding the prescription of SSRIs in
35
36 primary care.
37
38
39
40
41
42
43
44

45 **Recommendation**

46
47 Our results are not definitive, and due to the rare nature of the outcome and the intricacies of
48
49 the problem studied, it is difficult to think of a single study or study design that will be able to
50
51 provide a satisfying answer to the problem at hand. It is possible that the creation of a
52
53 pragmatic registry, similar to that proposed by van Staa and colleagues in their pragmatic
54
55 randomised trial⁴¹, will allow for active pharmacovigilance. Such a system would at low cost
56
57
58
59
60

1
2
3 and with no additional burden on clinician, health service or patient time, facilitate long term,
4
5 anonymous, unobtrusive follow-up for major clinical outcomes. As such, clinicians would be
6
7 prompted to monitor and record (the absence of) suicide-related events and ideation more
8
9 regularly and closely, using similar outcome measurements as those used in clinical trials, as
10
11 well as (changes in) depression severity.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Acknowledgements

We would like to thank the general practitioners who contributed data to THIN.

Contributors All authors were responsible for study conception and design. LPW was responsible for data analysis. LPW authors drafted the manuscript. All authors participated in the interpretation of data, critical revision and final approval of the manuscript.

Funding statement: The work was supported by a PhD studentship from the National Institute of Health Research English National School for Primary Care Research. The funding organisation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; and preparation, review or approval of the manuscript.

Competing interests statement: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: LPMMW had financial support in the form of a studentship from the National Institute of Health Research English National School for Primary Care Research for the submitted work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data sharing: Examples of statistical code used for the self-controlled case series method (including the adapted method for dealing with censored data) are available from the [Open University website](#). Statistical code is available from the corresponding author.

References

- 1
2
3
4
5 (1) Kessler RC, Avenevoli S, Ries Merikangas K. Mood disorders in children and
6 adolescents: an epidemiologic perspective. *Biological Psychiatry* 2001; 49(12):1002-
7 1014.
- 8
9
10 (2) Heron M. Deaths: leading causes for 2007. *National vital statistics reports* 2011;
11 59(8):1-95.
- 12
13 (3) Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drug for depression in
14 children and adolescents. *Cochrane Database Syst Rev* 2002;(4).
- 15
16 (4) Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant
17 prescribing in children and adolescents: A cohort study in The Health Improvement
18 Network (THIN). *PLoS One* 2012.
- 19
20 (5) Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and
21 suicide in adults: meta-analysis of drug company data from placebo controlled,
22 randomised controlled trials submitted to the MHRA's safety review. *BMJ* 2005;
23 330(7488):385.
- 24
25 (6) National Institute for Health and Clinical Excellence. CG28 Depression in children
26 and young people: NICE guideline. 2005. London, National Institute for Health and
27 Clinical Excellence.
- 28
29 (7) FDA. Suicidality in Children and Adolescents Being Treated With Antidepressant
30 Medications. US Food and Drug Administration [2004 [cited 2011 June 29];
31 Available from: URL:
32 [http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsa
33 ndProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisorie
34 s/ucm161679.htm](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679.htm)
- 35
36 (8) Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E.
37 Selective serotonin reuptake inhibitors in childhood depression: systematic review of
38 published versus unpublished data. *The Lancet* 2004; 363(9418):1341-1345.
- 39
40 (9) Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with
41 antidepressant drugs. *Arch Gen Psychiatry* 2006; 63(3):332-339.
- 42
43 (10) Rothman KJ, Michels KB. The continuing unethical use of placebo controls. *N Engl J*
44 *Med* 1994; 331(6):394-398.
- 45
46 (11) Grosso A, Douglas I, MacAllister R, Petersen I, Smeeth L, Hingorani AD. Use of the
47 self-controlled case series method in drug safety assessment. *Expert Opin Drug Saf*
48 2011; 10(3):337-340.
- 49
50 (12) Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA et al. Early
51 evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and
52 suicide in children and adolescents. *Am J Psychiatry* 2007; 164(9):1356-1363.
- 53
54
55
56
57
58
59
60

- 1
2
3 (13) Schneeweiss S, Patrick AR, Solomon DH, Dormuth CR, Miller M, Mehta J et al.
4 Comparative safety of antidepressant agents for children and adolescents regarding
5 suicidal acts. *Pediatrics* 2010; 125(5):876-888.
6
- 7 (14) Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. *JAMA*
8 2004; 292(3):338-343.
9
- 10 (15) Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely
11 depressed children and adults - A case-control study. *Arch Gen Psychiatry* 2006;
12 63(8):865-872.
13
- 14 (16) Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal Thoughts and Behavior
15 With Antidepressant Treatment: Reanalysis of the Randomized Placebo-Controlled
16 Studies of Fluoxetine and Venlafaxine. *Arch Gen Psychiatry* 2012;archgenpsychiatry.
17
- 18 (17) Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following
19 prescription of SSRIs and other antidepressants: confounding by indication. *Br J Clin*
20 *Pharmacol* 2005; 60(5):519-525.
21
- 22 (18) Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a
23 quality-evaluated database of primary care data. *Inform Prim Care* 2004; 12(3):171-
24 177.
25
- 26 (19) Booth N. What are the Read Codes? *Health Libr Rev* 1994; 11(3):177-182.
27
- 28 (20) Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General
29 Practice Research Database: a systematic review. *Br J Gen Pract* 2010; 60(572):e128-
30 e136.
31
- 32 (21) Arana A, Wentworth CE, yuso-Mateos JL, Arellano FM. Suicide-related events in
33 patients treated with antiepileptic drugs. *N Engl J Med* 2010; 363(6):542-551.
34
- 35 (22) Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary
36 care databases. *Pharmacoepidemiology and drug safety* 2009; 18(8):704-707.
37
- 38 (23) British National Formulary. 60 ed. London: BMJ group; RPS Publishing; 2010.
39
- 40 (24) The NHS Information Centre PaPCS. Prescription compliance: a review of the
41 proportion of prescriptions dispensed. 7-9-2011.
42
- 43 (25) Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the
44 self-controlled case series method. *Stat Med* 2006; 25(10):1768-1797.
45
- 46 (26) Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case
47 series studies. *Stat Methods Med Res* 2009; 18(1):7-26.
48
- 49 (27) Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective
50 serotonin reuptake inhibitor antidepressant action: systematic review and meta-
51 analysis. *Arch Gen Psychiatry* 2006; 63(11):1217-1223.
52
- 53 (28) Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored,
54 perturbed, or curtailed post-event exposures. *Biostatistics* 2009; 10(1):3-16.
55
56
57
58
59
60

- 1
2
3 (29) Windfuhr K, While D, Hunt I, Turnbull P, Lowe R, Burns J et al. Suicide in juveniles
4 and adolescents in the United Kingdom. *J Child Psychol Psychiatry* 2008;
5 49(11):1155-1165.
6
7 (30) Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. *J*
8 *Child Psychol Psychiatry* 2006; 47(3-4):372-394.
9
10 (31) Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A et al.
11 Antidepressant-induced jitteriness/anxiety syndrome: systematic review. *Br J*
12 *Psychiatry* 2009; 194(6):483-490.
13
14 (32) Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL.
15 Suicidality as a possible side effect of antidepressant treatment. *J Clin Psychiatry*
16 2004; 65(6):742-749.
17
18 (33) Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of
19 suicide: a systematic review of observational studies. *CMAJ* 2009; 180(3):291-297.
20
21 (34) Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drug for depression in
22 children and adolescents. *Cochrane Database Syst Rev* 2010;(4).
23
24 (35) Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation
25 antidepressants for depressive disorders in children and adolescents. *Cochrane*
26 *Database of Systematic Reviews* 2012.
27
28 (36) Wheeler BW, Gunnell D, Metcalfe C, Stephens P, Martin RM. The population impact
29 on incidence of suicide and non-fatal self harm of regulatory action against the use of
30 selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological
31 study. *BMJ* 2008; 336(7643):542-545.
32
33 (37) Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant
34 treatment. *Am J Psychiatry* 2006; 163(1):41-47.
35
36 (38) Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA et al. Clinical
37 response and risk for reported suicidal ideation and suicide attempts in pediatric
38 antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA* 2007;
39 297(15):1683-1696.
40
41 (39) Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP et al.
42 Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic
43 antidepressants: comparison of drug adherence. *Cochrane Database Syst Rev*
44 2000;(4):CD002791.
45
46 (40) Fitzpatrick C, Abayomi NN, Kehoe A, Devlin N, Glackin S, Power L et al. Do we
47 miss depressive disorders and suicidal behaviours in clinical practice? *Clinical Child*
48 *Psychology and Psychiatry* 2012; 17(3):449-458.
49
50 (41) van Staa T, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A et al.
51 Pragmatic randomised trials using routine electronic health records: putting them to
52 the test. *BMJ* 2012; 344.
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1: Risk periods included in self-controlled case series analysis for attempted suicide, suicidal ideation and self-harm and suicide. 1 = baseline; 2-5 = 1-month pre-exposure periods; 6 = prescription day; 7-10 = four 1-week exposure periods; 11 = remainder of antidepressant exposure; 12-14= three 1-month washout periods

Figure 2A, B, C: IRR for A) attempted suicide, B) suicidal ideation and C) self-harm for tricyclic antidepressants (TCAs) and selective serotonin inhibitors (SSRIs). The month before a prescription was issued (pre-exposure 4) was used as the reference.

TABLES

Table 1: Demographics by category of suicidal or self-harming behaviour

	Completed suicide 81	Attempted suicide 1496	Suicidal ideation 1178	Self-harm 2361	General population 952892
Girls (%)	24 (29.6)	1089 (72.8)	708 (60.1)	1752 (74.2)	461610 (48.4)
# taking ADs (%)	19 (23.1)	527 (36.6)	578 (52.8)	128 (5.7)	27632 (2.9)
# depressed (%)	21 (25.9)	728 (48.7)	819 (69.5)	173 (7.3)	41101 (4.3)
# Townsend score (%)					
1 (most affluent)	20 (24.7)	266 (17.8)	193 (16.4)	442 (18.7)	227178 (23.8)
2	5 (6.2)	240 (16.0)	202 (17.2)	405 (17.2)	198686 (20.9)
3	13 (16.1)	286 (19.1)	236 (20.0)	452 (19.1)	184934 (19.4)
4	25 (30.9)	364 (24.3)	283 (24.0)	571 (24.2)	169792 (17.8)
5 (most deprived)	16 (19.8)	316 (21.1)	241 (20.5)	446 (18.9)	120116 (12.6)
Median age in years at (first) event (5%-95% percentiles)	16.8 (12.0-18.8)	16.5 (12.9 - 18.7)	16.7 (12.0 - 18.7)	15.9 (12.6 - 18.7)	-
Median time in study in years (5%-95% percentiles)	3.5 (0.2 - 8.4)	5.5 (1.4 - 9.0)	5.9 (1.5 - 9.0)	5.9 (1.5 - 9.0)	-

Table 2: Incidence Rate Ratios (IRRs) for different types of suicidal or self-harming behaviour by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs			TCAs		
	Suicide attempt 423 events† IRR (95% CI)	Suicidal ideation 458 events† IRR (95% CI)	Self-harm 654 events† IRR (95% CI)	Suicide attempt 79 events† IRR (95% CI)	Suicidal ideation 81 events† IRR (95% CI)	Self-harm 118 events† IRR (95% CI)
Unexposed	0.09 (0.07 - 0.13)	0.07 (0.05 - 0.10)	0.12 (0.09 - 0.17)	0.20 (0.09 - 0.46)	0.09 (0.05 - 0.18)	0.15 (0.08 - 0.30)
Pre-exposure 1 (- 4 months)	0.19 (0.10 - 0.38)	0.29 (0.15 - 0.54)	0.37 (0.22 - 0.61)	0.61 (0.18 - 2.10)	0.15 (0.03 - 0.68)	0.29 (0.08 - 1.03)
Pre-exposure 2 (- 3 months)	0.31 (0.17 - 0.53)	0.45 (0.26 - 0.77)	0.59 (0.38 - 0.90)	0.29 (0.06 - 1.39)	0.30 (0.10 - 0.90)	0.09 (0.01 - 0.71)
Pre-exposure 3 (-2 months)	0.62 (0.40 - 0.96)	0.76 (0.48 - 1.19)	0.65 (0.43 - 0.98)	0.14 (0.02 - 1.16)	0.21 (0.06 - 0.74)	0.46 (0.16 - 1.33)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	4.17 (2.44 - 7.12)	33.41 (23.56 - 47.39)	11.48 (7.93 - 16.62)	8.82 (2.79 - 27.82)	14.00 (6.81 - 28.75)	3.47 (0.97 - 12.45)
Week 1	0.79 (0.40 - 1.55)	0.38 (0.13 - 1.05)	0.69 (0.35 - 1.35)	1.18 (0.24 - 5.68)	0.59 (0.13 - 2.59)	0.77 (0.17 - 3.50)
Week 2	0.74 (0.39 - 1.42)	0.57 (0.26 - 1.27)	0.96 (0.55 - 1.68)	1.02 (0.21 - 4.91)	0.25 (0.03 - 1.91)	0.33 (0.04 - 2.57)
Week 3	1.07 (0.61 - 1.86)	1.56 (0.91 - 2.68)	1.33 (0.82 - 2.19)	0.53 (0.06 - 4.29)	1.03 (0.34 - 3.13)	1.01 (0.28 - 3.61)
Week 4	0.52 (0.24 - 1.15)	0.98 (0.51 - 1.91)	1.23 (0.73 - 2.07)	0.57 (0.07 - 4.67)	0.84 (0.24 - 2.94)	0.37 (0.05 - 2.90)
Rest of AD episode	0.53 (0.36 - 0.78)	0.72 (0.49 - 1.08)	0.64 (0.45 - 0.90)	0.38 (0.11 - 1.33)	0.52 (0.20 - 1.35)	0.48 (0.18 - 1.25)
Wash-out 1 (+ 1 month)	0.42 (0.25 - 0.69)	0.40 (0.23 - 0.70)	0.28 (0.16 - 0.48)	0.66 (0.21 - 2.09)	0.43 (0.16 - 1.11)	0.09 (0.01 - 0.69)
Wash-out 2 (+ 2 months)	0.17 (0.09 - 0.35)	0.12 (0.06 - 0.29)	0.32 (0.19 - 0.55)	0.28 (0.06 - 1.33)	0.27 (0.09 - 0.83)	0.43 (0.15 - 1.25)
Wash-out 3 (+ 3 months)	0.15 (0.09 - 0.25)	0.20 (0.12 - 0.33)	0.19 (0.12 - 0.31)	0.41 (0.16 - 1.03)	0.13 (0.06 - 0.27)	0.35 (0.17 - 0.73)

† Number of events in young people taking antidepressants



Table 3: Incidence Rate Ratios (IRRs) for completed suicide by risk period and age



Risk period	Censoring model IRR (95% CI)	# deaths†
Prescription day	42.52 (4.48 – 403.43)	5
Week 1		
Week 2	No events	0
Week 3	8.00 (0.84 – 76.71)	1
Week 4	11.25 (1.09 – 115.58)	2
Rest of AD episode	5.42 (0.57 – 51.94)	1
Wash-out 1	2.27 (0.24 – 21.76)	1
Wash-out2	2.08 (0.22 – 19.69)	1
Age Groups		# total deaths‡
10-12	0.61 (0.21 – 1.77)	8
13-14	1.14 (0.45 – 2.90)	15
15-16	Reference	21
17-18	0.41 (0.12 – 1.39)	37

† Number of suicides during risk periods (only includes youths who were taking antidepressants at the time of suicide, or those who had recently stopped)

‡ Number of suicides by age category

FIGURES





Supplementary Tables

eTable 1: Incidence Rate Ratios (IRRs) for attempted suicide for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 423 events† IRR (95% CI)	fluoxetine 198 events† IRR (95% CI)	citalopram 111 events† IRR (95% CI)	sertraline 39 events† IRR (95% CI)	paroxetine 61 events† IRR (95% CI)	TCAs 79 events IRR (95% CI)
Unexposed	0.09 (0.07 - 0.13)	0.10 (0.06 - 0.16)	0.08 (0.05 - 0.14)	0.11 (0.04 - 0.31)	0.07 (0.03 - 0.14)	0.20 (0.09 - 0.46)
Pre-exposure 1 (- 4 months)	0.19 (0.10 - 0.38)	0.18 (0.06 - 0.53)	0.26 (0.10 - 0.67)	0.20 (0.02 - 1.71)	0.21 (0.05 - 0.97)	0.61 (0.18 - 2.10)
Pre-exposure 2 (- 3 months)	0.31 (0.17 - 0.53)	0.41 (0.19 - 0.89)	0.20 (0.07 - 0.59)	0.20 (0.02 - 1.70)	0.21 (0.05 - 0.96)	0.29 (0.06 - 1.39)
Pre-exposure 3 (-2 months)	0.62 (0.40 - 0.96)	0.72 (0.38 - 1.37)	0.35 (0.15 - 0.83)	1.19 (0.36 - 3.88)	0.41 (0.13 - 1.30)	0.14 (0.02 - 1.16)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	4.17 (2.44 - 7.12)	5.84 (2.76 - 12.34)	2.02 (0.60 - 6.79)	5.31 (1.03 - 27.37)	3.96 (1.09 - 14.39)	8.82 (2.79 - 27.82)
Week 1	0.79 (0.40 - 1.55)	0.98 (0.37 - 2.59)	0.45 (0.10 - 1.92)	2.64 (0.63 - 11.06)	0.44 (0.06 - 3.45)	1.18 (0.24 - 5.68)
Week 2	0.74 (0.39 - 1.42)	0.50 (0.15 - 1.68)	1.16 (0.47 - 2.90)	0.76 (0.09 - 6.48)	0.38 (0.05 - 2.98)	1.02 (0.21 - 4.91)
Week 3	1.07 (0.61 - 1.86)	1.51 (0.70 - 3.28)	0.57 (0.17 - 1.92)	0.74 (0.09 - 6.33)	1.14 (0.31 - 4.14)	0.53 (0.06 - 4.29)
Week 4	0.52 (0.24 - 1.15)	1.13 (0.46 - 2.79)	0.21 (0.03 - 1.58)	1.65 (0.32 - 8.56)	No events	0.57 (0.07 - 4.67)
Rest of AD episode	0.53 (0.36 - 0.78)	0.65 (0.37 - 1.14)	0.50 (0.25 - 0.98)	1.02 (0.33 - 3.11)	0.30 (0.11 - 0.80)	0.38 (0.11 - 1.33)
Wash-out 1 (+ 1 month)	0.42 (0.25 - 0.69)	0.54 (0.27 - 1.10)	0.43 (0.19 - 0.98)	No events	0.40 (0.13 - 1.30)	0.66 (0.21 - 2.09)
Wash-out 2 (+ 2 months)	0.17 (0.09 - 0.35)	0.18 (0.06 - 0.53)	0.22 (0.07 - 0.63)	No events	0.19 (0.04 - 0.89)	0.28 (0.06 - 1.33)
Wash-out 3 (+ 3 months)	0.15 (0.09 - 0.25)	0.25 (0.13 - 0.46)	0.16 (0.09 - 0.29)	0.27 (0.10 - 0.77)	0.24 (0.10 - 0.57)	0.41 (0.16 - 1.03)

†Number of events in young people taking antidepressant

eTable 2: Incidence Rate Ratios (IRRs) for self-harm for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 654 events† IRR (95% CI)	fluoxetine 347 events† IRR (95% CI)	citalopram 151 events† IRR (95% CI)	sertraline 71 events† IRR (95% CI)	paroxetine 55 events† IRR (95% CI)	TCAs 118 events IRR (95% CI)
Unexposed	0.12 (0.09 - 0.17)	0.12 (0.08 - 0.17)	0.19 (0.10 - 0.35)	0.14 (0.06 - 0.31)	0.06 (0.03 - 0.15)	0.15 (0.08 - 0.30)
Pre-exposure 1 (- 4 months)	0.37 (0.22 - 0.61)	0.37 (0.19 - 0.72)	0.43 (0.15 - 1.22)	0.62 (0.20 - 1.91)	0.47 (0.12 - 1.82)	0.29 (0.08 - 1.03)
Pre-exposure 2 (- 3 months)	0.59 (0.38 - 0.90)	0.68 (0.40 - 1.15)	0.58 (0.23 - 1.48)	0.75 (0.26 - 2.18)	0.32 (0.07 - 1.52)	0.09 (0.01 - 0.71)
Pre-exposure 3 (-2 months)	0.65 (0.43 - 0.98)	0.57 (0.33 - 0.99)	0.67 (0.27 - 1.63)	0.88 (0.32 - 2.42)	0.77 (0.24 - 2.44)	0.46 (0.16 - 1.33)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	11.48 (7.93 - 16.62)	8.63 (5.13 - 14.52)	18.21 (8.69 - 38.16)	12.58 (4.72 - 33.53)	3.73 (0.77 - 17.97)	3.47 (0.97 - 12.45)
Week 1	0.69 (0.35 - 1.35)	0.60 (0.24 - 1.54)	1.41 (0.45 - 4.38)	0.57 (0.07 - 4.60)	No events	0.77 (0.17 - 3.50)
Week 2	0.96 (0.55 - 1.68)	0.63 (0.26 - 1.49)	1.53 (0.54 - 4.35)	0.91 (0.19 - 4.31)	1.02 (0.21 - 4.90)	0.33 (0.04 - 2.57)
Week 3	1.33 (0.82 - 2.19)	0.96 (0.46 - 1.99)	2.17 (0.85 - 5.51)	0.45 (0.06 - 3.63)	2.02 (0.59 - 6.93)	1.01 (0.28 - 3.61)
Week 4	1.23 (0.73 - 2.07)	0.88 (0.41 - 1.90)	1.36 (0.44 - 4.23)	0.97 (0.21 - 4.57)	1.63 (0.42 - 6.35)	0.37 (0.05 - 2.90)
Rest of AD episode	0.64 (0.45 - 0.90)	0.60 (0.38 - 0.93)	1.13 (0.56 - 2.27)	0.31 (0.12 - 0.81)	0.39 (0.12 - 1.24)	0.48 (0.18 - 1.25)
Wash-out 1 (+ 1 month)	0.28 (0.16 - 0.48)	0.39 (0.21 - 0.72)	0.47 (0.18 - 1.26)	0.13 (0.02 - 1.01)	0.27 (0.05 - 1.29)	0.09 (0.01 - 0.69)
Wash-out 2 (+ 2 months)	0.32 (0.19 - 0.55)	0.28 (0.14 - 0.56)	0.41 (0.14 - 1.17)	0.26 (0.05 - 1.21)	0.14 (0.02 - 1.13)	0.43 (0.15 - 1.25)
Wash-out 3 (+ 3 months)	0.19 (0.12 - 0.31)	0.18 (0.11 - 0.30)	0.41 (0.21 - 0.81)	0.35 (0.16 - 0.79)	0.23 (0.09 - 0.60)	0.35 (0.17 - 0.73)

†Number of events in young people taking antidepressant

eTable 3: Incidence Rate Ratios (IRRs) for suicidal ideation for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 458 events† IRR (95% CI)	fluoxetine 240 events† IRR (95% CI)	citalopram 108 events† IRR (95% CI)	sertraline 36 events† IRR (95% CI)	paroxetine 41 events† IRR (95% CI)	TCAs 81 events IRR (95% CI)
Unexposed	0.07 (0.05 - 0.10)	0.06 (0.04 - 0.09)	0.14 (0.06 - 0.32)	0.13 (0.05 - 0.34)	0.06 (0.02 - 0.18)	0.09 (0.05 - 0.18)
Pre-exposure 1 (- 4 months)	0.29 (0.15 - 0.54)	0.17 (0.07 - 0.44)	0.75 (0.24 - 2.35)	0.36 (0.07 - 1.79)	0.21 (0.02 - 1.77)	0.15 (0.03 - 0.68)
Pre-exposure 2 (- 3 months)	0.45 (0.26 - 0.77)	0.31 (0.15 - 0.65)	0.87 (0.29 - 2.59)	0.55 (0.14 - 2.20)	0.40 (0.08 - 2.09)	0.30 (0.10 - 0.90)
Pre-exposure 3 (-2 months)	0.76 (0.48 - 1.19)	0.56 (0.31 - 1.02)	1.27 (0.47 - 3.41)	1.07 (0.35 - 3.33)	0.98 (0.28 - 3.38)	0.21 (0.06 - 0.74)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	33.41 (23.56 - 47.39)	25.34 (16.34 - 39.31)	71.07 (31.77 - 159.01)	8.43 (2.37 - 29.93)	20.90 (6.83 - 64.01)	14.00 (6.81 - 28.75)
Week 1	0.38 (0.13 - 1.05)	0.43 (0.13 - 1.40)	0.61 (0.07 - 4.95)	No events	No events	0.59 (0.13 - 2.59)
Week 2	0.57 (0.26 - 1.27)	0.25 (0.06 - 1.03)	0.52 (0.06 - 4.23)	1.20 (0.24 - 5.96)	No events	0.25 (0.03 - 1.91)
Week 3	1.56 (0.91 - 2.68)	1.24 (0.60 - 2.53)	4.17 (1.51 - 11.51)	No events	1.49 (0.29 - 7.70)	1.03 (0.34 - 3.13)
Week 4	0.98 (0.51 - 1.91)	1.23 (0.58 - 2.59)	0.55 (0.07 - 4.50)	0.62 (0.07 - 5.16)	No events	0.84 (0.24 - 2.94)
Rest of AD episode	0.72 (0.49 - 1.08)	0.49 (0.29 - 0.82)	1.40 (0.58 - 3.37)	0.47 (0.16 - 1.35)	1.30 (0.43 - 3.90)	0.52 (0.20 - 1.35)
Wash-out 1 (+ 1 month)	0.40 (0.23 - 0.70)	0.38 (0.20 - 0.75)	0.27 (0.06 - 1.31)	0.33 (0.07 - 1.66)	0.20 (0.02 - 1.72)	0.43 (0.16 - 1.11)
Wash-out 2 (+ 2 months)	0.12 (0.06 - 0.29)	0.13 (0.04 - 0.36)	0.55 (0.16 - 1.88)	0.34 (0.07 - 1.73)	0.57 (0.14 - 2.42)	0.27 (0.09 - 0.83)
Wash-out 3 (+ 3 months)	0.20 (0.12 - 0.33)	0.15 (0.08 - 2.73)	0.50 (0.21 - 1.18)	0.07 (0.02 - 0.21)	0.08 (0.02 - 0.27)	0.13 (0.06 - 0.27)

†Number of events in young people taking antidepressant

Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis

Linda PMM Wijlaars¹, doctoral student,
Irwin Nazareth¹, professor of Primary Care and Population Science,
Heather J Whitaker², lecturer in statistics,
Stephen JW Evans³, professor of pharmacoepidemiology,
Irene Petersen¹, senior lecturer in epidemiology and medical statistics

1. Department of Primary Care and Population Health
University College London Medical School
Royal Free Campus
Rowland Hill Street
London
NW3 2PF
2. Department of Mathematics and Statistics
The Faculty of Mathematics, Computing and Technology
The Open University
Walton Hall
Milton Keynes
Buckinghamshire
MK7 6AA
3. Department of Medical Statistics
London School of Hygiene and Tropical Medicine
Keppel Street
London
WC1E 7HT

Correspondence to: Linda PMM Wijlaars (linda.wijlaars.10@ucl.ac.uk), contact address as above

Abstract

Objectives: We aimed to examine the temporal association between SSRI and tricyclic antidepressant (TCA) prescriptions and suicide ~~e-related events~~al-behaviour in children and adolescents.

Design: Self-controlled case series.

Setting: Electronic health records were used from 479 general practices in The Health Improvement Network (THIN) UK primary care database from 1995 to 2009.

Participants: 81 young people aged 10-18 years with a record of completed suicide, 1,496 who attempted suicide, 1,178 with suicidal ideation and 2,361 with intentional self-harm.

Main outcome measures: Incidence Rate Ratios (IRRs) for completed and attempted suicide, suicidal ideation and intentional self-harm.

Results: For non-fatal suicide-related behaviour, IRRs were similar for the time the person was prescribed either SSRIs or TCAs: IRRs increased during pre-exposure, peaked on prescription day, were stable up to the fourth prescription-week, and decreased after prescriptions stopped. For both types of antidepressants, IRRs were lower or similar to pre-exposure levels during the period of prescription. For SSRIs, there was an increase in the IRR for completed suicide on the day of prescription (N=5; IRR=42.5, 95% CI: 4.5 to 403.4), and during the fourth week of SSRI prescription (N=2; IRR=11.3, 95% CI: 1.1 to 115.6).

Conclusions: Overall, there are no systematic differences between the association of TCAs and SSRIs with incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm, and apart from the day of prescription, rates did not exceed pre-exposure levels.

The pattern of ~~death from~~IRR for suicide for SSRIs was similar to that found in non-fatal suicide-related ~~events~~behaviour. Our results warrant a re-evaluation of the current prescribing of SSRIs in young people. We recommend the creation of a pragmatic registry for active pharmacovigilance.

Article summary

Article focus

- There has been concern that selective serotonin reuptake inhibitors (SSRIs) might be associated with an increased risk of suicide ~~e-related events at thinking and behaviour~~ in young people.
- We assess the temporal association between the risk of completed suicide, attempted suicide, suicidal ideation, intentional self-harm and antidepressant prescribing, comparing SSRIs and tricyclic antidepressants (TCAs) in adolescents using a large UK primary care database.

Key messages

- There are no systematic differences between the association of TCAs and SSRIs with incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm
- ~~We recommend the creation of a pragmatic registry that will allow for active pharmacovigilance at low cost and with no additional burden on clinician, health service or patient time, and which will facilitate long term, anonymous, unobtrusive follow-up for major clinical outcomes.~~
- Up to the fourth week of prescription, the IRRs for attempted suicide, suicidal ideation and self-harm remained around the levels experienced during the pre-exposure period, suggesting on-going close monitoring in the first month is important.

Strengths and limitations of this study

- The self-controlled case series method inherently controls for time-independent variables such as genetics, location and socio-economic status
- Changes in depression severity are poorly recorded over time, which is a limitation.

Introduction

Between 1-6% of adolescents in the community suffer from major depressive disorder¹. In addition, suicide is the third leading cause of death in 15-19 year olds at 6.9 per 100,000 population, and fourth for 10-14 year olds at 0.9 per 100,000 population². This calls for safe and effective depression treatments in this age group. As tricyclic antidepressants (TCAs) appear to lack efficacy for depression treatment in this age group, and have a poor side effect profile³, selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed pharmacological treatment for children and adolescents⁴.

However, there has been concern that SSRIs might be associated with an increased risk of suicidal behaviour e-related events in paediatric patients. Results from clinical trials led the Expert Working Group of the Committee on Safety of Medicines (CSM) to advise against initiation of treatment with selective serotonin inhibitors (SSRIs) for childhood depression in the UK in December 2003⁵. Fluoxetine, the only drug which is licensed to treat depression in young people in the UK, was exempted from this advice following review that concluded there was a favourable balance of benefits and risk⁶. The US Food and Drug Administration (FDA) issued similar advice in 2004⁷.

There is inconsistent evidence of an increased rate of suicide-related events suicidal behaviour—and intentional self-harm associated with SSRIs⁸. Data from randomized controlled trials in adolescents and young adults report an increased risk of suicide-related eventssuicidal behaviour⁹. Part of this difference appears to depend on the methodology used. If suicide-related events suicidal behaviour was were ascertained using the method of “adverse events” there was a small but significant increase in suicidal ideation. However, if

1
2
3 the studies used rating scales to assess suicide-related events~~suicidal behaviours~~, most studies
4
5 showed an improvement in suicide-related events~~suicidal behaviours~~.
6

7
8 The results from these trials should be interpreted with caution as they were not primarily
9
10 designed to measure suicide-related events~~suicidal behaviour~~ and it would be unethical to do
11
12 so using placebo as a control^{10;11}. Moreover, none of these trials on SSRIs recruited from a
13
14 general population setting and completed suicides have not occurred in any studies⁹.

15
16 Observational studies in young people have found mixed results: some indicate that SSRIs
17
18 protect from suicide-related events~~suicidal behaviour~~¹²; others find no effect^{13;14}; or an
19
20 increase in risk of suicide-related events~~suicidal behaviour~~^{15;16}. These studies, however, have
21
22 methodological limitations including small numbers, high attrition rates and, most
23
24 importantly, confounding by severity. Given the risk of death in overdose, the lack of
25
26 efficacy in children, and the side effects associated with them, a prescriber would be less
27
28 likely to prescribe tricyclic antidepressants (TCA) in preference to SSRIs for a person at risk
29
30 of suicide-related events~~suicidal behaviour~~¹⁷.
31
32
33
34
35

36
37 We have previously shown rates for SSRI prescriptions in children and adolescents increased
38
39 between 2005-2009⁴. Neither TCAs nor SSRIs are considered appropriate first line treatment
40
41 by the National Institute for Clinical Excellence (NICE) for depression in children and
42
43 adolescents. Only when children and adolescents are not responding to psychological
44
45 treatment should treatment with SSRIs be considered⁶. It is therefore important to reassess the
46
47 risks of existing clinical data to inform future practice. We aimed to assess the temporal
48
49 association between the risk of completed suicide, attempted suicide, suicidal thoughts,
50
51 intentional self-harm and antidepressant prescribing in adolescents, comparing SSRIs and
52
53 TCAs and correcting for age and sex, using a large UK primary care database.
54
55
56
57
58
59
60

Methods

Data Source

We used data from The Health Improvement Network (THIN) primary care database, including information from UK primary care data prospectively recorded between 1 January 1995 and 31 December 2009. THIN includes anonymised general practice records on more than 9 million patients from 479 practices in the United Kingdom and is one of the largest primary care databases available internationally. It is broadly representative of the UK general practice population in terms of demographics and consultation behaviour¹⁸. Data on diagnoses, interventions, symptoms, and referrals to secondary care are electronically recorded as Read Codes, a hierarchical coding system used in UK primary care¹⁹. All prescriptions are also electronically recorded. Clinical diagnoses recorded using Read codes have recently been shown to be accurate compared with other reliable sources²⁰.

Study population

This study included a cohort of young people and adolescents, aged 10-18 years who had a recorded suicidal or self-harm event. Patients were included if they were registered with a practice for at least six months between January 1995 and December 2009. Patients were followed up from the latest of the date they registered at the GP, 1 January 1995, or their 10th birthday, until (1) 31 December 2009, (2) their 19th birthday, (3) the date of death, or (4) the date they left the practice.

Measurements

Outcome - We identified completed suicides using relevant Read codes that were confirmed by a date of death within two weeks of the suicide event date. We searched a cause of death if available. The list of codes was an updated version of a published suicide code

1
2
3 list²¹. To make sure we did not miss any suicides, we extracted medical records on all young
4
5 people who died between the ages of 10 and 18 and examined the free text if there was no
6
7 clear cause of death (e.g. childhood cancer or a traffic accident) for possible suicides. We
8
9 excluded cases where there was doubt whether the death was due to suicide (i.e. 12 deaths
10
11 which received an open verdict by the coroner). Of these potential suicides, 1 patient had
12
13 records of TCA prescriptions, while 4 had records of SSRI prescriptions in the last year.
14
15 Suicide attempt, suicidal ideation and self-harm were identified using a Read code list that
16
17 was developed in line with published methods and reviewed by a general practitioner (IN)²².
18
19
20
21
22

23 *Exposure* - We used British National Formulary (BNF) codes representing antidepressants²³.
24
25 We classified antidepressants as TCAs, SSRIs and other antidepressants according to the
26
27 BNF. We excluded TCAs that were prescribed for nocturnal enuresis or neuropathic pain.
28
29 Comparing prescription data in THIN to dispensing data from NHS Prescription Services
30
31 showed that the mean practice redemption rate (the percentage of recorded prescriptions
32
33 which were dispensed) was as high as 96.7% for antidepressants²⁴.
34
35
36
37
38

39 We then identified the separate episodes of antidepressant prescription for each individual.
40
41 To constitute a new episode of antidepressant prescriptions, there had to be a preceding gap
42
43 of at least 3 months of no prescriptions. We choose 3 months as a prescription supply of
44
45 antidepressants is typically 1 month or less, and therefore a gap of at least 3 months between
46
47 prescriptions would likely represent a new episode of antidepressant prescriptions (although
48
49 not necessarily a new episode of depression). If a person switched from one drug to another
50
51 within 3 months, this did not constitute a new episode.
52
53
54
55
56
57
58
59
60

1
2
3 *Covariates* – We extracted information on sex, age and social deprivation score (Townsend
4 quintiles). Patients who were prescribed TCAs for nocturnal enuresis (as confirmed by Read
5 codes) were excluded. Finally, we considered consultation behaviour as a confounder.
6
7 Patients who consult infrequently with their GP, e.g. only when their prescription has run out,
8 might not have correctly timed records of all of their events. To correct for this we conducted
9 a sensitivity analysis where we only included patients who consulted at least once a week
10 during the month after their first antidepressant prescription.
11
12
13
14
15
16
17
18
19

20 **Statistical analysis**

21
22 *The Self-Controlled Case Series (SCCS) method* - We calculated incidence rate ratios (IRRs –
23 calculated by dividing the incidence rate in the exposed period by the incidence rate in the
24 control period) for completed suicide and ~~suicide-related events~~ ~~suicidal behaviour~~ using the
25 self-controlled case series (SCCS) method²⁵. The SCCS method was developed to investigate
26 associations between acute outcomes and transient exposures, using only data on cases. Since
27 each case served as his/her own control, the case-series method inherently accounts for
28 confounding factors that do not change over the observation period (such as variables related
29 to genetics, socio-economic status and gender). Using a Poisson model, IRRs can be
30 calculated for any number of pre-defined risk periods associated with the exposure, using the
31 time outside of these risk periods (the time when a subject is unexposed) as reference. A
32 major advantage of the SCCS is that it can have high efficiency relative to the retrospective
33 cohort method from which it is derived. As ~~suicide-related events~~ ~~suicidal behaviour are~~ ~~is~~
34 rare, even in depressed persons, the SCCS method is particularly suited for assessing its
35 association with antidepressants as it requires a much smaller number of persons to be
36 included. Moreover, in using a self-controlled design we circumvent the problem of selecting
37 appropriate controls that cohort or case-control designs encounter. In the case of ~~suicide-~~
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 | related events~~suicidal behaviour~~ and antidepressants this has proven crucial as patients who
4
5 are diagnosed as depressed but don't receive antidepressants might differ from patients who
6
7 are receiving antidepressants in severity of depression, a major confounder in the studied
8
9 association.

10
11 The SCCS method is limited in that it only works for non-recurrent events when the event
12
13 risk is small over the observation period, which is the case for completed suicide. Also, it
14
15 requires variability in the age at the time of event: if all events were to happen at exactly the
16
17 same age (which is not the case in our study), then the method would fail. Finally, the method
18
19 only produces estimates of relative incidence, rather than absolute incidence.
20
21
22
23

24
25 *Suicide attempts, suicidal ideation and self-harm* – For the analyses on suicide attempts,
26
27 suicidal ideation and self-harm we used an adapted version of the standard SCCS method,
28
29 allowing for repeated exposures and events and correcting by 1-year age groups^{25;26}. By
30
31 including a pre-exposure period, we corrected our estimates for event-dependent exposure. If
32
33 the probability of exposure to antidepressants is changed from baseline after an event, it
34
35 follows that the probability of the occurrence of an event is also changed in the immediate
36
37 pre-exposure period. Including a pre-exposure period removes this time from the baseline and
38
39 corrects the estimates accordingly.
40
41
42

43 Subjects who went on to commit suicide were excluded from these analyses. Using the SCCS
44
45 method, the incidence rate ratio for the three outcomes was estimated during 14 different risk
46
47 periods (Figure 1): baseline (or unexposed to antidepressants); four 1-month pre-exposure
48
49 periods, the last of which is the reference; the day of prescription; four 1-week early exposure
50
51 periods; a period of variable length to cover the remainder of the period of exposure to the
52
53 antidepressant for that episode; and three 1-month periods of washout after the end of the
54
55 antidepressant episode. We included the separate 1-week periods at the start of prescription as
56
57
58
59
60

1
2
3 it is known that antidepressants (especially SSRIs) take this amount of time to have an
4 effect²⁷. We also compared the effects of individual antidepressants on the IRR of the three
5
6
7 suicide-related event ~~suicidal behaviour~~ outcomes.
8
9

10
11 *Suicide* - We used an adapted method (SCCS for censored post-event exposures) to assess the
12 effects of antidepressants on childhood suicide as the original approach cannot deal with
13 deaths²⁸. This method takes account of the early cessation of the observation period due to
14 deaths and accordingly corrects the IRR estimates. We corrected for age by creating four age
15 groups: 10-12, 13-14, 15-16 and 17-18 year olds. We estimated IRRs for the same risk
16 periods as for the other outcomes, without the four pre-exposure risk periods and used
17 baseline (time unexposed to antidepressants) as reference.
18
19

20
21 All analyses were conducted with the use of Stata software, version 12.1 (Stata Corp, College
22 Station, Texas). The scheme for THIN to obtain and provide anonymous patient data to
23 researchers was approved by the National Health Service South-East Multicenter Research
24 Ethics Committee (MREC) in 2002 and scientific approval for this study was obtained from
25 CMD Medical Research's Scientific Review Committee in May 2011.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

There was a total follow-up time of 4,190,410 person-years of 10-18-year olds in THIN. In total, 81 young people were identified with a record of a completed suicide, 1,496 young people with a record of attempted suicide, 1,178 young people with a record of suicidal ideation, and 2,361 with a record of intentional self-harm. Of young people with completed suicides, 30% were female, compared to 60%, 73% and 74% of young people with a record of attempted suicide, suicidal ideation, or self-harm, respectively (Table 1). There was no significant difference in age of first event between the different outcomes. The data were complete for all variables except Townsend scores, which were missing for 92 (2%) persons.

Due to small numbers, we were not able to analyse antidepressants other than SSRIs or TCAs.

Attempted suicide, suicidal ideation and self-harm

For attempted suicide, suicidal ideation and self-harm, there were similar patterns between young people that were prescribed SSRIs and TCAs (Table 2 & Figures 2A, B & C): there was an upwards trend in the IRR during pre-exposure; a peak on the day of prescription; a stable or slightly increased rate ratio during the first weeks of prescription; and during the washout period levels decreased again. The increase on prescription day was highest for young people with a record of suicidal ideation (SSRIs: IRR=33.4, 95%CI: 23.6 to 47.4; TCAs: IRR=14.0, 95%CI: 6.8 to 28.8). There were no significant differences between IRRs for any of the behaviour-event types for any risk periods. Patterns were similar between individual SSRIs (fluoxetine, citalopram, sertraline and paroxetine, results in appendix).

The IRR for each type of behaviour-event has a strong relation with age. When compared to 15-16 year olds, 17-18 year olds are twice as likely to attempt suicide (IRR=1.90, 95%CI: 1.6

1
2
3 to 2.3 and IRR=2.1, 95%CI: 1.7 to 2.5 for SSRIs and TCAs, respectively) but those between
4
5 10-12 years old are less likely to attempt suicide (IRR=0.3, 95%CI: 0.2 to 0.4 and IRR=0.2,
6
7 95%CI: 0.1 to 0.2 for SSRIs and TCAs, respectively). Patterns were similar for the other
8
9 outcomes.

10
11
12
13
14 There were no statistically significant differences between boys and girls for either SSRIs or
15
16 TCAs (results not shown). A small group of 25 patients had a prescription for an
17
18 antidepressant and a primary diagnosis other than depression (obsessive compulsive disorder
19
20 (OCD) or anxiety). Due to the small size of this group we did not perform a subgroup
21
22 analysis. Finally, restricting the analyses to regular consulters (those who consulted at least
23
24 five times during the first four weeks of prescription) did not alter effect estimates. Of the
25
26 young people with a record of attempted suicide or intentional self-harm, 33% were regular
27
28 consulters, compared to 49% of young people with a record of suicidal ideation.
29
30
31
32
33

34 **Suicide**

35
36 Using an expected suicide rate of 3.28 (95%CI: 3.12 to 3.43) per 100,000 person-years in the
37
38 UK population of 10-18-year olds ²⁹, we would expect 137 (95%CI: 131 to 144) completed
39
40 suicides in our study population. However, 41% of suicides registered by the Office of
41
42 National Statistics (ONS) were of undetermined intent, leaving 59% or 81 (95%CI: 77 to 85)
43
44 expected suicides that received a verdict by a coroner. This estimate corresponds to the
45
46 number of 81 completed suicides we identified between 1995 and 2009 within the THIN
47
48 database. Of the 81 young people with a completed suicide, 21 (26%) had a prior record of a
49
50 depression diagnosis or depression symptoms. Nineteen young people (23%) were taking
51
52 antidepressants in the year before their suicide, and 11 (14%) were still taking them at the
53
54 time of, or shortly before their suicide. There was also a high proportion of young people
55
56
57
58
59
60

1
2
3 with (a history of) behaviour disorders 16 (20%), history of self-harm 8 (10%), a psychiatric
4
5 referral 19 (23%), a hyperkinetic disorder 5 (6%) or eating disorder 3 (4%).
6
7

8
9
10 There were no completed suicides within the risk periods for antidepressants other than
11
12 SSRIs (Table 3). Eleven (14%) completed suicides were within the risk periods. Similar to
13
14 the results from the data on suicide-related events~~suicidal behaviour~~, the IRR was highest on
15
16 the day of prescription (IRR=42.5, 95%CI: 4.5 to 403.4). There were no events in the first
17
18 two weeks of the SSRI episode, but there was an increased rate ratio in week three (IRR=8.0,
19
20 95%CI: 0.8 to 76.7, based on a single case) and a statistically significant increase in week 4
21
22 (IRR=11.3, 95%CI: 1.1 to 115.6, though based on two cases). After the fourth week of the
23
24 SSRI episode, the IRR decreased and returned to baseline levels during wash-out. There were
25
26 no significant differences between age groups.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Overall, there are no systematic differences between TCAs and SSRIs in incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm, and apart from an increase common to both TCAs and SSRIs on the day of prescription, rates were not statistically significantly different from pre-exposure levels. The pattern of incidence risk ratios for completed suicides for the 11 people prescribed SSRIs was similar to that found in attempted suicide, suicidal ideation and self-harm. However, concerns regarding antidepressants need to be weighed against the risk of untreated depression.

Pre-exposure IRRs for attempted suicide, suicidal ideation and self-harm appeared to be marginally higher, though not statistically significant, for SSRIs compared to TCAs. This could be because young people who are deemed to be more at risk of suicide-related events ~~suicidal behaviour~~ could preferentially be prescribed SSRIs over TCAs, given TCAs' toxicity in overdose¹⁷.

The high IRRs on the day of antidepressant prescription for all three non-fatal outcomes could be an artefact of GP recording behaviour. Rather than the antidepressant causing the suicide-related events ~~self-harming behaviour~~, the self-harming behaviour ~~event~~ is an indication for the GP to prescribe the drug and to record depression in the electronic records on the same day. As antidepressants should only be prescribed by child & adolescent psychiatrists (2005 NICE guidelines⁶), this artefact could also arise when GPs continue a prescription started in secondary care and record the initial indication when first prescribing this drug.

Up to the fourth week of prescription, the IRRs for attempted suicide, suicidal ideation and self-harm remained around the levels experienced during the pre-exposure period.

Considering that suicide-related events are ~~suicidal behaviour is~~ common in young depressed

1
2
3 people, some suicidal and self-harm events would be expected irrespective of whether SSRIs
4
5 are prescribed or not³⁰. The ~~suicide-related events suicidal behaviour~~ decreased when the
6
7 prescriptions were stopped. Given the nature of the data, it is difficult to know whether the
8
9 SSRIs were causing ~~suicide-related events suicidal behaviour~~ and these ~~behaviours events~~
10
11 improved when the SSRIs were discontinued, or if the SSRIs were discontinued when the
12
13 ~~child's young person's~~ depression (and as a consequence the ~~risk of suicide-related~~
14
15 ~~eventssuicidal behaviour~~) improved.
16
17

18
19 There are three possible explanations for the slightly increased IRRs during the first month of
20
21 prescription. One is that SSRIs fail to relieve the ~~risk of suicide-related eventssuicidal~~
22
23 ~~behaviour~~ associated with depression because of a lag in antidepressant effect, an incomplete
24
25 response, or a treatment-resistant depression. It is known that SSRIs take a couple of weeks
26
27 to reach their full antidepressant effects and hence reduce the risk of ~~suicide-related~~
28
29 ~~eventssuicidal behaviour~~²⁷.
30
31

32
33 A second possibility is that the SSRIs generate a novel set of suicidal emotions or behaviours.
34
35 Early improvements in clinical depression can lead to a person acting on existing suicidal
36
37 feelings. This activation syndrome has been described for both TCAs and SSRIs, and is
38
39 widely recognized by psychiatrists, as well as the FDA^{31;32}. While patients might be
40
41 demotivated and demoralized at the height of their depression, when they start treatment they
42
43 become more active during the first weeks of taking the drug. During this time the
44
45 antidepressant effect of the medication will not have reached its full effect resulting in
46
47 persistent depression but simultaneous increased activity. This could lead to a greater risk of
48
49 ~~suicide-related events suicidal behaviour~~ until the full effects of antidepressants are realized
50
51 few weeks later³¹.
52
53

54
55 Several studies and systematic reviews have shown an age effect in the risk of
56
57 ~~suicide-related events suicidal behaviour~~ with the use of SSRIs. In adults and the elderly the
58
59
60

1
2
3 risk is neutral or SSRIs show a protective effect, while in adolescents and young adults there
4
5 appears to be an increased risk of ~~suicide-related events~~~~suicidal behaviour~~^{9;15;33}.

6
7 Although we did not find a statistically significant sustained increase in ~~suicide-~~
8 ~~related events~~ ~~suicidal behaviour~~ with either SSRIs or TCAs, negative outcomes did not
9
10 appear to be decreased either – although our study was not designed to assess this. This is in
11
12 line with Cochrane reviews on both drug groups: the review on tricyclic antidepressants
13
14 concludes that these drugs are not useful in treating depression in pre-pubertal children, and
15
16 that there is only marginal evidence to support the use of TCAs in adolescents, although the
17
18 magnitude of the effect is likely to be moderate at best³⁴. Similarly, it is unclear what the
19
20 effect is of SSRIs on suicide completion. Although evidence from clinical trials implies an
21
22 increased risk of suicide-related outcomes (but not completed suicide), the evidence for this
23
24 association is of low quality³⁵.

31 32 **Comparison to other studies**

33
34 Our results build on the findings of Schneeweis et al.¹³. They found no statistically significant
35
36 differences in relative risk for attempted and completed suicide between different types of
37
38 antidepressants (fluoxetine, citalopram, fluvoxamine, paroxetine, sertraline and TCAs) when
39
40 examining 266 attempted and 3 completed suicides. Moreover, an ecological study found no
41
42 change in rates of completed suicides or hospital admissions for self-harm following the
43
44 CSM advice³⁶, suggesting there is no, or only a weak, relationship with antidepressant
45
46 prescriptions. Our findings are also similar to those of Simon et al.³⁷ who used computerised
47
48 health plan records and report the highest rates for attempted suicide in the month before
49
50 prescription, rather than after start of the prescription. Finally, a meta-analysis³⁸ found that, of
51
52 27 paediatric RCTs on antidepressants prescribed for major depressive disorder (MDD),
53
54 ~~obsessive compulsive disorder (OCD)~~ and non-OCD anxiety disorders, the risk of suicidal
55
56
57
58
59
60

1
2
3 ideation or attempt among patients on placebo was greater in trials assessing MDD. Although
4
5 this difference in baseline risk for suicide-related events~~suicidal thinking and behaviour~~ was
6
7 not statistically significant, it could indicate part of the association between antidepressants
8
9 and suicide-related events~~suicidal thinking and behaviour~~ can be explained by the underlying
10
11 disease, rather than the drug. Importantly, the authors concluded that relative to placebo, the
12
13 benefits (though only modest in MDD) outweigh the risks from suicidal ideation/suicide
14
15 attempts. Due to small numbers of patients with primary diagnoses of OCD and anxiety
16
17 disorders, we could not repeat the meta-analysis' sub-group comparison.
18
19
20
21
22

23 **Main strength and limitations**

24
25 The main strength of this study is its sample size that enables examination of outcomes
26
27 separately by completed and attempted suicide, suicidal ideation and self-harm, and by
28
29 individual antidepressants. However, even in using a database as large as THIN, we could
30
31 identify only a small number of completed suicides, leading to limited power in that analysis.
32
33 Similarly, power was limited for analysing individual antidepressants, which are presented in
34
35 the appendix. Nevertheless, the use of the SCCS method allows us to control for time-
36
37 independent confounders, making our estimations more robust.
38
39

40
41 A limitation to our study is that the THIN database only provides data on antidepressant
42
43 prescriptions. We do not know whether prescriptions were dispensed, or whether patients
44
45 adhered to prescription. However, though it is known that adherence levels are around 50%
46
47 for young people taking SSRIs, and even lower for TCAs³⁹, our data does represent a real-life
48
49 situation. Moreover, by assessing episodes of antidepressant prescription, we take account of
50
51 multiple prescriptions per patient, which increases the likelihood of adherence as we expect
52
53 patients who are not taking their medication would not come back for a new prescription.
54
55
56
57
58
59
60

1
2
3 Moreover, it is known that suicide-related events are suicidal behaviour is often missed in
4 clinical assessment⁴⁰. However, it is likely that the most severe forms (attempted suicides and
5 severe suicidal ideation) are most likely to be recorded by clinicians. Also, in using a self-
6 controlled design, we decrease the chance of misclassifying controls. There is some
7 suggestion that antidepressants might specifically increase suicide-related events suicidal
8 thinking and behaviour in patients who did not experience these behaviours events prior to
9 starting antidepressant treatment. Due to variation in clinicians' assessment and recording of
10 (the absence of) suicide-related events suicidal thinking and behaviour, we could not examine
11 this hypothesis using this database. Finally, we were not able to account for changes in
12 depression severity over time as this is poorly recorded.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 Conclusion

28
29 Our study shows that there are similar incidence rate ratio patterns for attempted suicide,
30 suicidal ideation and self-harm for SSRIs and TCAs. Also, the pattern for completed suicides
31 associated with SSRI prescriptions is similar, though there are no records of completed
32 suicides within our pre-defined risk periods for TCAs. Although the CSM's warning was a
33 sensible cautionary recommendation at the time, it appears that the current line of evidence
34 suggests a reverse causality: it is the underlying depression that leads to suicide-related
35 events suicidal behaviour and the prescribing of antidepressants, although a causal effect of
36 SSRIs, or no effect at all cannot be ruled out. Moreover, even if antidepressant drugs would
37 temporarily increase the risk of suicide-related events suicidal behaviour in young persons,
38 the risk untreated depression poses is far greater. In conclusion, our results indicate that the
39 association of suicide-related events suicidal behaviour associated with antidepressants
40 occurs primarily around the day of prescription, suggesting depression severity and GP
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 recording behaviour as the culprit rather than antidepressants, and thus warrant a re-
4
5 evaluation of the current guidelines regarding the prescription of SSRIs in primary care.
6
7
8

9 10 **Recommendation**

11
12 Our results are not definitive, and due to the rare nature of the outcome and the intricacies of
13
14 the problem studied, it is difficult to think of a single study or study design that will be able to
15
16 provide a satisfying answer to the problem at hand. It is possible that the creation of a
17
18 pragmatic registry, similar to that proposed by van Staa and colleagues in their pragmatic
19
20 randomised trial⁴¹, will allow for active pharmacovigilance. Such a system would at low cost
21
22 and with no additional burden on clinician, health service or patient time, facilitate long term,
23
24 anonymous, unobtrusive follow-up for major clinical outcomes. As such, clinicians would be
25
26 prompted to monitor and record (the absence of) suicide-related events ~~suicidal behaviour~~
27
28 and ideation more regularly and closely, using similar outcome measurements as those used
29
30 in clinical trials, as well as (changes in) depression severity.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We would like to thank the general practitioners who contributed data to THIN.

Contributors All authors were responsible for study conception and design. LPW was responsible for data analysis. LPW authors drafted the manuscript. All authors participated in the interpretation of data, critical revision and final approval of the manuscript.

Funding statement: The work was supported by a PhD studentship from the National Institute of Health Research English National School for Primary Care Research. The funding organisation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; and preparation, review or approval of the manuscript.

Competing interests statement: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: LPMMW had financial support in the form of a studentship from the National Institute of Health Research English National School for Primary Care Research for the submitted work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data sharing: Examples of statistical code used for the self-controlled case series method (including the adapted method for dealing with censored data) are available from the [Open University website](#). Statistical code is available from the corresponding author.

References

- 1
2
3
4
5 (1) Kessler RC, Avenevoli S, Ries Merikangas K. Mood disorders in children and
6 adolescents: an epidemiologic perspective. *Biological Psychiatry* 2001; 49(12):1002-
7 1014.
- 8
9
10 (2) Heron M. Deaths: leading causes for 2007. *National vital statistics reports* 2011;
11 59(8):1-95.
- 12
13 (3) Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drug for depression in
14 children and adolescents. *Cochrane Database Syst Rev* 2002;(4).
- 15
16 (4) Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant
17 prescribing in children and adolescents: A cohort study in The Health Improvement
18 Network (THIN). *PLoS One* 2012.
- 19
20 (5) Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and
21 suicide in adults: meta-analysis of drug company data from placebo controlled,
22 randomised controlled trials submitted to the MHRA's safety review. *BMJ* 2005;
23 330(7488):385.
- 24
25 (6) National Institute for Health and Clinical Excellence. CG28 Depression in children
26 and young people: NICE guideline. 2005. London, National Institute for Health and
27 Clinical Excellence.
- 28
29 (7) FDA. Suicidality in Children and Adolescents Being Treated With Antidepressant
30 Medications. US Food and Drug Administration [2004 [cited 2011 June 29];
31 Available from: URL:
32 [http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsa
33 ndProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisorie
34 s/ucm161679.htm](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679.htm)
- 35
36 (8) Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E.
37 Selective serotonin reuptake inhibitors in childhood depression: systematic review of
38 published versus unpublished data. *The Lancet* 2004; 363(9418):1341-1345.
- 39
40 (9) Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with
41 antidepressant drugs. *Arch Gen Psychiatry* 2006; 63(3):332-339.
- 42
43 (10) Rothman KJ, Michels KB. The continuing unethical use of placebo controls. *N Engl J*
44 *Med* 1994; 331(6):394-398.
- 45
46 (11) Grosso A, Douglas I, MacAllister R, Petersen I, Smeeth L, Hingorani AD. Use of the
47 self-controlled case series method in drug safety assessment. *Expert Opin Drug Saf*
48 2011; 10(3):337-340.
- 49
50 (12) Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA et al. Early
51 evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and
52 suicide in children and adolescents. *Am J Psychiatry* 2007; 164(9):1356-1363.
- 53
54
55
56
57
58
59
60

- 1
2
3 (13) Schneeweiss S, Patrick AR, Solomon DH, Dormuth CR, Miller M, Mehta J et al.
4 Comparative safety of antidepressant agents for children and adolescents regarding
5 suicidal acts. *Pediatrics* 2010; 125(5):876-888.
6
- 7 (14) Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. *JAMA*
8 2004; 292(3):338-343.
9
- 10 (15) Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely
11 depressed children and adults - A case-control study. *Arch Gen Psychiatry* 2006;
12 63(8):865-872.
13
- 14 (16) Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal Thoughts and Behavior
15 With Antidepressant Treatment: Reanalysis of the Randomized Placebo-Controlled
16 Studies of Fluoxetine and Venlafaxine. *Arch Gen Psychiatry* 2012;archgenpsychiatry.
17
- 18 (17) Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following
19 prescription of SSRIs and other antidepressants: confounding by indication. *Br J Clin*
20 *Pharmacol* 2005; 60(5):519-525.
21
- 22 (18) Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a
23 quality-evaluated database of primary care data. *Inform Prim Care* 2004; 12(3):171-
24 177.
25
- 26 (19) Booth N. What are the Read Codes? *Health Libr Rev* 1994; 11(3):177-182.
27
- 28 (20) Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General
29 Practice Research Database: a systematic review. *Br J Gen Pract* 2010; 60(572):e128-
30 e136.
31
- 32 (21) Arana A, Wentworth CE, yuso-Mateos JL, Arellano FM. Suicide-related events in
33 patients treated with antiepileptic drugs. *N Engl J Med* 2010; 363(6):542-551.
34
- 35 (22) Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary
36 care databases. *Pharmacoepidemiology and drug safety* 2009; 18(8):704-707.
37
- 38 (23) British National Formulary. 60 ed. London: BMJ group; RPS Publishing; 2010.
39
- 40 (24) The NHS Information Centre PaPCS. Prescription compliance: a review of the
41 proportion of prescriptions dispensed. 7-9-2011.
42
- 43 (25) Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the
44 self-controlled case series method. *Stat Med* 2006; 25(10):1768-1797.
45
- 46 (26) Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case
47 series studies. *Stat Methods Med Res* 2009; 18(1):7-26.
48
- 49 (27) Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective
50 serotonin reuptake inhibitor antidepressant action: systematic review and meta-
51 analysis. *Arch Gen Psychiatry* 2006; 63(11):1217-1223.
52
- 53 (28) Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored,
54 perturbed, or curtailed post-event exposures. *Biostatistics* 2009; 10(1):3-16.
55
56
57
58
59
60

- 1
2
3 (29) Windfuhr K, While D, Hunt I, Turnbull P, Lowe R, Burns J et al. Suicide in juveniles
4 and adolescents in the United Kingdom. *J Child Psychol Psychiatry* 2008;
5 49(11):1155-1165.
6
7 (30) Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. *J*
8 *Child Psychol Psychiatry* 2006; 47(3-4):372-394.
9
10 (31) Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A et al.
11 Antidepressant-induced jitteriness/anxiety syndrome: systematic review. *Br J*
12 *Psychiatry* 2009; 194(6):483-490.
13
14 (32) Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL.
15 Suicidality as a possible side effect of antidepressant treatment. *J Clin Psychiatry*
16 2004; 65(6):742-749.
17
18 (33) Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of
19 suicide: a systematic review of observational studies. *CMAJ* 2009; 180(3):291-297.
20
21 (34) Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drug for depression in
22 children and adolescents. *Cochrane Database Syst Rev* 2010;(4).
23
24 (35) Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation
25 antidepressants for depressive disorders in children and adolescents. *Cochrane*
26 *Database of Systematic Reviews* 2012.
27
28 (36) Wheeler BW, Gunnell D, Metcalfe C, Stephens P, Martin RM. The population impact
29 on incidence of suicide and non-fatal self harm of regulatory action against the use of
30 selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological
31 study. *BMJ* 2008; 336(7643):542-545.
32
33 (37) Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant
34 treatment. *Am J Psychiatry* 2006; 163(1):41-47.
35
36 (38) Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA et al. Clinical
37 response and risk for reported suicidal ideation and suicide attempts in pediatric
38 antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA* 2007;
39 297(15):1683-1696.
40
41 (39) Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP et al.
42 Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic
43 antidepressants: comparison of drug adherence. *Cochrane Database Syst Rev*
44 2000;(4):CD002791.
45
46 (40) Fitzpatrick C, Abayomi NN, Kehoe A, Devlin N, Glackin S, Power L et al. Do we
47 miss depressive disorders and suicidal behaviours in clinical practice? *Clinical Child*
48 *Psychology and Psychiatry* 2012; 17(3):449-458.
49
50 (41) van Staa T, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A et al.
51 Pragmatic randomised trials using routine electronic health records: putting them to
52 the test. *BMJ* 2012; 344.
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1: Risk periods included in self-controlled case series analysis for attempted suicide, suicidal ideation and self-harm and suicide. 1 = baseline; 2-5 = 1-month pre-exposure periods; 6 = prescription day; 7-10 = four 1-week exposure periods; 11 = remainder of antidepressant exposure; 12-14= three 1-month washout periods

Figure 2A, B, C: IRR for A) attempted suicide, B) suicidal ideation and C) self-harm for tricyclic antidepressants (TCAs) and selective serotonin inhibitors (SSRIs). The month before a prescription was issued (pre-exposure 4) was used as the reference.

TABLES

Table 1: Demographics by category of suicidal or self-harming behaviour

	Completed suicide 81	Attempted suicide 1496	Suicidal ideation 1178	Self-harm 2361	General population 952892
Girls (%)	24 (29.6)	1089 (72.8)	708 (60.1)	1752 (74.2)	461610 (48.4)
# taking ADs (%)	19 (23.1)	527 (36.6)	578 (52.8)	128 (5.7)	27632 (2.9)
# depressed (%)	21 (25.9)	728 (48.7)	819 (69.5)	173 (7.3)	41101 (4.3)
# Townsend score (%)					
1 (most affluent)	20 (24.7)	266 (17.8)	193 (16.4)	442 (18.7)	227178 (23.8)
2	5 (6.2)	240 (16.0)	202 (17.2)	405 (17.2)	198686 (20.9)
3	13 (16.1)	286 (19.1)	236 (20.0)	452 (19.1)	184934 (19.4)
4	25 (30.9)	364 (24.3)	283 (24.0)	571 (24.2)	169792 (17.8)
5 (most deprived)	16 (19.8)	316 (21.1)	241 (20.5)	446 (18.9)	120116 (12.6)
Median age in years at (first) event (5%-95% percentiles)	16.8 (12.0-18.8)	16.5 (12.9 - 18.7)	16.7 (12.0 - 18.7)	15.9 (12.6 - 18.7)	-
Median time in study in years (5%-95% percentiles)	3.5 (0.2 - 8.4)	5.5 (1.4 - 9.0)	5.9 (1.5 - 9.0)	5.9 (1.5 - 9.0)	-

Table 2: Incidence Rate Ratios (IRRs) for different types of suicidal or self-harming behaviour by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs			TCAs		
	Suicide attempt 423 events† IRR (95% CI)	Suicidal ideation 458 events† IRR (95% CI)	Self-harm 654 events† IRR (95% CI)	Suicide attempt 79 events† IRR (95% CI)	Suicidal ideation 81 events† IRR (95% CI)	Self-harm 118 events† IRR (95% CI)
Unexposed	0.09 (0.07 - 0.13)	0.07 (0.05 - 0.10)	0.12 (0.09 - 0.17)	0.20 (0.09 - 0.46)	0.09 (0.05 - 0.18)	0.15 (0.08 - 0.30)
Pre-exposure 1 (- 4 months)	0.19 (0.10 - 0.38)	0.29 (0.15 - 0.54)	0.37 (0.22 - 0.61)	0.61 (0.18 - 2.10)	0.15 (0.03 - 0.68)	0.29 (0.08 - 1.03)
Pre-exposure 2 (- 3 months)	0.31 (0.17 - 0.53)	0.45 (0.26 - 0.77)	0.59 (0.38 - 0.90)	0.29 (0.06 - 1.39)	0.30 (0.10 - 0.90)	0.09 (0.01 - 0.71)
Pre-exposure 3 (-2 months)	0.62 (0.40 - 0.96)	0.76 (0.48 - 1.19)	0.65 (0.43 - 0.98)	0.14 (0.02 - 1.16)	0.21 (0.06 - 0.74)	0.46 (0.16 - 1.33)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	4.17 (2.44 - 7.12)	33.41 (23.56 - 47.39)	11.48 (7.93 - 16.62)	8.82 (2.79 - 27.82)	14.00 (6.81 - 28.75)	3.47 (0.97 - 12.45)
Week 1	0.79 (0.40 - 1.55)	0.38 (0.13 - 1.05)	0.69 (0.35 - 1.35)	1.18 (0.24 - 5.68)	0.59 (0.13 - 2.59)	0.77 (0.17 - 3.50)
Week 2	0.74 (0.39 - 1.42)	0.57 (0.26 - 1.27)	0.96 (0.55 - 1.68)	1.02 (0.21 - 4.91)	0.25 (0.03 - 1.91)	0.33 (0.04 - 2.57)
Week 3	1.07 (0.61 - 1.86)	1.56 (0.91 - 2.68)	1.33 (0.82 - 2.19)	0.53 (0.06 - 4.29)	1.03 (0.34 - 3.13)	1.01 (0.28 - 3.61)
Week 4	0.52 (0.24 - 1.15)	0.98 (0.51 - 1.91)	1.23 (0.73 - 2.07)	0.57 (0.07 - 4.67)	0.84 (0.24 - 2.94)	0.37 (0.05 - 2.90)
Rest of AD episode	0.53 (0.36 - 0.78)	0.72 (0.49 - 1.08)	0.64 (0.45 - 0.90)	0.38 (0.11 - 1.33)	0.52 (0.20 - 1.35)	0.48 (0.18 - 1.25)
Wash-out 1 (+ 1 month)	0.42 (0.25 - 0.69)	0.40 (0.23 - 0.70)	0.28 (0.16 - 0.48)	0.66 (0.21 - 2.09)	0.43 (0.16 - 1.11)	0.09 (0.01 - 0.69)
Wash-out 2 (+ 2 months)	0.17 (0.09 - 0.35)	0.12 (0.06 - 0.29)	0.32 (0.19 - 0.55)	0.28 (0.06 - 1.33)	0.27 (0.09 - 0.83)	0.43 (0.15 - 1.25)
Wash-out 3 (+ 3 months)	0.15 (0.09 - 0.25)	0.20 (0.12 - 0.33)	0.19 (0.12 - 0.31)	0.41 (0.16 - 1.03)	0.13 (0.06 - 0.27)	0.35 (0.17 - 0.73)

† Number of events in young people taking antidepressants



Table 3: Incidence Rate Ratios (IRRs) for completed suicide by risk period and age



Risk period	Censoring model IRR (95% CI)	# deaths†
Prescription day	42.52 (4.48 – 403.43)	5
Week 1		
Week 2	No events	0
Week 3	8.00 (0.84 – 76.71)	1
Week 4	11.25 (1.09 – 115.58)	2
Rest of AD episode	5.42 (0.57 – 51.94)	1
Wash-out 1	2.27 (0.24 – 21.76)	1
Wash-out2	2.08 (0.22 – 19.69)	1
Age Groups		# total deaths‡
10-12	0.61 (0.21 – 1.77)	8
13-14	1.14 (0.45 – 2.90)	15
15-16	Reference	21
17-18	0.41 (0.12 – 1.39)	37

† Number of suicides during risk periods (only includes youths who were taking antidepressants at the time of suicide, or those who had recently stopped)

‡ Number of suicides by age category

FIGURES





Supplementary Tables

eTable 1: Incidence Rate Ratios (IRRs) for attempted suicide for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 423 events [†] IRR (95% CI)	fluoxetine 198 events [†] IRR (95% CI)	citalopram 111 events [†] IRR (95% CI)	sertraline 39 events [†] IRR (95% CI)	paroxetine 61 events [†] IRR (95% CI)	TCAs 79 events IRR (95% CI)
Unexposed	0.09 (0.07 - 0.13)	0.10 (0.06 - 0.16)	0.08 (0.05 - 0.14)	0.11 (0.04 - 0.31)	0.07 (0.03 - 0.14)	0.20 (0.09 - 0.46)
Pre-exposure 1 (- 4 months)	0.19 (0.10 - 0.38)	0.18 (0.06 - 0.53)	0.26 (0.10 - 0.67)	0.20 (0.02 - 1.71)	0.21 (0.05 - 0.97)	0.61 (0.18 - 2.10)
Pre-exposure 2 (- 3 months)	0.31 (0.17 - 0.53)	0.41 (0.19 - 0.89)	0.20 (0.07 - 0.59)	0.20 (0.02 - 1.70)	0.21 (0.05 - 0.96)	0.29 (0.06 - 1.39)
Pre-exposure 3 (-2 months)	0.62 (0.40 - 0.96)	0.72 (0.38 - 1.37)	0.35 (0.15 - 0.83)	1.19 (0.36 - 3.88)	0.41 (0.13 - 1.30)	0.14 (0.02 - 1.16)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	4.17 (2.44 - 7.12)	5.84 (2.76 - 12.34)	2.02 (0.60 - 6.79)	5.31 (1.03 - 27.37)	3.96 (1.09 - 14.39)	8.82 (2.79 - 27.82)
Week 1	0.79 (0.40 - 1.55)	0.98 (0.37 - 2.59)	0.45 (0.10 - 1.92)	2.64 (0.63 - 11.06)	0.44 (0.06 - 3.45)	1.18 (0.24 - 5.68)
Week 2	0.74 (0.39 - 1.42)	0.50 (0.15 - 1.68)	1.16 (0.47 - 2.90)	0.76 (0.09 - 6.48)	0.38 (0.05 - 2.98)	1.02 (0.21 - 4.91)
Week 3	1.07 (0.61 - 1.86)	1.51 (0.70 - 3.28)	0.57 (0.17 - 1.92)	0.74 (0.09 - 6.33)	1.14 (0.31 - 4.14)	0.53 (0.06 - 4.29)
Week 4	0.52 (0.24 - 1.15)	1.13 (0.46 - 2.79)	0.21 (0.03 - 1.58)	1.65 (0.32 - 8.56)	No events	0.57 (0.07 - 4.67)
Rest of AD episode	0.53 (0.36 - 0.78)	0.65 (0.37 - 1.14)	0.50 (0.25 - 0.98)	1.02 (0.33 - 3.11)	0.30 (0.11 - 0.80)	0.38 (0.11 - 1.33)
Wash-out 1 (+ 1 month)	0.42 (0.25 - 0.69)	0.54 (0.27 - 1.10)	0.43 (0.19 - 0.98)	No events	0.40 (0.13 - 1.30)	0.66 (0.21 - 2.09)
Wash-out 2 (+ 2 months)	0.17 (0.09 - 0.35)	0.18 (0.06 - 0.53)	0.22 (0.07 - 0.63)	No events	0.19 (0.04 - 0.89)	0.28 (0.06 - 1.33)
Wash-out 3 (+ 3 months)	0.15 (0.09 - 0.25)	0.25 (0.13 - 0.46)	0.16 (0.09 - 0.29)	0.27 (0.10 - 0.77)	0.24 (0.10 - 0.57)	0.41 (0.16 - 1.03)

[†]Number of events in young people taking antidepressant

eTable 2: Incidence Rate Ratios (IRRs) for self-harm for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 654 events† IRR (95% CI)	fluoxetine 347 events† IRR (95% CI)	citalopram 151 events† IRR (95% CI)	sertraline 71 events† IRR (95% CI)	paroxetine 55 events† IRR (95% CI)	TCAs 118 events IRR (95% CI)
Unexposed	0.12 (0.09 - 0.17)	0.12 (0.08 - 0.17)	0.19 (0.10 - 0.35)	0.14 (0.06 - 0.31)	0.06 (0.03 - 0.15)	0.15 (0.08 - 0.30)
Pre-exposure 1 (- 4 months)	0.37 (0.22 - 0.61)	0.37 (0.19 - 0.72)	0.43 (0.15 - 1.22)	0.62 (0.20 - 1.91)	0.47 (0.12 - 1.82)	0.29 (0.08 - 1.03)
Pre-exposure 2 (- 3 months)	0.59 (0.38 - 0.90)	0.68 (0.40 - 1.15)	0.58 (0.23 - 1.48)	0.75 (0.26 - 2.18)	0.32 (0.07 - 1.52)	0.09 (0.01 - 0.71)
Pre-exposure 3 (-2 months)	0.65 (0.43 - 0.98)	0.57 (0.33 - 0.99)	0.67 (0.27 - 1.63)	0.88 (0.32 - 2.42)	0.77 (0.24 - 2.44)	0.46 (0.16 - 1.33)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	11.48 (7.93 - 16.62)	8.63 (5.13 - 14.52)	18.21 (8.69 - 38.16)	12.58 (4.72 - 33.53)	3.73 (0.77 - 17.97)	3.47 (0.97 - 12.45)
Week 1	0.69 (0.35 - 1.35)	0.60 (0.24 - 1.54)	1.41 (0.45 - 4.38)	0.57 (0.07 - 4.60)	No events	0.77 (0.17 - 3.50)
Week 2	0.96 (0.55 - 1.68)	0.63 (0.26 - 1.49)	1.53 (0.54 - 4.35)	0.91 (0.19 - 4.31)	1.02 (0.21 - 4.90)	0.33 (0.04 - 2.57)
Week 3	1.33 (0.82 - 2.19)	0.96 (0.46 - 1.99)	2.17 (0.85 - 5.51)	0.45 (0.06 - 3.63)	2.02 (0.59 - 6.93)	1.01 (0.28 - 3.61)
Week 4	1.23 (0.73 - 2.07)	0.88 (0.41 - 1.90)	1.36 (0.44 - 4.23)	0.97 (0.21 - 4.57)	1.63 (0.42 - 6.35)	0.37 (0.05 - 2.90)
Rest of AD episode	0.64 (0.45 - 0.90)	0.60 (0.38 - 0.93)	1.13 (0.56 - 2.27)	0.31 (0.12 - 0.81)	0.39 (0.12 - 1.24)	0.48 (0.18 - 1.25)
Wash-out 1 (+ 1 month)	0.28 (0.16 - 0.48)	0.39 (0.21 - 0.72)	0.47 (0.18 - 1.26)	0.13 (0.02 - 1.01)	0.27 (0.05 - 1.29)	0.09 (0.01 - 0.69)
Wash-out 2 (+ 2 months)	0.32 (0.19 - 0.55)	0.28 (0.14 - 0.56)	0.41 (0.14 - 1.17)	0.26 (0.05 - 1.21)	0.14 (0.02 - 1.13)	0.43 (0.15 - 1.25)
Wash-out 3 (+ 3 months)	0.19 (0.12 - 0.31)	0.18 (0.11 - 0.30)	0.41 (0.21 - 0.81)	0.35 (0.16 - 0.79)	0.23 (0.09 - 0.60)	0.35 (0.17 - 0.73)

†Number of events in young people taking antidepressant

eTable 3: Incidence Rate Ratios (IRRs) for suicidal ideation for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 458 events† IRR (95% CI)	fluoxetine 240 events† IRR (95% CI)	citalopram 108 events† IRR (95% CI)	sertraline 36 events† IRR (95% CI)	paroxetine 41 events† IRR (95% CI)	TCAs 81 events IRR (95% CI)
Unexposed	0.07 (0.05 - 0.10)	0.06 (0.04 - 0.09)	0.14 (0.06 - 0.32)	0.13 (0.05 - 0.34)	0.06 (0.02 - 0.18)	0.09 (0.05 - 0.18)
Pre-exposure 1 (- 4 months)	0.29 (0.15 - 0.54)	0.17 (0.07 - 0.44)	0.75 (0.24 - 2.35)	0.36 (0.07 - 1.79)	0.21 (0.02 - 1.77)	0.15 (0.03 - 0.68)
Pre-exposure 2 (- 3 months)	0.45 (0.26 - 0.77)	0.31 (0.15 - 0.65)	0.87 (0.29 - 2.59)	0.55 (0.14 - 2.20)	0.40 (0.08 - 2.09)	0.30 (0.10 - 0.90)
Pre-exposure 3 (-2 months)	0.76 (0.48 - 1.19)	0.56 (0.31 - 1.02)	1.27 (0.47 - 3.41)	1.07 (0.35 - 3.33)	0.98 (0.28 - 3.38)	0.21 (0.06 - 0.74)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	33.41 (23.56 - 47.39)	25.34 (16.34 - 39.31)	71.07 (31.77 - 159.01)	8.43 (2.37 - 29.93)	20.90 (6.83 - 64.01)	14.00 (6.81 - 28.75)
Week 1	0.38 (0.13 - 1.05)	0.43 (0.13 - 1.40)	0.61 (0.07 - 4.95)	No events	No events	0.59 (0.13 - 2.59)
Week 2	0.57 (0.26 - 1.27)	0.25 (0.06 - 1.03)	0.52 (0.06 - 4.23)	1.20 (0.24 - 5.96)	No events	0.25 (0.03 - 1.91)
Week 3	1.56 (0.91 - 2.68)	1.24 (0.60 - 2.53)	4.17 (1.51 - 11.51)	No events	1.49 (0.29 - 7.70)	1.03 (0.34 - 3.13)
Week 4	0.98 (0.51 - 1.91)	1.23 (0.58 - 2.59)	0.55 (0.07 - 4.50)	0.62 (0.07 - 5.16)	No events	0.84 (0.24 - 2.94)
Rest of AD episode	0.72 (0.49 - 1.08)	0.49 (0.29 - 0.82)	1.40 (0.58 - 3.37)	0.47 (0.16 - 1.35)	1.30 (0.43 - 3.90)	0.52 (0.20 - 1.35)
Wash-out 1 (+ 1 month)	0.40 (0.23 - 0.70)	0.38 (0.20 - 0.75)	0.27 (0.06 - 1.31)	0.33 (0.07 - 1.66)	0.20 (0.02 - 1.72)	0.43 (0.16 - 1.11)
Wash-out 2 (+ 2 months)	0.12 (0.06 - 0.29)	0.13 (0.04 - 0.36)	0.55 (0.16 - 1.88)	0.34 (0.07 - 1.73)	0.57 (0.14 - 2.42)	0.27 (0.09 - 0.83)
Wash-out 3 (+ 3 months)	0.20 (0.12 - 0.33)	0.15 (0.08 - 2.73)	0.50 (0.21 - 1.18)	0.07 (0.02 - 0.21)	0.08 (0.02 - 0.27)	0.13 (0.06 - 0.27)

†Number of events in young people taking antidepressant

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5-9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	n/a
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	7-9
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-9
		(b) Describe any methods used to examine subgroups and interactions	7-9
		(c) Explain how missing data were addressed	10
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	10-11

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	10
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-12
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



**Suicide-related events in young people following
prescription of SSRIs and other antidepressants: a self-
controlled case series analysis**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003247.R2
Article Type:	Research
Date Submitted by the Author:	05-Aug-2013
Complete List of Authors:	Wijlaars, Linda; UCL, Primary Care and Population Health Nazareth, Irwin; UCL, Primary Care and Population Health Whitaker, Heather; Open University, Department of Mathematics and Statistics Evans, Stephen; LSHTM, Medical Statistics Unit Petersen, Irene; UCL, Primary Care and Population Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	General practice / Family practice, Mental health, Paediatrics, Public health, Pharmacology and therapeutics
Keywords:	EPIDEMIOLOGY, MENTAL HEALTH, Suicide & self-harm < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY, Child & adolescent psychiatry < PSYCHIATRY

SCHOLARONE™
Manuscripts

Only

Suicide-related events in young people following prescription of SSRI and other antidepressants: a self-controlled case series analysis

Linda PMM Wijlaars¹, doctoral student,
Irwin Nazareth¹, professor of Primary Care and Population Science,
Heather J Whitaker², lecturer in statistics,
Stephen JW Evans³, professor of pharmacoepidemiology,
Irene Petersen¹, senior lecturer in epidemiology and medical statistics

1. Department of Primary Care and Population Health
University College London Medical School
Royal Free Campus
Rowland Hill Street
London
NW3 2PF
2. Department of Mathematics and Statistics
The Faculty of Mathematics, Computing and Technology
The Open University
Walton Hall
Milton Keynes
Buckinghamshire
MK7 6AA
3. Department of Medical Statistics
London School of Hygiene and Tropical Medicine
Keppel Street
London
WC1E 7HT

Correspondence to: Linda PMM Wijlaars (linda.wijlaars.10@ucl.ac.uk), contact address as above

Abstract

Objectives: We aimed to examine the temporal association between SSRI and tricyclic antidepressant (TCA) prescriptions and suicide-related events in children and adolescents.

Design: Self-controlled case series.

Setting: Electronic health records were used from 479 general practices in The Health Improvement Network (THIN) UK primary care database from 1995 to 2009.

Participants: 81 young people aged 10-18 years with a record of completed suicide, 1,496 who attempted suicide, 1,178 with suicidal ideation and 2,361 with intentional self-harm.

Main outcome measures: Incidence Rate Ratios (IRRs) for completed and attempted suicide, suicidal ideation and intentional self-harm.

Results: For non-fatal suicide-related behaviour, IRRs were similar for the time the person was prescribed either SSRIs or TCAs: IRRs increased during pre-exposure, peaked on prescription day, were stable up to the fourth prescription-week, and decreased after prescriptions stopped. For both types of antidepressants, IRRs were lower or similar to pre-exposure levels during the period of prescription. For SSRIs, there was an increase in the IRR for completed suicide on the day of prescription (N=5; IRR=42.5, 95% CI: 4.5 to 403.4), and during the fourth week of SSRI prescription (N=2; IRR=11.3, 95% CI: 1.1 to 115.6).

Conclusions: We found that a very small number of young people were prescribed antidepressants and the absence of a sustained increase in rates of suicide-related events in this group. There were no systematic differences between the association of TCAs and SSRIs and the incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm, and apart from the day of prescription, rates did not exceed pre-exposure levels. The pattern of IRR for suicide for SSRIs was similar to that found in non-fatal suicide-related events. Our results warrant a re-evaluation of the current prescribing of SSRIs in young people. We recommend the creation of a pragmatic registry for active pharmacovigilance.

Article summary

Article focus

- There has been concern that selective serotonin reuptake inhibitors (SSRIs) might be associated with an increased risk of suicide-related events in young people.
- We assess the temporal association between the risk of completed suicide, attempted suicide, suicidal ideation, intentional self-harm and antidepressant prescribing, comparing SSRIs and tricyclic antidepressants (TCAs) in adolescents using a large UK primary care database.

Key messages

- There are no systematic differences between the association of TCAs and SSRIs with incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm
- Up to the fourth week of prescription, the IRRs for attempted suicide, suicidal ideation and self-harm remained around the levels experienced during the pre-exposure period, suggesting continued on-going close monitoring in the first month is important.

Strengths and limitations of this study

- Only a limited number of young people had a prescription for an antidepressant in the year before their suicide-related event making it difficult to interpret the findings of this study.
- The self-controlled case series method inherently controls for time-independent variables such as genetics, location and socio-economic status.
- Changes in depression severity are poorly recorded over time, which is a limitation.

Introduction

Between 1-6% of adolescents in the community suffer from major depressive disorder¹. In addition, suicide is the third leading cause of death in 15-19 year olds at 6.9 per 100,000 population, and fourth for 10-14 year olds at 0.9 per 100,000 population². This calls for safe and effective depression treatments in this age group. As tricyclic antidepressants (TCAs) lack efficacy for depression treatment in this age group, and have a poor side effect profile³, selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed pharmacological treatment for children and adolescents⁴.

However, there has been concern that SSRIs might be associated with an increased risk of suicide-related events in paediatric patients. Results from clinical trials led the Expert Working Group of the Committee on Safety of Medicines (CSM) to advise against initiation of treatment with selective serotonin inhibitors (SSRIs) for childhood depression in the UK in December 2003⁵. Fluoxetine, the only drug which is licensed to treat depression in young people in the UK, was exempted from this advice following review that concluded there was a favourable balance of benefits and risk⁶. The US Food and Drug Administration (FDA) issued similar advice in 2004⁷.

There is inconsistent evidence of an increased rate of suicide-related events and intentional self-harm associated with SSRIs⁸. Data from randomized controlled trials in adolescents and young adults report an increased risk of suicide-related events⁹. Part of this difference appears to depend on the methodology used. If suicide-related events were ascertained using the method of "adverse events" there was a small but significant increase in suicidal ideation. However, if the studies used rating scales to assess suicide-related events, most studies showed an improvement in suicide-related events.

1
2
3 The results from these trials should be interpreted with caution as they were not primarily
4 designed to measure suicide-related events and it would be unethical to do so using placebo
5 as a control^{10;11}. Moreover, none of these trials on SSRIs recruited from a general population
6 setting and completed suicides have not occurred in any studies⁹.
7
8
9

10
11
12
13
14 Observational studies in young people have found mixed results: some indicate that SSRIs
15 protect from suicide-related events¹²; others find no effect^{13;14}; or an increase in risk of
16 suicide-related events^{15;16}. These studies, however, have methodological limitations including
17 small numbers, high attrition rates and, most importantly, confounding by severity.
18
19
20

21
22
23
24
25 We have previously shown rates for SSRI prescriptions in children and adolescents increased
26 between 2005-2009⁴. Neither TCAs nor SSRIs are considered appropriate first line treatment
27 by the National Institute for Clinical Excellence (NICE) for depression in children and
28 adolescents. Given the risk of death in overdose, the lack of efficacy in children, and the side
29 effects associated with them, a prescriber would be less likely to prescribe TCAs in
30 preference to SSRIs for a person at risk of suicide-related events¹⁷.
31
32
33

34
35
36
37
38 Only when children and adolescents are not responding to psychological treatment should
39 treatment with SSRIs be considered⁶. It is therefore important to reassess the risks of existing
40 clinical data to inform future practice. We aimed to assess the temporal association between
41 the risk of completed suicide, attempted suicide, suicidal thoughts, intentional self-harm and
42 antidepressant prescribing in adolescents, comparing SSRIs and TCAs and correcting for age
43 and sex, using a large UK primary care database.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

Data Source

We used data from The Health Improvement Network (THIN) primary care database, including information from UK primary care data prospectively recorded between 1 January 1995 and 31 December 2009. THIN includes anonymised general practice records on more than 9 million patients from 479 practices in the United Kingdom and is one of the largest primary care databases available internationally. It is broadly representative of the UK general practice population in terms of demographics and consultation behaviour¹⁸. Data on diagnoses, interventions, symptoms, and referrals to secondary care are electronically recorded as Read Codes, a hierarchical coding system used in UK primary care¹⁹. All prescriptions are also electronically recorded. Clinical diagnoses recorded using Read codes have recently been shown to be accurate compared with other reliable sources²⁰.

Study population

This study included a cohort of young people and adolescents, aged 10-18 years who had a recorded suicidal or self-harm event. Patients were included if they were registered with a practice for at least six months between January 1995 and December 2009. Patients were followed up from the latest of the date they registered at the GP, 1 January 1995, or their 10th birthday, until (1) 31 December 2009, (2) their 19th birthday, (3) the date of death, or (4) the date they left the practice.

Measurements

Outcome - We identified completed suicides using relevant Read codes that were confirmed by a date of death within two weeks of the suicide event date. We searched a cause of death if available. The list of codes was an updated version of a published suicide code

1
2
3 list²¹. To make sure we did not miss any suicides, we extracted medical records on all young
4
5 people who died between the ages of 10 and 18 and examined the free text if there was no
6
7 clear cause of death (e.g. childhood cancer or a traffic accident) for possible suicides. We
8
9 excluded cases where there was doubt whether the death was due to suicide (i.e. 12 deaths
10
11 which received an open verdict by the coroner). Of these potential suicides, 1 patient had
12
13 records of TCA prescriptions, while 4 had records of SSRI prescriptions in the last year.
14
15 Suicide attempt, suicidal ideation and self-harm were identified using a Read code list that
16
17 was developed in line with published methods and reviewed by a general practitioner (IN)²².
18
19
20
21
22

23 *Exposure* - We used British National Formulary (BNF) codes representing antidepressants²³.
24
25 We classified antidepressants as TCAs, SSRIs and other antidepressants according to the
26
27 BNF. We excluded TCAs that were prescribed for nocturnal enuresis or neuropathic pain.
28
29 Comparing prescription data in THIN to dispensing data from NHS Prescription Services
30
31 showed that the mean practice redemption rate (the percentage of recorded prescriptions
32
33 which were dispensed) was as high as 96.7% for antidepressants²⁴.
34
35
36
37
38

39 We then identified the separate episodes of antidepressant prescription for each individual.
40
41 To constitute a new episode of antidepressant prescriptions, there had to be a preceding gap
42
43 of at least 3 months of no prescriptions. We choose 3 months as a prescription supply of
44
45 antidepressants is typically 1 month or less, and therefore a gap of at least 3 months between
46
47 prescriptions would likely represent a new episode of antidepressant prescriptions (although
48
49 not necessarily a new episode of depression). If a person switched from one drug to another
50
51 within 3 months, this did not constitute a new episode.
52
53
54
55
56
57
58
59
60

1
2
3 *Covariates* – We extracted information on sex, age and social deprivation score (Townsend
4 quintiles). Patients who were prescribed TCAs for nocturnal enuresis (as confirmed by Read
5 codes) were excluded. Finally, we considered consultation behaviour as a confounder.
6
7 Patients who consult infrequently with their GP, e.g. only when their prescription has run out,
8 might not have correctly timed records of all of their events. To correct for this we conducted
9 a sensitivity analysis where we only included patients who consulted at least once a week
10 during the month after their first antidepressant prescription.
11
12
13
14
15
16
17
18
19

20 **Statistical analysis**

21
22 *The Self-Controlled Case Series (SCCS) method* - We calculated incidence rate ratios (IRRs –
23 calculated by dividing the incidence rate in the exposed period by the incidence rate in the
24 control period) for completed suicide and suicide-related events using the self-controlled case
25 series (SCCS) method²⁵. The SCCS method was developed to investigate associations
26 between acute outcomes and transient exposures, using only data on cases. Since each case
27 served as his/her own control, the case-series method inherently accounts for confounding
28 factors that do not change over the observation period (such as variables related to genetics,
29 socio-economic status and gender). Using a Poisson model, IRRs can be calculated for any
30 number of pre-defined risk periods associated with the exposure, using the time outside of
31 these risk periods (the time when a subject is unexposed) as reference. A major advantage of
32 the SCCS is that it can have high efficiency relative to the retrospective cohort method from
33 which it is derived. As suicide-related events are rare, even in depressed persons, the SCCS
34 method is particularly suited for assessing its association with antidepressants as it requires a
35 much smaller number of persons to be included. Moreover, in using a self-controlled design
36 we circumvent the problem of selecting appropriate controls that cohort or case-control
37 designs encounter. In the case of suicide-related events and antidepressants this has proven
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 crucial as patients who are diagnosed as depressed but don't receive antidepressants might
4 differ from patients who are receiving antidepressants in severity of depression, a major
5 confounder in the studied association.
6
7

8
9 The SCCS method is limited in that it only works for non-recurrent events when the event
10 risk is small over the observation period, which is the case for completed suicide. Also, it
11 requires variability in the age at the time of event: if all events were to happen at exactly the
12 same age (which is not the case in our study), then the method would fail. Finally, the method
13 only produces estimates of relative incidence, rather than absolute incidence.
14
15
16
17
18
19
20
21
22

23 *Suicide attempts, suicidal ideation and self-harm* – For the analyses on suicide attempts,
24 suicidal ideation and self-harm we used an adapted version of the standard SCCS method,
25 allowing for repeated exposures and events and correcting by 1-year age groups^{25;26}. By
26 including a pre-exposure period, we corrected our estimates for event-dependent exposure. If
27 the probability of exposure to antidepressants is changed from baseline after an event, it
28 follows that the probability of the occurrence of an event is also changed in the immediate
29 pre-exposure period. Including a pre-exposure period removes this time from the baseline and
30 corrects the estimates accordingly.
31
32
33
34
35
36
37
38
39

40 Subjects who went on to commit suicide were excluded from these analyses. Using the SCCS
41 method, the incidence rate ratio for the three outcomes was estimated during 14 different risk
42 periods (Figure 1): baseline (or unexposed to antidepressants); four 1-month pre-exposure
43 periods, the last of which is the reference; the day of prescription; four 1-week early exposure
44 periods; a period of variable length to cover the remainder of the period of exposure to the
45 antidepressant for that episode; and three 1-month periods of washout after the end of the
46 antidepressant episode. We included the separate 1-week periods at the start of prescription as
47 it is known that antidepressants (especially SSRIs) take this amount of time to have an
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 effect²⁷. We also compared the effects of individual antidepressants on the IRR of the three
4
5 suicide-related event outcomes.
6
7

8
9
10 *Suicide* - We used an adapted method (SCCS for censored post-event exposures) to assess the
11 effects of antidepressants on childhood suicide as the original approach cannot deal with
12 deaths²⁸. This method takes account of the early cessation of the observation period due to
13
14 deaths and accordingly corrects the IRR estimates. We corrected for age by creating four age
15
16 groups: 10-12, 13-14, 15-16 and 17-18 year olds. We estimated IRRs for the same risk
17
18 periods as for the other outcomes, without the four pre-exposure risk periods and used
19
20 baseline (time unexposed to antidepressants) as reference.
21
22

23
24 All analyses were conducted with the use of Stata software, version 12.1 (Stata Corp, College
25
26 Station, Texas). The scheme for THIN to obtain and provide anonymous patient data to
27
28 researchers was approved by the National Health Service South-East Multicenter Research
29
30 Ethics Committee (MREC) in 2002 and scientific approval for this study was obtained from
31
32 CMD Medical Research's Scientific Review Committee in May 2011.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

There was a total follow-up time of 4,190,410 person-years of 10-18-year olds in THIN. In total, 81 young people were identified with a record of a completed suicide, 1,496 young people with a record of attempted suicide, 1,178 young people with a record of suicidal ideation, and 2,361 with a record of intentional self-harm. Of young people with completed suicides, 30% were female, compared to 60%, 73% and 74% of young people with a record of attempted suicide, suicidal ideation, or self-harm, respectively (Table 1). There was no significant difference in age of first event between the different outcomes. The data were complete for all variables except Townsend scores, which were missing for 92 (2%) persons. Due to small numbers, we were not able to analyse antidepressants other than SSRIs or TCAs.

Attempted suicide, suicidal ideation and self-harm

For attempted suicide, suicidal ideation and self-harm, there were similar patterns between young people that were prescribed SSRIs and TCAs (Table 2 & Figures 2A, B & C): there was an upwards trend in the IRR during pre-exposure; a peak on the day of prescription; a stable or slightly increased rate ratio during the first weeks of prescription; and during the washout period levels decreased again. The increase on prescription day was highest for young people with a record of suicidal ideation (SSRIs: IRR=33.4, 95%CI: 23.6 to 47.4; TCAs: IRR=14.0, 95%CI: 6.8 to 28.8). There were no significant differences between IRRs for any of the event types for any risk periods. Patterns were similar between individual SSRIs (fluoxetine, citalopram, sertraline and paroxetine, results in appendix).

The IRR for each type of event has a strong relation with age. When compared to 15-16 year olds, 17-18 year olds are twice as likely to attempt suicide (IRR=1.90, 95%CI: 1.6 to 2.3 and

1
2
3 IRR=2.1, 95%CI: 1.7 to 2.5 for SSRIs and TCAs, respectively) but those between 10-12
4
5 years old are less likely to attempt suicide (IRR=0.3, 95%CI: 0.2 to 0.4 and IRR=0.2, 95%CI:
6
7 0.1 to 0.2 for SSRIs and TCAs, respectively). Patterns were similar for the other outcomes.
8
9

10
11
12 There were no statistically significant differences between boys and girls for either SSRIs or
13
14 TCAs (results not shown). A small group of 25 patients had a prescription for an
15
16 antidepressant and a primary diagnosis other than depression (obsessive compulsive disorder
17
18 (OCD) or anxiety). Due to the small size of this group we did not perform a subgroup
19
20 analysis. Finally, restricting the analyses to regular consulters (those who consulted at least
21
22 five times during the first four weeks of prescription) did not alter effect estimates. Of the
23
24 young people with a record of attempted suicide or intentional self-harm, 33% were regular
25
26 consulters, compared to 49% of young people with a record of suicidal ideation.
27
28
29
30
31

32 **Suicide**

33
34 Using an expected suicide rate of 3.28 (95%CI: 3.12 to 3.43) per 100,000 person-years in the
35
36 UK population of 10-18-year olds ²⁹, we would expect 137 (95%CI: 131 to 144) completed
37
38 suicides in our study population. However, 41% of suicides registered by the Office of
39
40 National Statistics (ONS) were of undetermined intent, leaving 59% or 81 (95%CI: 77 to 85)
41
42 expected suicides that received a verdict by a coroner. This estimate corresponds to the
43
44 number of 81 completed suicides we identified between 1995 and 2009 within the THIN
45
46 database. Of the 81 young people with a completed suicide, 21 (26%) had a prior record of a
47
48 depression diagnosis or depression symptoms. Nineteen young people (23%) were taking
49
50 antidepressants in the year before their suicide, and 11 (14%) were still taking them at the
51
52 time of, or shortly before their suicide. There was also a high proportion of young people
53
54
55
56
57
58
59
60

1
2
3 with (a history of) behaviour disorders 16 (20%), history of self-harm 8 (10%), a psychiatric
4
5 referral 19 (23%), a hyperkinetic disorder 5 (6%) or eating disorder 3 (4%).
6
7

8
9
10 There were no completed suicides within the risk periods for antidepressants other than
11
12 SSRIs (Table 3). Eleven (14%) completed suicides were within the risk periods. Similar to
13
14 the results from the data on suicide-related events, the IRR was highest on the day of
15
16 prescription (IRR=42.5, 95%CI: 4.5 to 403.4). There were no events in the first two weeks of
17
18 the SSRI episode, but there was an increased rate ratio in week three (IRR=8.0, 95%CI: 0.8
19
20 to 76.7, based on a single case) and a statistically significant increase in week 4 (IRR=11.3,
21
22 95%CI: 1.1 to 115.6, though based on two cases). After the fourth week of the SSRI episode,
23
24 the IRR decreased and returned to baseline levels during wash-out. There were no significant
25
26 differences between age groups.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Overall, there are no systematic differences between TCAs and SSRIs in incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm, and apart from an increase common to both TCAs and SSRIs on the day of prescription, rates were not statistically significantly different from pre-exposure levels. The pattern of incidence risk ratios for completed suicides for the 11 people prescribed SSRIs was similar to that found in attempted suicide, suicidal ideation and self-harm. However, concerns regarding antidepressants need to be weighed against the risk of untreated depression.

Pre-exposure IRRs for attempted suicide, suicidal ideation and self-harm appeared to be marginally higher, though not statistically significant, for SSRIs compared to TCAs. This could be because young people who are deemed to be more at risk of suicide-related events could preferentially be prescribed SSRIs over TCAs, given TCAs' toxicity in overdose¹⁷.

The high IRRs on the day of antidepressant prescription for all three non-fatal outcomes could be an artefact of GP recording behaviour. Rather than the antidepressant causing the suicide-related events, the event is an indication for the GP to prescribe the drug and to record depression in the electronic records on the same day. As antidepressants should only be prescribed by child & adolescent psychiatrists (2005 NICE guidelines⁶), this artefact could also arise when GPs continue a prescription started in secondary care and record the initial indication when first prescribing this drug.

Up to the fourth week of prescription, the IRRs for attempted suicide, suicidal ideation and self-harm remained around the levels experienced during the pre-exposure period. Considering that suicide-related events are common in young depressed people, some suicidal and self-harm events would be expected irrespective of whether SSRIs are prescribed or not³⁰. The rate of suicide-related events decreased when the prescriptions were stopped.

1
2
3 Given the nature of the data, it is difficult to know whether the SSRIs were causing suicide-
4 related events and these events improved when the SSRIs were discontinued, or if the SSRIs
5 were discontinued when the young person's depression (and as a consequence the risk of
6 suicide-related events) improved.
7
8

9
10
11 There are three possible explanations for the slightly increased IRRs during the first month of
12 prescription. One is that SSRIs fail to relieve the risk of suicide-related events associated with
13 depression because of a lag in antidepressant effect, an incomplete response, or a treatment-
14 resistant depression. It is known that SSRIs take a couple of weeks to reach their full
15 antidepressant effects and hence reduce the risk of suicide-related events²⁷.
16
17
18

19
20
21 A second possibility is that the SSRIs generate a novel set of suicidal emotions or behaviours.
22 Early improvements in clinical depression can lead to a person acting on existing suicidal
23 feelings. This activation syndrome has been described for both TCAs and SSRIs, and is
24 widely recognized by psychiatrists, as well as the FDA^{31;32}. While patients might be
25 demotivated and demoralized at the height of their depression, when they start treatment they
26 become more active during the first weeks of taking the drug. During this time the
27 antidepressant effect of the medication will not have reached its full effect resulting in
28 persistent depression but simultaneous increased activity. This could lead to a greater risk of
29 suicide-related events until the full effects of antidepressants are realized few weeks later³¹.
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Several studies and systematic reviews have shown an age effect in the risk of
44 suicide-related events with the use of SSRIs. In adults and the elderly the risk is neutral or
45 SSRIs show a protective effect, while in adolescents and young adults there appears to be an
46 increased risk of suicide-related events^{9;15;33}.
47
48
49
50
51

52 Although we did not find a statistically significant sustained increase in suicide-
53 related events with either SSRIs or TCAs, negative outcomes did not appear to be decreased
54 either – although our study was not designed to assess this. This is in line with Cochrane
55
56
57
58
59
60

1
2
3 reviews on both drug groups: the review on tricyclic antidepressants concludes that these
4 drugs are not useful in treating depression in pre-pubertal children, and that there is only
5 marginal evidence to support the use of TCAs in adolescents, although the magnitude of the
6 effect is likely to be moderate at best³⁴. Similarly, it is unclear what the effect is of SSRIs on
7 suicide completion. Although evidence from clinical trials implies an increased risk of
8 suicide-related outcomes (but not completed suicide), the evidence for this association is of
9 low quality³⁵.

20 21 **Comparison to other studies**

22 Our results build on the findings of Schneeweis et al.¹³. They found no statistically significant
23 differences in relative risk for attempted and completed suicide between different types of
24 antidepressants (fluoxetine, citalopram, fluvoxamine, paroxetine, sertraline and TCAs) when
25 examining 266 attempted and 3 completed suicides. Moreover, an ecological study found no
26 change in rates of completed suicides or hospital admissions for self-harm following the
27 CSM advice³⁶, suggesting there is no, or only a weak, relationship with antidepressant
28 prescriptions. Our findings are also similar to those of Simon et al.³⁷ who used computerised
29 health plan records and report the highest rates for attempted suicide in the month before
30 prescription, rather than after start of the prescription. Finally, a meta-analysis³⁸ found that, of
31 27 paediatric RCTs on antidepressants prescribed for major depressive disorder (MDD),
32 OCD and non-OCD anxiety disorders, the risk of suicidal ideation or attempt among patients
33 on placebo was greater in trials assessing MDD. Although this difference in baseline risk for
34 suicide-related events was not statistically significant, it could indicate part of the association
35 between antidepressants and suicide-related events can be explained by the underlying
36 disease, rather than the drug. Importantly, the authors concluded that relative to placebo, the
37 benefits (though only modest in MDD) outweigh the risks from suicidal ideation/suicide
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 attempts. Due to small numbers of patients with primary diagnoses of OCD and anxiety
4 disorders, we could not repeat the meta-analysis' sub-group comparison.
5
6
7

8 9 10 **Main strength and limitations**

11 The main strength of this study is its sample size that enables examination of outcomes
12 separately by completed and attempted suicide, suicidal ideation and self-harm, and by
13 individual antidepressants. However, even in using a database as large as THIN, we could
14 identify only a small number of completed suicides, leading to limited power in that analysis.
15
16 Similarly, power was limited for analysing individual antidepressants, which are presented in
17 the appendix. Nevertheless, the use of the SCCS method allows us to control for time-
18 independent confounders, making our estimations more robust.
19
20

21 A limitation to our study is that the THIN database only provides data on antidepressant
22 prescriptions. We do not know whether prescriptions were dispensed, or whether patients
23 adhered to prescription. However, though it is known that adherence levels are around 50%
24 for young people taking SSRIs, and even lower for TCAs³⁹, our data does represent a real-life
25 situation. Moreover, by assessing episodes of antidepressant prescription, we take account of
26 multiple prescriptions per patient, which increases the likelihood of adherence as we expect
27 patients who are not taking their medication would not come back for a new prescription.
28
29

30 Moreover, it is known that suicide-related events are often missed in clinical assessment⁴⁰.
31
32 However, it is likely that the most severe forms (attempted suicides and severe suicidal
33 ideation) are most likely to be recorded by clinicians. Also, in using a self-controlled design,
34 we decrease the chance of misclassifying controls. There is some suggestion that
35 antidepressants might specifically increase suicide-related events in patients who did not
36 experience these events prior to starting antidepressant treatment. Due to variation in
37 clinicians' assessment and recording of (the absence of) suicide-related events, we could not
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 examine this hypothesis using this database. Furthermore, the relatively low number of young
4
5 people who had a prescription for an antidepressant at the time of their suicide-related event
6
7 limits the interpretation of our results. However, Windfuhr et al. also found that mental health
8
9 service contact is low in juveniles who committed suicide: only 14% contacted services in the
10
11 year before they died²⁹. Finally, we were not able to account for changes in depression
12
13 severity over time as this is poorly recorded.
14
15

16 17 18 **Conclusion**

19
20 Our study shows that there are similar incidence rate ratio patterns for attempted suicide,
21
22 suicidal ideation and self-harm for SSRIs and TCAs. Also, the pattern for completed suicides
23
24 associated with SSRI prescriptions is similar, though there are no records of completed
25
26 suicides within our pre-defined risk periods for TCAs. Although the CSM's warning was a
27
28 sensible cautionary recommendation at the time, it appears that the current line of evidence
29
30 suggests a reverse causality: it is the underlying depression that leads to suicide-related
31
32 events and the prescribing of antidepressants, although a causal effect of SSRIs, or no effect
33
34 at all cannot be ruled out. Moreover, even if antidepressant drugs would temporarily increase
35
36 the risk of suicide-related events in young persons, the risk untreated depression poses is far
37
38 greater. In conclusion, our results indicate that the association of suicide-related events
39
40 associated with antidepressants occurs primarily around the day of prescription, suggesting
41
42 depression severity and GP recording behaviour as the culprit rather than antidepressants, and
43
44 thus warrant a re-evaluation of the current guidelines regarding the prescription of SSRIs in
45
46 primary care.
47
48
49
50

51 52 53 **Recommendation**

1
2
3 Our results are not definitive, and due to the rare nature of the outcome and the intricacies of
4 the problem studied, it is difficult to think of a single study or study design that will be able to
5 provide a satisfying answer to the problem at hand. It is possible that the creation of a
6 pragmatic registry, similar to that proposed by van Staa and colleagues in their pragmatic
7 randomised trial⁴¹, will allow for active pharmacovigilance. Such a system would at low cost
8 and with no additional burden on clinician, health service or patient time, facilitate long term,
9 anonymous, unobtrusive follow-up for major clinical outcomes. As such, clinicians would be
10 prompted to monitor and record (the absence of) suicide-related events and ideation more
11 regularly and closely, using similar outcome measurements as those used in clinical trials, as
12 well as (changes in) depression severity.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We would like to thank the general practitioners who contributed data to THIN.

Contributors All authors were responsible for study conception and design. LPW was responsible for data analysis. LPW authors drafted the manuscript. All authors participated in the interpretation of data, critical revision and final approval of the manuscript.

Funding statement: The work was supported by a PhD studentship from the National Institute of Health Research English National School for Primary Care Research. The funding organisation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; and preparation, review or approval of the manuscript.

Competing interests statement: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: LPMMW had financial support in the form of a studentship from the National Institute of Health Research English National School for Primary Care Research for the submitted work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data sharing: Examples of statistical code used for the self-controlled case series method (including the adapted method for dealing with censored data) are available from the [Open University website](#). Statistical code is available from the corresponding author.

References

- 1
2
3
4
5 (1) Kessler RC, Avenevoli S, Ries Merikangas K. Mood disorders in children and
6 adolescents: an epidemiologic perspective. *Biological Psychiatry* 2001; 49(12):1002-
7 1014.
- 8
9
10 (2) Heron M. Deaths: leading causes for 2007. *National vital statistics reports* 2011;
11 59(8):1-95.
- 12
13 (3) Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drug for depression in
14 children and adolescents. *Cochrane Database Syst Rev* 2002;(4).
- 15
16 (4) Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant
17 prescribing in children and adolescents: A cohort study in The Health Improvement
18 Network (THIN). *PLoS One* 2012.
- 19
20 (5) Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and
21 suicide in adults: meta-analysis of drug company data from placebo controlled,
22 randomised controlled trials submitted to the MHRA's safety review. *BMJ* 2005;
23 330(7488):385.
- 24
25 (6) National Institute for Health and Clinical Excellence. CG28 Depression in children
26 and young people: NICE guideline. 2005. London, National Institute for Health and
27 Clinical Excellence.
- 28
29 (7) FDA. Suicidality in Children and Adolescents Being Treated With Antidepressant
30 Medications. US Food and Drug Administration [2004 [cited 2011 June 29];
31 Available from: URL:
32 [http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsa
33 ndProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisorie
34 s/ucm161679.htm](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679.htm)
- 35
36 (8) Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E.
37 Selective serotonin reuptake inhibitors in childhood depression: systematic review of
38 published versus unpublished data. *The Lancet* 2004; 363(9418):1341-1345.
- 39
40 (9) Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with
41 antidepressant drugs. *Arch Gen Psychiatry* 2006; 63(3):332-339.
- 42
43 (10) Rothman KJ, Michels KB. The continuing unethical use of placebo controls. *N Engl J*
44 *Med* 1994; 331(6):394-398.
- 45
46 (11) Grosso A, Douglas I, MacAllister R, Petersen I, Smeeth L, Hingorani AD. Use of the
47 self-controlled case series method in drug safety assessment. *Expert Opin Drug Saf*
48 2011; 10(3):337-340.
- 49
50 (12) Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA et al. Early
51 evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and
52 suicide in children and adolescents. *Am J Psychiatry* 2007; 164(9):1356-1363.
- 53
54
55
56
57
58
59
60

- 1
2
3 (13) Schneeweiss S, Patrick AR, Solomon DH, Dormuth CR, Miller M, Mehta J et al.
4 Comparative safety of antidepressant agents for children and adolescents regarding
5 suicidal acts. *Pediatrics* 2010; 125(5):876-888.
6
- 7 (14) Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. *JAMA*
8 2004; 292(3):338-343.
9
- 10 (15) Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely
11 depressed children and adults - A case-control study. *Arch Gen Psychiatry* 2006;
12 63(8):865-872.
13
- 14 (16) Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal Thoughts and Behavior
15 With Antidepressant Treatment: Reanalysis of the Randomized Placebo-Controlled
16 Studies of Fluoxetine and Venlafaxine. *Arch Gen Psychiatry* 2012;archgenpsychiatry.
17
- 18 (17) Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following
19 prescription of SSRIs and other antidepressants: confounding by indication. *Br J Clin*
20 *Pharmacol* 2005; 60(5):519-525.
21
- 22 (18) Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a
23 quality-evaluated database of primary care data. *Inform Prim Care* 2004; 12(3):171-
24 177.
25
- 26 (19) Booth N. What are the Read Codes? *Health Libr Rev* 1994; 11(3):177-182.
27
- 28 (20) Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General
29 Practice Research Database: a systematic review. *Br J Gen Pract* 2010; 60(572):e128-
30 e136.
31
- 32 (21) Arana A, Wentworth CE, yuso-Mateos JL, Arellano FM. Suicide-related events in
33 patients treated with antiepileptic drugs. *N Engl J Med* 2010; 363(6):542-551.
34
- 35 (22) Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary
36 care databases. *Pharmacoepidemiology and drug safety* 2009; 18(8):704-707.
37
- 38 (23) British National Formulary. 60 ed. London: BMJ group; RPS Publishing; 2010.
39
- 40 (24) The NHS Information Centre PaPCS. Prescription compliance: a review of the
41 proportion of prescriptions dispensed. 7-9-2011.
42
- 43 (25) Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the
44 self-controlled case series method. *Stat Med* 2006; 25(10):1768-1797.
45
- 46 (26) Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case
47 series studies. *Stat Methods Med Res* 2009; 18(1):7-26.
48
- 49 (27) Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective
50 serotonin reuptake inhibitor antidepressant action: systematic review and meta-
51 analysis. *Arch Gen Psychiatry* 2006; 63(11):1217-1223.
52
- 53 (28) Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored,
54 perturbed, or curtailed post-event exposures. *Biostatistics* 2009; 10(1):3-16.
55
56
57
58
59
60

- 1
2
3 (29) Windfuhr K, While D, Hunt I, Turnbull P, Lowe R, Burns J et al. Suicide in juveniles
4 and adolescents in the United Kingdom. *J Child Psychol Psychiatry* 2008;
5 49(11):1155-1165.
6
7 (30) Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. *J*
8 *Child Psychol Psychiatry* 2006; 47(3-4):372-394.
9
10 (31) Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A et al.
11 Antidepressant-induced jitteriness/anxiety syndrome: systematic review. *Br J*
12 *Psychiatry* 2009; 194(6):483-490.
13
14 (32) Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL.
15 Suicidality as a possible side effect of antidepressant treatment. *J Clin Psychiatry*
16 2004; 65(6):742-749.
17
18 (33) Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of
19 suicide: a systematic review of observational studies. *CMAJ* 2009; 180(3):291-297.
20
21 (34) Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drug for depression in
22 children and adolescents. *Cochrane Database Syst Rev* 2010;(4).
23
24 (35) Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation
25 antidepressants for depressive disorders in children and adolescents. *Cochrane*
26 *Database of Systematic Reviews* 2012.
27
28 (36) Wheeler BW, Gunnell D, Metcalfe C, Stephens P, Martin RM. The population impact
29 on incidence of suicide and non-fatal self harm of regulatory action against the use of
30 selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological
31 study. *BMJ* 2008; 336(7643):542-545.
32
33 (37) Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant
34 treatment. *Am J Psychiatry* 2006; 163(1):41-47.
35
36 (38) Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA et al. Clinical
37 response and risk for reported suicidal ideation and suicide attempts in pediatric
38 antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA* 2007;
39 297(15):1683-1696.
40
41 (39) Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP et al.
42 Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic
43 antidepressants: comparison of drug adherence. *Cochrane Database Syst Rev*
44 2000;(4):CD002791.
45
46 (40) Fitzpatrick C, Abayomi NN, Kehoe A, Devlin N, Glackin S, Power L et al. Do we
47 miss depressive disorders and suicidal behaviours in clinical practice? *Clinical Child*
48 *Psychology and Psychiatry* 2012; 17(3):449-458.
49
50 (41) van Staa T, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A et al.
51 Pragmatic randomised trials using routine electronic health records: putting them to
52 the test. *BMJ* 2012; 344.
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1: Risk periods included in self-controlled case series analysis for attempted suicide, suicidal ideation and self-harm and suicide. 1 = baseline; 2-5 = 1-month pre-exposure periods; 6 = prescription day; 7-10 = four 1-week exposure periods; 11 = remainder of antidepressant exposure; 12-14= three 1-month washout periods

Figure 2A, B, C: IRR for A) attempted suicide, B) suicidal ideation and C) self-harm for tricyclic antidepressants (TCAs) and selective serotonin inhibitors (SSRIs). The month before a prescription was issued (pre-exposure 4) was used as the reference.

TABLES

Table 1: Demographics by category of suicidal or self-harming behaviour

	Completed suicide 81	Attempted suicide 1496	Suicidal ideation 1178	Self-harm 2361	General population 952892
Girls (%)	24 (29.6)	1089 (72.8)	708 (60.1)	1752 (74.2)	461610 (48.4)
# taking ADs (%)	19 (23.1)	527 (36.6)	578 (52.8)	128 (5.7)	27632 (2.9)
# depressed (%)	21 (25.9)	728 (48.7)	819 (69.5)	173 (7.3)	41101 (4.3)
# Townsend score (%)					
1 (most affluent)	20 (24.7)	266 (17.8)	193 (16.4)	442 (18.7)	227178 (23.8)
2	5 (6.2)	240 (16.0)	202 (17.2)	405 (17.2)	198686 (20.9)
3	13 (16.1)	286 (19.1)	236 (20.0)	452 (19.1)	184934 (19.4)
4	25 (30.9)	364 (24.3)	283 (24.0)	571 (24.2)	169792 (17.8)
5 (most deprived)	16 (19.8)	316 (21.1)	241 (20.5)	446 (18.9)	120116 (12.6)
Median age in years at (first) event (5%-95% percentiles)	16.8 (12.0-18.8)	16.5 (12.9 - 18.7)	16.7 (12.0 - 18.7)	15.9 (12.6 - 18.7)	-
Median time in study in years (5%-95% percentiles)	3.5 (0.2 - 8.4)	5.5 (1.4 - 9.0)	5.9 (1.5 - 9.0)	5.9 (1.5 - 9.0)	-

Table 2: Incidence Rate Ratios (IRRs) for different types of suicidal or self-harming behaviour by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs			TCAs		
	Suicide attempt 423 events† IRR (95% CI)	Suicidal ideation 458 events† IRR (95% CI)	Self-harm 654 events† IRR (95% CI)	Suicide attempt 79 events† IRR (95% CI)	Suicidal ideation 81 events† IRR (95% CI)	Self-harm 118 events† IRR (95% CI)
Unexposed	0.09 (0.07 - 0.13)	0.07 (0.05 - 0.10)	0.12 (0.09 - 0.17)	0.20 (0.09 - 0.46)	0.09 (0.05 - 0.18)	0.15 (0.08 - 0.30)
Pre-exposure 1 (- 4 months)	0.19 (0.10 - 0.38)	0.29 (0.15 - 0.54)	0.37 (0.22 - 0.61)	0.61 (0.18 - 2.10)	0.15 (0.03 - 0.68)	0.29 (0.08 - 1.03)
Pre-exposure 2 (- 3 months)	0.31 (0.17 - 0.53)	0.45 (0.26 - 0.77)	0.59 (0.38 - 0.90)	0.29 (0.06 - 1.39)	0.30 (0.10 - 0.90)	0.09 (0.01 - 0.71)
Pre-exposure 3 (-2 months)	0.62 (0.40 - 0.96)	0.76 (0.48 - 1.19)	0.65 (0.43 - 0.98)	0.14 (0.02 - 1.16)	0.21 (0.06 - 0.74)	0.46 (0.16 - 1.33)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	4.17 (2.44 - 7.12)	33.41 (23.56 - 47.39)	11.48 (7.93 - 16.62)	8.82 (2.79 - 27.82)	14.00 (6.81 - 28.75)	3.47 (0.97 - 12.45)
Week 1	0.79 (0.40 - 1.55)	0.38 (0.13 - 1.05)	0.69 (0.35 - 1.35)	1.18 (0.24 - 5.68)	0.59 (0.13 - 2.59)	0.77 (0.17 - 3.50)
Week 2	0.74 (0.39 - 1.42)	0.57 (0.26 - 1.27)	0.96 (0.55 - 1.68)	1.02 (0.21 - 4.91)	0.25 (0.03 - 1.91)	0.33 (0.04 - 2.57)
Week 3	1.07 (0.61 - 1.86)	1.56 (0.91 - 2.68)	1.33 (0.82 - 2.19)	0.53 (0.06 - 4.29)	1.03 (0.34 - 3.13)	1.01 (0.28 - 3.61)
Week 4	0.52 (0.24 - 1.15)	0.98 (0.51 - 1.91)	1.23 (0.73 - 2.07)	0.57 (0.07 - 4.67)	0.84 (0.24 - 2.94)	0.37 (0.05 - 2.90)
Rest of AD episode	0.53 (0.36 - 0.78)	0.72 (0.49 - 1.08)	0.64 (0.45 - 0.90)	0.38 (0.11 - 1.33)	0.52 (0.20 - 1.35)	0.48 (0.18 - 1.25)
Wash-out 1 (+ 1 month)	0.42 (0.25 - 0.69)	0.40 (0.23 - 0.70)	0.28 (0.16 - 0.48)	0.66 (0.21 - 2.09)	0.43 (0.16 - 1.11)	0.09 (0.01 - 0.69)
Wash-out 2 (+ 2 months)	0.17 (0.09 - 0.35)	0.12 (0.06 - 0.29)	0.32 (0.19 - 0.55)	0.28 (0.06 - 1.33)	0.27 (0.09 - 0.83)	0.43 (0.15 - 1.25)
Wash-out 3 (+ 3 months)	0.15 (0.09 - 0.25)	0.20 (0.12 - 0.33)	0.19 (0.12 - 0.31)	0.41 (0.16 - 1.03)	0.13 (0.06 - 0.27)	0.35 (0.17 - 0.73)

† Number of events in young people taking antidepressants



Table 3: Incidence Rate Ratios (IRRs) for completed suicide by risk period and age



Risk period	Censoring model IRR (95% CI)	# deaths†
Prescription day	42.52 (4.48 – 403.43)	5
Week 1		
Week 2	No events	0
Week 3	8.00 (0.84 – 76.71)	1
Week 4	11.25 (1.09 – 115.58)	2
Rest of AD episode	5.42 (0.57 – 51.94)	1
Wash-out 1	2.27 (0.24 – 21.76)	1
Wash-out2	2.08 (0.22 – 19.69)	1
Age Groups		# total deaths‡
10-12	0.61 (0.21 – 1.77)	8
13-14	1.14 (0.45 – 2.90)	15
15-16	Reference	21
17-18	0.41 (0.12 – 1.39)	37

† Number of suicides during risk periods (only includes youths who were taking antidepressants at the time of suicide, or those who had recently stopped)

‡ Number of suicides by age category

FIGURES





Supplementary Tables

eTable 1: Incidence Rate Ratios (IRRs) for attempted suicide for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 423 events [†] IRR (95% CI)	fluoxetine 198 events [†] IRR (95% CI)	citalopram 111 events [†] IRR (95% CI)	sertraline 39 events [†] IRR (95% CI)	paroxetine 61 events [†] IRR (95% CI)	TCAs 79 events IRR (95% CI)
Unexposed	0.09 (0.07 - 0.13)	0.10 (0.06 - 0.16)	0.08 (0.05 - 0.14)	0.11 (0.04 - 0.31)	0.07 (0.03 - 0.14)	0.20 (0.09 - 0.46)
Pre-exposure 1 (- 4 months)	0.19 (0.10 - 0.38)	0.18 (0.06 - 0.53)	0.26 (0.10 - 0.67)	0.20 (0.02 - 1.71)	0.21 (0.05 - 0.97)	0.61 (0.18 - 2.10)
Pre-exposure 2 (- 3 months)	0.31 (0.17 - 0.53)	0.41 (0.19 - 0.89)	0.20 (0.07 - 0.59)	0.20 (0.02 - 1.70)	0.21 (0.05 - 0.96)	0.29 (0.06 - 1.39)
Pre-exposure 3 (-2 months)	0.62 (0.40 - 0.96)	0.72 (0.38 - 1.37)	0.35 (0.15 - 0.83)	1.19 (0.36 - 3.88)	0.41 (0.13 - 1.30)	0.14 (0.02 - 1.16)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	4.17 (2.44 - 7.12)	5.84 (2.76 - 12.34)	2.02 (0.60 - 6.79)	5.31 (1.03 - 27.37)	3.96 (1.09 - 14.39)	8.82 (2.79 - 27.82)
Week 1	0.79 (0.40 - 1.55)	0.98 (0.37 - 2.59)	0.45 (0.10 - 1.92)	2.64 (0.63 - 11.06)	0.44 (0.06 - 3.45)	1.18 (0.24 - 5.68)
Week 2	0.74 (0.39 - 1.42)	0.50 (0.15 - 1.68)	1.16 (0.47 - 2.90)	0.76 (0.09 - 6.48)	0.38 (0.05 - 2.98)	1.02 (0.21 - 4.91)
Week 3	1.07 (0.61 - 1.86)	1.51 (0.70 - 3.28)	0.57 (0.17 - 1.92)	0.74 (0.09 - 6.33)	1.14 (0.31 - 4.14)	0.53 (0.06 - 4.29)
Week 4	0.52 (0.24 - 1.15)	1.13 (0.46 - 2.79)	0.21 (0.03 - 1.58)	1.65 (0.32 - 8.56)	No events	0.57 (0.07 - 4.67)
Rest of AD episode	0.53 (0.36 - 0.78)	0.65 (0.37 - 1.14)	0.50 (0.25 - 0.98)	1.02 (0.33 - 3.11)	0.30 (0.11 - 0.80)	0.38 (0.11 - 1.33)
Wash-out 1 (+ 1 month)	0.42 (0.25 - 0.69)	0.54 (0.27 - 1.10)	0.43 (0.19 - 0.98)	No events	0.40 (0.13 - 1.30)	0.66 (0.21 - 2.09)
Wash-out 2 (+ 2 months)	0.17 (0.09 - 0.35)	0.18 (0.06 - 0.53)	0.22 (0.07 - 0.63)	No events	0.19 (0.04 - 0.89)	0.28 (0.06 - 1.33)
Wash-out 3 (+ 3 months)	0.15 (0.09 - 0.25)	0.25 (0.13 - 0.46)	0.16 (0.09 - 0.29)	0.27 (0.10 - 0.77)	0.24 (0.10 - 0.57)	0.41 (0.16 - 1.03)

[†]Number of events in young people taking antidepressant

eTable 2: Incidence Rate Ratios (IRRs) for self-harm for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 654 events† IRR (95% CI)	fluoxetine 347 events† IRR (95% CI)	citalopram 151 events† IRR (95% CI)	sertraline 71 events† IRR (95% CI)	paroxetine 55 events† IRR (95% CI)	TCAs 118 events IRR (95% CI)
Unexposed	0.12 (0.09 - 0.17)	0.12 (0.08 - 0.17)	0.19 (0.10 - 0.35)	0.14 (0.06 - 0.31)	0.06 (0.03 - 0.15)	0.15 (0.08 - 0.30)
Pre-exposure 1 (- 4 months)	0.37 (0.22 - 0.61)	0.37 (0.19 - 0.72)	0.43 (0.15 - 1.22)	0.62 (0.20 - 1.91)	0.47 (0.12 - 1.82)	0.29 (0.08 - 1.03)
Pre-exposure 2 (- 3 months)	0.59 (0.38 - 0.90)	0.68 (0.40 - 1.15)	0.58 (0.23 - 1.48)	0.75 (0.26 - 2.18)	0.32 (0.07 - 1.52)	0.09 (0.01 - 0.71)
Pre-exposure 3 (-2 months)	0.65 (0.43 - 0.98)	0.57 (0.33 - 0.99)	0.67 (0.27 - 1.63)	0.88 (0.32 - 2.42)	0.77 (0.24 - 2.44)	0.46 (0.16 - 1.33)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	11.48 (7.93 - 16.62)	8.63 (5.13 - 14.52)	18.21 (8.69 - 38.16)	12.58 (4.72 - 33.53)	3.73 (0.77 - 17.97)	3.47 (0.97 - 12.45)
Week 1	0.69 (0.35 - 1.35)	0.60 (0.24 - 1.54)	1.41 (0.45 - 4.38)	0.57 (0.07 - 4.60)	No events	0.77 (0.17 - 3.50)
Week 2	0.96 (0.55 - 1.68)	0.63 (0.26 - 1.49)	1.53 (0.54 - 4.35)	0.91 (0.19 - 4.31)	1.02 (0.21 - 4.90)	0.33 (0.04 - 2.57)
Week 3	1.33 (0.82 - 2.19)	0.96 (0.46 - 1.99)	2.17 (0.85 - 5.51)	0.45 (0.06 - 3.63)	2.02 (0.59 - 6.93)	1.01 (0.28 - 3.61)
Week 4	1.23 (0.73 - 2.07)	0.88 (0.41 - 1.90)	1.36 (0.44 - 4.23)	0.97 (0.21 - 4.57)	1.63 (0.42 - 6.35)	0.37 (0.05 - 2.90)
Rest of AD episode	0.64 (0.45 - 0.90)	0.60 (0.38 - 0.93)	1.13 (0.56 - 2.27)	0.31 (0.12 - 0.81)	0.39 (0.12 - 1.24)	0.48 (0.18 - 1.25)
Wash-out 1 (+ 1 month)	0.28 (0.16 - 0.48)	0.39 (0.21 - 0.72)	0.47 (0.18 - 1.26)	0.13 (0.02 - 1.01)	0.27 (0.05 - 1.29)	0.09 (0.01 - 0.69)
Wash-out 2 (+ 2 months)	0.32 (0.19 - 0.55)	0.28 (0.14 - 0.56)	0.41 (0.14 - 1.17)	0.26 (0.05 - 1.21)	0.14 (0.02 - 1.13)	0.43 (0.15 - 1.25)
Wash-out 3 (+ 3 months)	0.19 (0.12 - 0.31)	0.18 (0.11 - 0.30)	0.41 (0.21 - 0.81)	0.35 (0.16 - 0.79)	0.23 (0.09 - 0.60)	0.35 (0.17 - 0.73)

†Number of events in young people taking antidepressant

eTable 3: Incidence Rate Ratios (IRRs) for suicidal ideation for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 458 events† IRR (95% CI)	fluoxetine 240 events† IRR (95% CI)	citalopram 108 events† IRR (95% CI)	sertraline 36 events† IRR (95% CI)	paroxetine 41 events† IRR (95% CI)	TCAs 81 events IRR (95% CI)
Unexposed	0.07 (0.05 - 0.10)	0.06 (0.04 - 0.09)	0.14 (0.06 - 0.32)	0.13 (0.05 - 0.34)	0.06 (0.02 - 0.18)	0.09 (0.05 - 0.18)
Pre-exposure 1 (- 4 months)	0.29 (0.15 - 0.54)	0.17 (0.07 - 0.44)	0.75 (0.24 - 2.35)	0.36 (0.07 - 1.79)	0.21 (0.02 - 1.77)	0.15 (0.03 - 0.68)
Pre-exposure 2 (- 3 months)	0.45 (0.26 - 0.77)	0.31 (0.15 - 0.65)	0.87 (0.29 - 2.59)	0.55 (0.14 - 2.20)	0.40 (0.08 - 2.09)	0.30 (0.10 - 0.90)
Pre-exposure 3 (-2 months)	0.76 (0.48 - 1.19)	0.56 (0.31 - 1.02)	1.27 (0.47 - 3.41)	1.07 (0.35 - 3.33)	0.98 (0.28 - 3.38)	0.21 (0.06 - 0.74)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	33.41 (23.56 - 47.39)	25.34 (16.34 - 39.31)	71.07 (31.77 - 159.01)	8.43 (2.37 - 29.93)	20.90 (6.83 - 64.01)	14.00 (6.81 - 28.75)
Week 1	0.38 (0.13 - 1.05)	0.43 (0.13 - 1.40)	0.61 (0.07 - 4.95)	No events	No events	0.59 (0.13 - 2.59)
Week 2	0.57 (0.26 - 1.27)	0.25 (0.06 - 1.03)	0.52 (0.06 - 4.23)	1.20 (0.24 - 5.96)	No events	0.25 (0.03 - 1.91)
Week 3	1.56 (0.91 - 2.68)	1.24 (0.60 - 2.53)	4.17 (1.51 - 11.51)	No events	1.49 (0.29 - 7.70)	1.03 (0.34 - 3.13)
Week 4	0.98 (0.51 - 1.91)	1.23 (0.58 - 2.59)	0.55 (0.07 - 4.50)	0.62 (0.07 - 5.16)	No events	0.84 (0.24 - 2.94)
Rest of AD episode	0.72 (0.49 - 1.08)	0.49 (0.29 - 0.82)	1.40 (0.58 - 3.37)	0.47 (0.16 - 1.35)	1.30 (0.43 - 3.90)	0.52 (0.20 - 1.35)
Wash-out 1 (+ 1 month)	0.40 (0.23 - 0.70)	0.38 (0.20 - 0.75)	0.27 (0.06 - 1.31)	0.33 (0.07 - 1.66)	0.20 (0.02 - 1.72)	0.43 (0.16 - 1.11)
Wash-out 2 (+ 2 months)	0.12 (0.06 - 0.29)	0.13 (0.04 - 0.36)	0.55 (0.16 - 1.88)	0.34 (0.07 - 1.73)	0.57 (0.14 - 2.42)	0.27 (0.09 - 0.83)
Wash-out 3 (+ 3 months)	0.20 (0.12 - 0.33)	0.15 (0.08 - 2.73)	0.50 (0.21 - 1.18)	0.07 (0.02 - 0.21)	0.08 (0.02 - 0.27)	0.13 (0.06 - 0.27)

†Number of events in young people taking antidepressant

Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis

Linda PMM Wijlaars¹, doctoral student,
Irwin Nazareth¹, professor of Primary Care and Population Science,
Heather J Whitaker², lecturer in statistics,
Stephen JW Evans³, professor of pharmacoepidemiology,
Irene Petersen¹, senior lecturer in epidemiology and medical statistics

1. Department of Primary Care and Population Health
University College London Medical School
Royal Free Campus
Rowland Hill Street
London
NW3 2PF
2. Department of Mathematics and Statistics
The Faculty of Mathematics, Computing and Technology
The Open University
Walton Hall
Milton Keynes
Buckinghamshire
MK7 6AA
3. Department of Medical Statistics
London School of Hygiene and Tropical Medicine
Keppel Street
London
WC1E 7HT

Correspondence to: Linda PMM Wijlaars (linda.wijlaars.10@ucl.ac.uk), contact address as above

Abstract

Objectives: We aimed to examine the temporal association between SSRI and tricyclic antidepressant (TCA) prescriptions and suicide ~~e-related events~~ ~~behaviour~~ in children and adolescents.

Design: Self-controlled case series.

Setting: Electronic health records were used from 479 general practices in The Health Improvement Network (THIN) UK primary care database from 1995 to 2009.

Participants: 81 young people aged 10-18 years with a record of completed suicide, 1,496 who attempted suicide, 1,178 with suicidal ideation and 2,361 with intentional self-harm.

Main outcome measures: Incidence Rate Ratios (IRRs) for completed and attempted suicide, suicidal ideation and intentional self-harm.

Results: For non-fatal suicide-related behaviour, IRRs were similar for the time the person was prescribed either SSRIs or TCAs: IRRs increased during pre-exposure, peaked on prescription day, were stable up to the fourth prescription-week, and decreased after prescriptions stopped. For both types of antidepressants, IRRs were lower or similar to pre-exposure levels during the period of prescription. For SSRIs, there was an increase in the IRR for completed suicide on the day of prescription (N=5; IRR=42.5, 95% CI: 4.5 to 403.4), and during the fourth week of SSRI prescription (N=2; IRR=11.3, 95% CI: 1.1 to 115.6).

Conclusions: We found that a very small number of young people were prescribed antidepressants and the absences of a sustained increase in rates of suicide-related events in this group. Overall, ~~†~~There were no systematic differences between the association of TCAs and SSRIs and the ~~with~~ incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm, and apart from the day of prescription, rates did not exceed pre-exposure levels. The pattern of ~~death from~~ IRR for suicide for SSRIs was similar to that found in non-fatal suicide-related ~~events~~ ~~behaviour~~. Our results warrant a re-evaluation of the

1
2
3 current prescribing of SSRIs in young people. We recommend the creation of a pragmatic
4
5 registry for active pharmacovigilance. ~~Although we did not find a sustained increase in rates~~
6
7 ~~of suicide related events, our results should be interpreted with caution as the number of~~
8
9 ~~young people on antidepressants was relatively low.~~
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article summary

Article focus

- There has been concern that selective serotonin reuptake inhibitors (SSRIs) might be associated with an increased risk of suicide ~~e-related events at thinking and behaviour~~ in young people.
- We assess the temporal association between the risk of completed suicide, attempted suicide, suicidal ideation, intentional self-harm and antidepressant prescribing, comparing SSRIs and tricyclic antidepressants (TCAs) in adolescents using a large UK primary care database.

Key messages

- There are no systematic differences between the association of TCAs and SSRIs with incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm
- ~~We recommend the creation of a pragmatic registry that will allow for active pharmacovigilance at low cost and with no additional burden on clinician, health service or patient time, and which will facilitate long term, anonymous, unobtrusive follow-up for major clinical outcomes.~~
- Up to the fourth week of prescription, the IRRs for attempted suicide, suicidal ideation and self-harm remained around the levels experienced during the pre-exposure period, suggesting continued on-going close monitoring in the first month is important.

Strengths and limitations of this study

- Only a limited number of young people had a prescription for an antidepressant in the year before their suicide-related event making it difficult to interpret the findings of this study, limiting interpretation of our analysis.
- The self-controlled case series method inherently controls for time-independent variables such as genetics, location and socio-economic status.
- Changes in depression severity are poorly recorded over time, which is a limitation.

Introduction

Between 1-6% of adolescents in the community suffer from major depressive disorder¹. In addition, suicide is the third leading cause of death in 15-19 year olds at 6.9 per 100,000 population, and fourth for 10-14 year olds at 0.9 per 100,000 population². This calls for safe and effective depression treatments in this age group. As tricyclic antidepressants (TCAs) ~~appear to~~ lack efficacy for depression treatment in this age group, and have a poor side effect profile³, selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed pharmacological treatment for children and adolescents⁴.

However, there has been concern that SSRIs might be associated with an increased risk of ~~suicidal behaviour e-related events~~ in paediatric patients. Results from clinical trials led the Expert Working Group of the Committee on Safety of Medicines (CSM) to advise against initiation of treatment with selective serotonin inhibitors (SSRIs) for childhood depression in the UK in December 2003⁵. Fluoxetine, the only drug which is licensed to treat depression in young people in the UK, was exempted from this advice following review that concluded there was a favourable balance of benefits and risk⁶. The US Food and Drug Administration (FDA) issued similar advice in 2004⁷.

There is inconsistent evidence of an increased rate of ~~suicide-related events suicidal behaviour~~ and intentional self-harm associated with SSRIs⁸. Data from randomized controlled trials in adolescents and young adults report an increased risk of ~~suicide-related eventssuicidal behaviour~~⁹. Part of this difference appears to depend on the methodology used. If ~~suicide-related events suicidal behaviour was were~~ ascertained using the method of “adverse events” there was a small but significant increase in suicidal ideation. However, if

1
2
3 the studies used rating scales to assess suicide-related events~~suicidal behaviours~~, most studies
4 showed an improvement in suicide-related events~~suicidal behaviours~~.

5
6
7 The results from these trials should be interpreted with caution as they were not primarily
8 designed to measure suicide-related events~~suicidal behaviour~~ and it would be unethical to do
9 so using placebo as a control^{10;11}. Moreover, none of these trials on SSRIs recruited from a
10 general population setting and completed suicides have not occurred in any studies⁹.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Observational studies in young people have found mixed results: some indicate that SSRIs
protect from suicide-related events~~suicidal behaviour~~¹²; others find no effect^{13;14}; or an
increase in risk of suicide-related events~~suicidal behaviour~~^{15;16}. These studies, however, have
methodological limitations including small numbers, high attrition rates and, most
importantly, confounding by severity.

~~Given the risk of death in overdose, the lack of efficacy in children, and the side effects
associated with them, a prescriber would be less likely to prescribe tricyclic antidepressants
(TCA) in preference to SSRIs for a person at risk of suicidal behaviour¹⁷.~~

We have previously shown rates for SSRI prescriptions in children and adolescents increased
between 2005-2009⁴. Neither TCAs nor SSRIs are considered appropriate first line treatment
by the National Institute for Clinical Excellence (NICE) for depression in children and
adolescents. Given the risk of death in overdose, the lack of efficacy in children, and the side
effects associated with them, a prescriber would be less likely to prescribe TCAs in
preference to SSRIs for a person at risk of suicide-related events¹⁷.

Only when children and adolescents are not responding to psychological treatment should
treatment with SSRIs be considered⁶. It is therefore important to reassess the risks of existing
clinical data to inform future practice. We aimed to assess the temporal association between

1
2
3 the risk of completed suicide, attempted suicide, suicidal thoughts, intentional self-harm and
4
5 antidepressant prescribing in adolescents, comparing SSRIs and TCAs and correcting for age
6
7 and sex, using a large UK primary care database.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Methods

Data Source

We used data from The Health Improvement Network (THIN) primary care database, including information from UK primary care data prospectively recorded between 1 January 1995 and 31 December 2009. THIN includes anonymised general practice records on more than 9 million patients from 479 practices in the United Kingdom and is one of the largest primary care databases available internationally. It is broadly representative of the UK general practice population in terms of demographics and consultation behaviour¹⁸. Data on diagnoses, interventions, symptoms, and referrals to secondary care are electronically recorded as Read Codes, a hierarchical coding system used in UK primary care¹⁹. All prescriptions are also electronically recorded. Clinical diagnoses recorded using Read codes have recently been shown to be accurate compared with other reliable sources²⁰.

Study population

This study included a cohort of young people and adolescents, aged 10-18 years who had a recorded suicidal or self-harm event. Patients were included if they were registered with a practice for at least six months between January 1995 and December 2009. Patients were followed up from the latest of the date they registered at the GP, 1 January 1995, or their 10th birthday, until (1) 31 December 2009, (2) their 19th birthday, (3) the date of death, or (4) the date they left the practice.

Measurements

Outcome - We identified completed suicides using relevant Read codes that were confirmed by a date of death within two weeks of the suicide event date. We searched a cause of death if available. The list of codes was an updated version of a published suicide code

1
2
3 list²¹. To make sure we did not miss any suicides, we extracted medical records on all young
4
5 people who died between the ages of 10 and 18 and examined the free text if there was no
6
7 clear cause of death (e.g. childhood cancer or a traffic accident) for possible suicides. We
8
9 excluded cases where there was doubt whether the death was due to suicide (i.e. 12 deaths
10
11 which received an open verdict by the coroner). Of these potential suicides, 1 patient had
12
13 records of TCA prescriptions, while 4 had records of SSRI prescriptions in the last year.
14
15 Suicide attempt, suicidal ideation and self-harm were identified using a Read code list that
16
17 was developed in line with published methods and reviewed by a general practitioner (IN)²².
18
19
20
21
22

23 *Exposure* - We used British National Formulary (BNF) codes representing antidepressants²³.
24
25 We classified antidepressants as TCAs, SSRIs and other antidepressants according to the
26
27 BNF. We excluded TCAs that were prescribed for nocturnal enuresis or neuropathic pain.
28
29 Comparing prescription data in THIN to dispensing data from NHS Prescription Services
30
31 showed that the mean practice redemption rate (the percentage of recorded prescriptions
32
33 which were dispensed) was as high as 96.7% for antidepressants²⁴.
34
35
36
37
38

39 We then identified the separate episodes of antidepressant prescription for each individual.
40
41 To constitute a new episode of antidepressant prescriptions, there had to be a preceding gap
42
43 of at least 3 months of no prescriptions. We choose 3 months as a prescription supply of
44
45 antidepressants is typically 1 month or less, and therefore a gap of at least 3 months between
46
47 prescriptions would likely represent a new episode of antidepressant prescriptions (although
48
49 not necessarily a new episode of depression). If a person switched from one drug to another
50
51 within 3 months, this did not constitute a new episode.
52
53
54
55
56
57
58
59
60

1
2
3 *Covariates* – We extracted information on sex, age and social deprivation score (Townsend
4 quintiles). Patients who were prescribed TCAs for nocturnal enuresis (as confirmed by Read
5 codes) were excluded. Finally, we considered consultation behaviour as a confounder.
6
7 Patients who consult infrequently with their GP, e.g. only when their prescription has run out,
8 might not have correctly timed records of all of their events. To correct for this we conducted
9 a sensitivity analysis where we only included patients who consulted at least once a week
10 during the month after their first antidepressant prescription.
11
12
13
14
15
16
17
18
19

20 **Statistical analysis**

21
22 *The Self-Controlled Case Series (SCCS) method* - We calculated incidence rate ratios (IRRs –
23 calculated by dividing the incidence rate in the exposed period by the incidence rate in the
24 control period) for completed suicide and ~~suicide-related events~~ ~~suicidal behaviour~~ using the
25 self-controlled case series (SCCS) method²⁵. The SCCS method was developed to investigate
26 associations between acute outcomes and transient exposures, using only data on cases. Since
27 each case served as his/her own control, the case-series method inherently accounts for
28 confounding factors that do not change over the observation period (such as variables related
29 to genetics, socio-economic status and gender). Using a Poisson model, IRRs can be
30 calculated for any number of pre-defined risk periods associated with the exposure, using the
31 time outside of these risk periods (the time when a subject is unexposed) as reference. A
32 major advantage of the SCCS is that it can have high efficiency relative to the retrospective
33 cohort method from which it is derived. As ~~suicide-related events~~ ~~suicidal behaviour are is~~
34 rare, even in depressed persons, the SCCS method is particularly suited for assessing its
35 association with antidepressants as it requires a much smaller number of persons to be
36 included. Moreover, in using a self-controlled design we circumvent the problem of selecting
37 appropriate controls that cohort or case-control designs encounter. In the case of ~~suicide-~~
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 | related events~~suicidal behaviour~~ and antidepressants this has proven crucial as patients who
4
5 are diagnosed as depressed but don't receive antidepressants might differ from patients who
6
7 are receiving antidepressants in severity of depression, a major confounder in the studied
8
9 association.

10
11 The SCCS method is limited in that it only works for non-recurrent events when the event
12
13 risk is small over the observation period, which is the case for completed suicide. Also, it
14
15 requires variability in the age at the time of event: if all events were to happen at exactly the
16
17 same age (which is not the case in our study), then the method would fail. Finally, the method
18
19 only produces estimates of relative incidence, rather than absolute incidence.
20
21

22
23
24
25 *Suicide attempts, suicidal ideation and self-harm* – For the analyses on suicide attempts,
26
27 suicidal ideation and self-harm we used an adapted version of the standard SCCS method,
28
29 allowing for repeated exposures and events and correcting by 1-year age groups^{25;26}. By
30
31 including a pre-exposure period, we corrected our estimates for event-dependent exposure. If
32
33 the probability of exposure to antidepressants is changed from baseline after an event, it
34
35 follows that the probability of the occurrence of an event is also changed in the immediate
36
37 pre-exposure period. Including a pre-exposure period removes this time from the baseline and
38
39 corrects the estimates accordingly.
40
41

42
43 Subjects who went on to commit suicide were excluded from these analyses. Using the SCCS
44
45 method, the incidence rate ratio for the three outcomes was estimated during 14 different risk
46
47 periods (Figure 1): baseline (or unexposed to antidepressants); four 1-month pre-exposure
48
49 periods, the last of which is the reference; the day of prescription; four 1-week early exposure
50
51 periods; a period of variable length to cover the remainder of the period of exposure to the
52
53 antidepressant for that episode; and three 1-month periods of washout after the end of the
54
55 antidepressant episode. We included the separate 1-week periods at the start of prescription as
56
57
58
59
60

1
2
3 it is known that antidepressants (especially SSRIs) take this amount of time to have an
4 effect²⁷. We also compared the effects of individual antidepressants on the IRR of the three
5
6
7 suicide-related event ~~suicidal behaviour~~ outcomes.
8
9

10
11 *Suicide* - We used an adapted method (SCCS for censored post-event exposures) to assess the
12 effects of antidepressants on childhood suicide as the original approach cannot deal with
13 deaths²⁸. This method takes account of the early cessation of the observation period due to
14 deaths and accordingly corrects the IRR estimates. We corrected for age by creating four age
15 groups: 10-12, 13-14, 15-16 and 17-18 year olds. We estimated IRRs for the same risk
16 periods as for the other outcomes, without the four pre-exposure risk periods and used
17 baseline (time unexposed to antidepressants) as reference.
18
19

20
21 All analyses were conducted with the use of Stata software, version 12.1 (Stata Corp, College
22 Station, Texas). The scheme for THIN to obtain and provide anonymous patient data to
23 researchers was approved by the National Health Service South-East Multicenter Research
24 Ethics Committee (MREC) in 2002 and scientific approval for this study was obtained from
25 CMD Medical Research's Scientific Review Committee in May 2011.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

There was a total follow-up time of 4,190,410 person-years of 10-18-year olds in THIN. In total, 81 young people were identified with a record of a completed suicide, 1,496 young people with a record of attempted suicide, 1,178 young people with a record of suicidal ideation, and 2,361 with a record of intentional self-harm. Of young people with completed suicides, 30% were female, compared to 60%, 73% and 74% of young people with a record of attempted suicide, suicidal ideation, or self-harm, respectively (Table 1). There was no significant difference in age of first event between the different outcomes. The data were complete for all variables except Townsend scores, which were missing for 92 (2%) persons.

Due to small numbers, we were not able to analyse antidepressants other than SSRIs or TCAs.

Attempted suicide, suicidal ideation and self-harm

For attempted suicide, suicidal ideation and self-harm, there were similar patterns between young people that were prescribed SSRIs and TCAs (Table 2 & Figures 2A, B & C): there was an upwards trend in the IRR during pre-exposure; a peak on the day of prescription; a stable or slightly increased rate ratio during the first weeks of prescription; and during the washout period levels decreased again. The increase on prescription day was highest for young people with a record of suicidal ideation (SSRIs: IRR=33.4, 95%CI: 23.6 to 47.4; TCAs: IRR=14.0, 95%CI: 6.8 to 28.8). There were no significant differences between IRRs for any of the behaviour-event types for any risk periods. Patterns were similar between individual SSRIs (fluoxetine, citalopram, sertraline and paroxetine, results in appendix).

The IRR for each type of behaviour-event has a strong relation with age. When compared to 15-16 year olds, 17-18 year olds are twice as likely to attempt suicide (IRR=1.90, 95%CI: 1.6

1
2
3 to 2.3 and IRR=2.1, 95%CI: 1.7 to 2.5 for SSRIs and TCAs, respectively) but those between
4
5 10-12 years old are less likely to attempt suicide (IRR=0.3, 95%CI: 0.2 to 0.4 and IRR=0.2,
6
7 95%CI: 0.1 to 0.2 for SSRIs and TCAs, respectively). Patterns were similar for the other
8
9 outcomes.

10
11
12
13
14 There were no statistically significant differences between boys and girls for either SSRIs or
15
16 TCAs (results not shown). A small group of 25 patients had a prescription for an
17
18 antidepressant and a primary diagnosis other than depression (obsessive compulsive disorder
19
20 (OCD) or anxiety). Due to the small size of this group we did not perform a subgroup
21
22 analysis. Finally, restricting the analyses to regular consulters (those who consulted at least
23
24 five times during the first four weeks of prescription) did not alter effect estimates. Of the
25
26 young people with a record of attempted suicide or intentional self-harm, 33% were regular
27
28 consulters, compared to 49% of young people with a record of suicidal ideation.
29
30
31
32
33

34 **Suicide**

35
36 Using an expected suicide rate of 3.28 (95%CI: 3.12 to 3.43) per 100,000 person-years in the
37
38 UK population of 10-18-year olds ²⁹, we would expect 137 (95%CI: 131 to 144) completed
39
40 suicides in our study population. However, 41% of suicides registered by the Office of
41
42 National Statistics (ONS) were of undetermined intent, leaving 59% or 81 (95%CI: 77 to 85)
43
44 expected suicides that received a verdict by a coroner. This estimate corresponds to the
45
46 number of 81 completed suicides we identified between 1995 and 2009 within the THIN
47
48 database. Of the 81 young people with a completed suicide, 21 (26%) had a prior record of a
49
50 depression diagnosis or depression symptoms. Nineteen young people (23%) were taking
51
52 antidepressants in the year before their suicide, and 11 (14%) were still taking them at the
53
54 time of, or shortly before their suicide. There was also a high proportion of young people
55
56
57
58
59
60

1
2
3 with (a history of) behaviour disorders 16 (20%), history of self-harm 8 (10%), a psychiatric
4 referral 19 (23%), a hyperkinetic disorder 5 (6%) or eating disorder 3 (4%).
5
6
7

8
9
10 There were no completed suicides within the risk periods for antidepressants other than
11 SSRIs (Table 3). Eleven (14%) completed suicides were within the risk periods. Similar to
12 the results from the data on [suicide-related events](#)~~suicidal behaviour~~, the IRR was highest on
13 the day of prescription (IRR=42.5, 95%CI: 4.5 to 403.4). There were no events in the first
14 two weeks of the SSRI episode, but there was an increased rate ratio in week three (IRR=8.0,
15 95%CI: 0.8 to 76.7, based on a single case) and a statistically significant increase in week 4
16 (IRR=11.3, 95%CI: 1.1 to 115.6, though based on two cases). After the fourth week of the
17 SSRI episode, the IRR decreased and returned to baseline levels during wash-out. There were
18 no significant differences between age groups.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Overall, there are no systematic differences between TCAs and SSRIs in incidence risk ratios for attempted suicide, suicidal ideation or intentional self-harm, and apart from an increase common to both TCAs and SSRIs on the day of prescription, rates were not statistically significantly different from pre-exposure levels. The pattern of incidence risk ratios for completed suicides for the 11 people prescribed SSRIs was similar to that found in attempted suicide, suicidal ideation and self-harm. However, concerns regarding antidepressants need to be weighed against the risk of untreated depression.

Pre-exposure IRRs for attempted suicide, suicidal ideation and self-harm appeared to be marginally higher, though not statistically significant, for SSRIs compared to TCAs. This could be because young people who are deemed to be more at risk of suicide-related events ~~suicidal behaviour~~ could preferentially be prescribed SSRIs over TCAs, given TCAs' toxicity in overdose¹⁷.

The high IRRs on the day of antidepressant prescription for all three non-fatal outcomes could be an artefact of GP recording behaviour. Rather than the antidepressant causing the suicide-related events ~~self-harming behaviour~~, the self-harming behaviour ~~event~~ is an indication for the GP to prescribe the drug and to record depression in the electronic records on the same day. As antidepressants should only be prescribed by child & adolescent psychiatrists (2005 NICE guidelines⁶), this artefact could also arise when GPs continue a prescription started in secondary care and record the initial indication when first prescribing this drug.

Up to the fourth week of prescription, the IRRs for attempted suicide, suicidal ideation and self-harm remained around the levels experienced during the pre-exposure period.

Considering that suicide-related events are ~~suicidal behaviour is~~ common in young depressed

1
2
3 people, some suicidal and self-harm events would be expected irrespective of whether SSRIs
4
5 are prescribed or not³⁰. The rate of suicide-related events suicidal behaviour decreased when
6
7 the prescriptions were stopped. Given the nature of the data, it is difficult to know whether
8
9 the SSRIs were causing suicide-related events suicidal behaviour and these behaviours-events
10
11 improved when the SSRIs were discontinued, or if the SSRIs were discontinued when the
12
13 child's-young person's depression (and as a consequence the risk of suicide-related
14
15 eventssuicidal behaviour) improved.

16
17 There are three possible explanations for the slightly increased IRRs during the first month of
18
19 prescription. One is that SSRIs fail to relieve the risk of suicide-related eventssuicidal
20
21 behaviour associated with depression because of a lag in antidepressant effect, an incomplete
22
23 response, or a treatment-resistant depression. It is known that SSRIs take a couple of weeks
24
25 to reach their full antidepressant effects and hence reduce the risk of suicide-related
26
27 eventssuicidal behaviour²⁷.

28
29 A second possibility is that the SSRIs generate a novel set of suicidal emotions or behaviours.
30
31 Early improvements in clinical depression can lead to a person acting on existing suicidal
32
33 feelings. This activation syndrome has been described for both TCAs and SSRIs, and is
34
35 widely recognized by psychiatrists, as well as the FDA^{31;32}. While patients might be
36
37 demotivated and demoralized at the height of their depression, when they start treatment they
38
39 become more active during the first weeks of taking the drug. During this time the
40
41 antidepressant effect of the medication will not have reached its full effect resulting in
42
43 persistent depression but simultaneous increased activity. This could lead to a greater risk of
44
45 suicide-related events suicidal behaviour until the full effects of antidepressants are realized
46
47 few weeks later³¹.

48
49 Several studies and systematic reviews have shown an age effect in the risk of
50
51 suicide-related events suicidal behaviour with the use of SSRIs. In adults and the elderly the
52
53
54
55
56
57
58
59
60

1
2
3 risk is neutral or SSRIs show a protective effect, while in adolescents and young adults there
4
5 appears to be an increased risk of ~~suicide-related events~~~~suicidal behaviour~~^{9;15;33}.

6
7 Although we did not find a statistically significant sustained increase in ~~suicide-~~
8 ~~related events~~ ~~suicidal behaviour~~ with either SSRIs or TCAs, negative outcomes did not
9
10 appear to be decreased either – although our study was not designed to assess this. This is in
11
12 line with Cochrane reviews on both drug groups: the review on tricyclic antidepressants
13
14 concludes that these drugs are not useful in treating depression in pre-pubertal children, and
15
16 that there is only marginal evidence to support the use of TCAs in adolescents, although the
17
18 magnitude of the effect is likely to be moderate at best³⁴. Similarly, it is unclear what the
19
20 effect is of SSRIs on suicide completion. Although evidence from clinical trials implies an
21
22 increased risk of suicide-related outcomes (but not completed suicide), the evidence for this
23
24 association is of low quality³⁵.

31 32 **Comparison to other studies**

33
34 Our results build on the findings of Schneeweis et al.¹³. They found no statistically significant
35
36 differences in relative risk for attempted and completed suicide between different types of
37
38 antidepressants (fluoxetine, citalopram, fluvoxamine, paroxetine, sertraline and TCAs) when
39
40 examining 266 attempted and 3 completed suicides. Moreover, an ecological study found no
41
42 change in rates of completed suicides or hospital admissions for self-harm following the
43
44 CSM advice³⁶, suggesting there is no, or only a weak, relationship with antidepressant
45
46 prescriptions. Our findings are also similar to those of Simon et al.³⁷ who used computerised
47
48 health plan records and report the highest rates for attempted suicide in the month before
49
50 prescription, rather than after start of the prescription. Finally, a meta-analysis³⁸ found that, of
51
52 27 paediatric RCTs on antidepressants prescribed for major depressive disorder (MDD),
53
54 ~~obsessive compulsive disorder (OCD)~~ and non-OCD anxiety disorders, the risk of suicidal
55
56
57
58
59
60

1
2
3 ideation or attempt among patients on placebo was greater in trials assessing MDD. Although
4
5 this difference in baseline risk for suicide-related events~~suicidal thinking and behaviour~~ was
6
7 not statistically significant, it could indicate part of the association between antidepressants
8
9 and suicide-related events~~suicidal thinking and behaviour~~ can be explained by the underlying
10
11 disease, rather than the drug. Importantly, the authors concluded that relative to placebo, the
12
13 benefits (though only modest in MDD) outweigh the risks from suicidal ideation/suicide
14
15 attempts. Due to small numbers of patients with primary diagnoses of OCD and anxiety
16
17 disorders, we could not repeat the meta-analysis' sub-group comparison.
18
19
20
21
22

23 **Main strength and limitations**

24
25 The main strength of this study is its sample size that enables examination of outcomes
26
27 separately by completed and attempted suicide, suicidal ideation and self-harm, and by
28
29 individual antidepressants. However, even in using a database as large as THIN, we could
30
31 identify only a small number of completed suicides, leading to limited power in that analysis.
32
33 Similarly, power was limited for analysing individual antidepressants, which are presented in
34
35 the appendix. Nevertheless, the use of the SCCS method allows us to control for time-
36
37 independent confounders, making our estimations more robust.
38
39

40
41 A limitation to our study is that the THIN database only provides data on antidepressant
42
43 prescriptions. We do not know whether prescriptions were dispensed, or whether patients
44
45 adhered to prescription. However, though it is known that adherence levels are around 50%
46
47 for young people taking SSRIs, and even lower for TCAs³⁹, our data does represent a real-life
48
49 situation. Moreover, by assessing episodes of antidepressant prescription, we take account of
50
51 multiple prescriptions per patient, which increases the likelihood of adherence as we expect
52
53 patients who are not taking their medication would not come back for a new prescription.
54
55
56
57
58
59
60

Moreover, it is known that suicide-related events are suicidal behaviour is often missed in clinical assessment⁴⁰. However, it is likely that the most severe forms (attempted suicides and severe suicidal ideation) are most likely to be recorded by clinicians. Also, in using a self-controlled design, we decrease the chance of misclassifying controls. There is some suggestion that antidepressants might specifically increase suicide-related events suicidal thinking and behaviour in patients who did not experience these behaviours events prior to starting antidepressant treatment. Due to variation in clinicians' assessment and recording of (the absence of) suicide-related events suicidal thinking and behaviour, we could not examine this hypothesis using this database. Furthermore, the relatively low number of young people who had a prescription for an antidepressant at the time of their suicide-related event, limits the interpretation of our results. However, Windfuhr et al. also found that mental health service contact is low in juveniles who committed suicide: only 14% contacted services in the year before they died²⁹. Finally, we were not able to account for changes in depression severity over time as this is poorly recorded.

Conclusion

Our study shows that there are similar incidence rate ratio patterns for attempted suicide, suicidal ideation and self-harm for SSRIs and TCAs. Also, the pattern for completed suicides associated with SSRI prescriptions is similar, though there are no records of completed suicides within our pre-defined risk periods for TCAs. Although the CSM's warning was a sensible cautionary recommendation at the time, it appears that the current line of evidence suggests a reverse causality: it is the underlying depression that leads to suicide-related events suicidal behaviour and the prescribing of antidepressants, although a causal effect of SSRIs, or no effect at all cannot be ruled out. Moreover, even if antidepressant drugs would temporarily increase the risk of suicide-related events suicidal behaviour in young persons,

1
2
3 the risk untreated depression poses is far greater. In conclusion, our results indicate that the
4
5 association of suicide-related events ~~suicidal behaviour~~ associated with antidepressants
6
7 occurs primarily around the day of prescription, suggesting depression severity and GP
8
9 recording behaviour as the culprit rather than antidepressants, and thus warrant a re-
10
11 evaluation of the current guidelines regarding the prescription of SSRIs in primary care.
12
13

14 15 16 **Recommendation**

17
18 Our results are not definitive, and due to the rare nature of the outcome and the intricacies of
19
20 the problem studied, it is difficult to think of a single study or study design that will be able to
21
22 provide a satisfying answer to the problem at hand. It is possible that the creation of a
23
24 pragmatic registry, similar to that proposed by van Staa and colleagues in their pragmatic
25
26 randomised trial⁴¹, will allow for active pharmacovigilance. Such a system would at low cost
27
28 and with no additional burden on clinician, health service or patient time, facilitate long term,
29
30 anonymous, unobtrusive follow-up for major clinical outcomes. As such, clinicians would be
31
32 prompted to monitor and record (the absence of) suicide-related events ~~suicidal behaviour~~
33
34 and ideation more regularly and closely, using similar outcome measurements as those used
35
36 in clinical trials, as well as (changes in) depression severity.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We would like to thank the general practitioners who contributed data to THIN.

Contributors All authors were responsible for study conception and design. LPW was responsible for data analysis. LPW authors drafted the manuscript. All authors participated in the interpretation of data, critical revision and final approval of the manuscript.

Funding statement: The work was supported by a PhD studentship from the National Institute of Health Research English National School for Primary Care Research. The funding organisation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; and preparation, review or approval of the manuscript.

Competing interests statement: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: LPMMW had financial support in the form of a studentship from the National Institute of Health Research English National School for Primary Care Research for the submitted work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data sharing: Examples of statistical code used for the self-controlled case series method (including the adapted method for dealing with censored data) are available from the [Open University website](#). Statistical code is available from the corresponding author.

References

- 1
2
3
4
5 (1) Kessler RC, Avenevoli S, Ries Merikangas K. Mood disorders in children and
6 adolescents: an epidemiologic perspective. *Biological Psychiatry* 2001; 49(12):1002-
7 1014.
- 8
9
10 (2) Heron M. Deaths: leading causes for 2007. *National vital statistics reports* 2011;
11 59(8):1-95.
- 12
13 (3) Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drug for depression in
14 children and adolescents. *Cochrane Database Syst Rev* 2002;(4).
- 15
16 (4) Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant
17 prescribing in children and adolescents: A cohort study in The Health Improvement
18 Network (THIN). *PLoS One* 2012.
- 19
20 (5) Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and
21 suicide in adults: meta-analysis of drug company data from placebo controlled,
22 randomised controlled trials submitted to the MHRA's safety review. *BMJ* 2005;
23 330(7488):385.
- 24
25 (6) National Institute for Health and Clinical Excellence. CG28 Depression in children
26 and young people: NICE guideline. 2005. London, National Institute for Health and
27 Clinical Excellence.
- 28
29 (7) FDA. Suicidality in Children and Adolescents Being Treated With Antidepressant
30 Medications. US Food and Drug Administration [2004 [cited 2011 June 29];
31 Available from: URL:
32 [http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsa
33 ndProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisorie
34 s/ucm161679.htm](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679.htm)
- 35
36 (8) Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E.
37 Selective serotonin reuptake inhibitors in childhood depression: systematic review of
38 published versus unpublished data. *The Lancet* 2004; 363(9418):1341-1345.
- 39
40 (9) Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with
41 antidepressant drugs. *Arch Gen Psychiatry* 2006; 63(3):332-339.
- 42
43 (10) Rothman KJ, Michels KB. The continuing unethical use of placebo controls. *N Engl J*
44 *Med* 1994; 331(6):394-398.
- 45
46 (11) Grosso A, Douglas I, MacAllister R, Petersen I, Smeeth L, Hingorani AD. Use of the
47 self-controlled case series method in drug safety assessment. *Expert Opin Drug Saf*
48 2011; 10(3):337-340.
- 49
50 (12) Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA et al. Early
51 evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and
52 suicide in children and adolescents. *Am J Psychiatry* 2007; 164(9):1356-1363.
- 53
54
55
56
57
58
59
60

- 1
2
3 (13) Schneeweiss S, Patrick AR, Solomon DH, Dormuth CR, Miller M, Mehta J et al.
4 Comparative safety of antidepressant agents for children and adolescents regarding
5 suicidal acts. *Pediatrics* 2010; 125(5):876-888.
6
- 7 (14) Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. *JAMA*
8 2004; 292(3):338-343.
9
- 10 (15) Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely
11 depressed children and adults - A case-control study. *Arch Gen Psychiatry* 2006;
12 63(8):865-872.
13
- 14 (16) Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal Thoughts and Behavior
15 With Antidepressant Treatment: Reanalysis of the Randomized Placebo-Controlled
16 Studies of Fluoxetine and Venlafaxine. *Arch Gen Psychiatry* 2012;archgenpsychiatry.
17
- 18 (17) Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following
19 prescription of SSRIs and other antidepressants: confounding by indication. *Br J Clin*
20 *Pharmacol* 2005; 60(5):519-525.
21
- 22 (18) Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a
23 quality-evaluated database of primary care data. *Inform Prim Care* 2004; 12(3):171-
24 177.
25
- 26 (19) Booth N. What are the Read Codes? *Health Libr Rev* 1994; 11(3):177-182.
27
- 28 (20) Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General
29 Practice Research Database: a systematic review. *Br J Gen Pract* 2010; 60(572):e128-
30 e136.
31
- 32 (21) Arana A, Wentworth CE, yuso-Mateos JL, Arellano FM. Suicide-related events in
33 patients treated with antiepileptic drugs. *N Engl J Med* 2010; 363(6):542-551.
34
- 35 (22) Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary
36 care databases. *Pharmacoepidemiology and drug safety* 2009; 18(8):704-707.
37
- 38 (23) British National Formulary. 60 ed. London: BMJ group; RPS Publishing; 2010.
39
- 40 (24) The NHS Information Centre PaPCS. Prescription compliance: a review of the
41 proportion of prescriptions dispensed. 7-9-2011.
42
- 43 (25) Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the
44 self-controlled case series method. *Stat Med* 2006; 25(10):1768-1797.
45
- 46 (26) Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case
47 series studies. *Stat Methods Med Res* 2009; 18(1):7-26.
48
- 49 (27) Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective
50 serotonin reuptake inhibitor antidepressant action: systematic review and meta-
51 analysis. *Arch Gen Psychiatry* 2006; 63(11):1217-1223.
52
- 53 (28) Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored,
54 perturbed, or curtailed post-event exposures. *Biostatistics* 2009; 10(1):3-16.
55
56
57
58
59
60

- 1
2
3 (29) Windfuhr K, While D, Hunt I, Turnbull P, Lowe R, Burns J et al. Suicide in juveniles
4 and adolescents in the United Kingdom. *J Child Psychol Psychiatry* 2008;
5 49(11):1155-1165.
6
7 (30) Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. *J*
8 *Child Psychol Psychiatry* 2006; 47(3-4):372-394.
9
10 (31) Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A et al.
11 Antidepressant-induced jitteriness/anxiety syndrome: systematic review. *Br J*
12 *Psychiatry* 2009; 194(6):483-490.
13
14 (32) Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL.
15 Suicidality as a possible side effect of antidepressant treatment. *J Clin Psychiatry*
16 2004; 65(6):742-749.
17
18 (33) Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of
19 suicide: a systematic review of observational studies. *CMAJ* 2009; 180(3):291-297.
20
21 (34) Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drug for depression in
22 children and adolescents. *Cochrane Database Syst Rev* 2010;(4).
23
24 (35) Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation
25 antidepressants for depressive disorders in children and adolescents. *Cochrane*
26 *Database of Systematic Reviews* 2012.
27
28 (36) Wheeler BW, Gunnell D, Metcalfe C, Stephens P, Martin RM. The population impact
29 on incidence of suicide and non-fatal self harm of regulatory action against the use of
30 selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological
31 study. *BMJ* 2008; 336(7643):542-545.
32
33 (37) Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant
34 treatment. *Am J Psychiatry* 2006; 163(1):41-47.
35
36 (38) Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA et al. Clinical
37 response and risk for reported suicidal ideation and suicide attempts in pediatric
38 antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA* 2007;
39 297(15):1683-1696.
40
41 (39) Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP et al.
42 Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic
43 antidepressants: comparison of drug adherence. *Cochrane Database Syst Rev*
44 2000;(4):CD002791.
45
46 (40) Fitzpatrick C, Abayomi NN, Kehoe A, Devlin N, Glackin S, Power L et al. Do we
47 miss depressive disorders and suicidal behaviours in clinical practice? *Clinical Child*
48 *Psychology and Psychiatry* 2012; 17(3):449-458.
49
50 (41) van Staa T, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A et al.
51 Pragmatic randomised trials using routine electronic health records: putting them to
52 the test. *BMJ* 2012; 344.
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1: Risk periods included in self-controlled case series analysis for attempted suicide, suicidal ideation and self-harm and suicide. 1 = baseline; 2-5 = 1-month pre-exposure periods; 6 = prescription day; 7-10 = four 1-week exposure periods; 11 = remainder of antidepressant exposure; 12-14= three 1-month washout periods

Figure 2A, B, C: IRR for A) attempted suicide, B) suicidal ideation and C) self-harm for tricyclic antidepressants (TCAs) and selective serotonin inhibitors (SSRIs). The month before a prescription was issued (pre-exposure 4) was used as the reference.

TABLES

Table 1: Demographics by category of suicidal or self-harming behaviour

	Completed suicide 81	Attempted suicide 1496	Suicidal ideation 1178	Self-harm 2361	General population 952892
Girls (%)	24 (29.6)	1089 (72.8)	708 (60.1)	1752 (74.2)	461610 (48.4)
# taking ADs (%)	19 (23.1)	527 (36.6)	578 (52.8)	128 (5.7)	27632 (2.9)
# depressed (%)	21 (25.9)	728 (48.7)	819 (69.5)	173 (7.3)	41101 (4.3)
# Townsend score (%)					
1 (most affluent)	20 (24.7)	266 (17.8)	193 (16.4)	442 (18.7)	227178 (23.8)
2	5 (6.2)	240 (16.0)	202 (17.2)	405 (17.2)	198686 (20.9)
3	13 (16.1)	286 (19.1)	236 (20.0)	452 (19.1)	184934 (19.4)
4	25 (30.9)	364 (24.3)	283 (24.0)	571 (24.2)	169792 (17.8)
5 (most deprived)	16 (19.8)	316 (21.1)	241 (20.5)	446 (18.9)	120116 (12.6)
Median age in years at (first) event (5%-95% percentiles)	16.8 (12.0-18.8)	16.5 (12.9 - 18.7)	16.7 (12.0 - 18.7)	15.9 (12.6 - 18.7)	-
Median time in study in years (5%-95% percentiles)	3.5 (0.2 - 8.4)	5.5 (1.4 - 9.0)	5.9 (1.5 - 9.0)	5.9 (1.5 - 9.0)	-

Table 2: Incidence Rate Ratios (IRRs) for different types of suicidal or self-harming behaviour by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs			TCAs		
	Suicide attempt 423 events† IRR (95% CI)	Suicidal ideation 458 events† IRR (95% CI)	Self-harm 654 events† IRR (95% CI)	Suicide attempt 79 events† IRR (95% CI)	Suicidal ideation 81 events† IRR (95% CI)	Self-harm 118 events† IRR (95% CI)
Unexposed	0.09 (0.07 - 0.13)	0.07 (0.05 - 0.10)	0.12 (0.09 - 0.17)	0.20 (0.09 - 0.46)	0.09 (0.05 - 0.18)	0.15 (0.08 - 0.30)
Pre-exposure 1 (- 4 months)	0.19 (0.10 - 0.38)	0.29 (0.15 - 0.54)	0.37 (0.22 - 0.61)	0.61 (0.18 - 2.10)	0.15 (0.03 - 0.68)	0.29 (0.08 - 1.03)
Pre-exposure 2 (- 3 months)	0.31 (0.17 - 0.53)	0.45 (0.26 - 0.77)	0.59 (0.38 - 0.90)	0.29 (0.06 - 1.39)	0.30 (0.10 - 0.90)	0.09 (0.01 - 0.71)
Pre-exposure 3 (-2 months)	0.62 (0.40 - 0.96)	0.76 (0.48 - 1.19)	0.65 (0.43 - 0.98)	0.14 (0.02 - 1.16)	0.21 (0.06 - 0.74)	0.46 (0.16 - 1.33)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	4.17 (2.44 - 7.12)	33.41 (23.56 - 47.39)	11.48 (7.93 - 16.62)	8.82 (2.79 - 27.82)	14.00 (6.81 - 28.75)	3.47 (0.97 - 12.45)
Week 1	0.79 (0.40 - 1.55)	0.38 (0.13 - 1.05)	0.69 (0.35 - 1.35)	1.18 (0.24 - 5.68)	0.59 (0.13 - 2.59)	0.77 (0.17 - 3.50)
Week 2	0.74 (0.39 - 1.42)	0.57 (0.26 - 1.27)	0.96 (0.55 - 1.68)	1.02 (0.21 - 4.91)	0.25 (0.03 - 1.91)	0.33 (0.04 - 2.57)
Week 3	1.07 (0.61 - 1.86)	1.56 (0.91 - 2.68)	1.33 (0.82 - 2.19)	0.53 (0.06 - 4.29)	1.03 (0.34 - 3.13)	1.01 (0.28 - 3.61)
Week 4	0.52 (0.24 - 1.15)	0.98 (0.51 - 1.91)	1.23 (0.73 - 2.07)	0.57 (0.07 - 4.67)	0.84 (0.24 - 2.94)	0.37 (0.05 - 2.90)
Rest of AD episode	0.53 (0.36 - 0.78)	0.72 (0.49 - 1.08)	0.64 (0.45 - 0.90)	0.38 (0.11 - 1.33)	0.52 (0.20 - 1.35)	0.48 (0.18 - 1.25)
Wash-out 1 (+ 1 month)	0.42 (0.25 - 0.69)	0.40 (0.23 - 0.70)	0.28 (0.16 - 0.48)	0.66 (0.21 - 2.09)	0.43 (0.16 - 1.11)	0.09 (0.01 - 0.69)
Wash-out 2 (+ 2 months)	0.17 (0.09 - 0.35)	0.12 (0.06 - 0.29)	0.32 (0.19 - 0.55)	0.28 (0.06 - 1.33)	0.27 (0.09 - 0.83)	0.43 (0.15 - 1.25)
Wash-out 3 (+ 3 months)	0.15 (0.09 - 0.25)	0.20 (0.12 - 0.33)	0.19 (0.12 - 0.31)	0.41 (0.16 - 1.03)	0.13 (0.06 - 0.27)	0.35 (0.17 - 0.73)

† Number of events in young people taking antidepressants



Table 3: Incidence Rate Ratios (IRRs) for completed suicide by risk period and age



Risk period	Censoring model IRR (95% CI)	# deaths†
Prescription day	42.52 (4.48 – 403.43)	5
Week 1		
Week 2	No events	0
Week 3	8.00 (0.84 – 76.71)	1
Week 4	11.25 (1.09 – 115.58)	2
Rest of AD episode	5.42 (0.57 – 51.94)	1
Wash-out 1	2.27 (0.24 – 21.76)	1
Wash-out2	2.08 (0.22 – 19.69)	1
Age Groups		# total deaths‡
10-12	0.61 (0.21 – 1.77)	8
13-14	1.14 (0.45 – 2.90)	15
15-16	Reference	21
17-18	0.41 (0.12 – 1.39)	37

† Number of suicides during risk periods (only includes youths who were taking antidepressants at the time of suicide, or those who had recently stopped)

‡ Number of suicides by age category

FIGURES





Supplementary Tables

eTable 1: Incidence Rate Ratios (IRRs) for attempted suicide for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 423 events [†] IRR (95% CI)	fluoxetine 198 events [†] IRR (95% CI)	citalopram 111 events [†] IRR (95% CI)	sertraline 39 events [†] IRR (95% CI)	paroxetine 61 events [†] IRR (95% CI)	TCAs 79 events IRR (95% CI)
Unexposed	0.09 (0.07 - 0.13)	0.10 (0.06 - 0.16)	0.08 (0.05 - 0.14)	0.11 (0.04 - 0.31)	0.07 (0.03 - 0.14)	0.20 (0.09 - 0.46)
Pre-exposure 1 (- 4 months)	0.19 (0.10 - 0.38)	0.18 (0.06 - 0.53)	0.26 (0.10 - 0.67)	0.20 (0.02 - 1.71)	0.21 (0.05 - 0.97)	0.61 (0.18 - 2.10)
Pre-exposure 2 (- 3 months)	0.31 (0.17 - 0.53)	0.41 (0.19 - 0.89)	0.20 (0.07 - 0.59)	0.20 (0.02 - 1.70)	0.21 (0.05 - 0.96)	0.29 (0.06 - 1.39)
Pre-exposure 3 (-2 months)	0.62 (0.40 - 0.96)	0.72 (0.38 - 1.37)	0.35 (0.15 - 0.83)	1.19 (0.36 - 3.88)	0.41 (0.13 - 1.30)	0.14 (0.02 - 1.16)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	4.17 (2.44 - 7.12)	5.84 (2.76 - 12.34)	2.02 (0.60 - 6.79)	5.31 (1.03 - 27.37)	3.96 (1.09 - 14.39)	8.82 (2.79 - 27.82)
Week 1	0.79 (0.40 - 1.55)	0.98 (0.37 - 2.59)	0.45 (0.10 - 1.92)	2.64 (0.63 - 11.06)	0.44 (0.06 - 3.45)	1.18 (0.24 - 5.68)
Week 2	0.74 (0.39 - 1.42)	0.50 (0.15 - 1.68)	1.16 (0.47 - 2.90)	0.76 (0.09 - 6.48)	0.38 (0.05 - 2.98)	1.02 (0.21 - 4.91)
Week 3	1.07 (0.61 - 1.86)	1.51 (0.70 - 3.28)	0.57 (0.17 - 1.92)	0.74 (0.09 - 6.33)	1.14 (0.31 - 4.14)	0.53 (0.06 - 4.29)
Week 4	0.52 (0.24 - 1.15)	1.13 (0.46 - 2.79)	0.21 (0.03 - 1.58)	1.65 (0.32 - 8.56)	No events	0.57 (0.07 - 4.67)
Rest of AD episode	0.53 (0.36 - 0.78)	0.65 (0.37 - 1.14)	0.50 (0.25 - 0.98)	1.02 (0.33 - 3.11)	0.30 (0.11 - 0.80)	0.38 (0.11 - 1.33)
Wash-out 1 (+ 1 month)	0.42 (0.25 - 0.69)	0.54 (0.27 - 1.10)	0.43 (0.19 - 0.98)	No events	0.40 (0.13 - 1.30)	0.66 (0.21 - 2.09)
Wash-out 2 (+ 2 months)	0.17 (0.09 - 0.35)	0.18 (0.06 - 0.53)	0.22 (0.07 - 0.63)	No events	0.19 (0.04 - 0.89)	0.28 (0.06 - 1.33)
Wash-out 3 (+ 3 months)	0.15 (0.09 - 0.25)	0.25 (0.13 - 0.46)	0.16 (0.09 - 0.29)	0.27 (0.10 - 0.77)	0.24 (0.10 - 0.57)	0.41 (0.16 - 1.03)

[†]Number of events in young people taking antidepressant

eTable 2: Incidence Rate Ratios (IRRs) for self-harm for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 654 events† IRR (95% CI)	fluoxetine 347 events† IRR (95% CI)	citalopram 151 events† IRR (95% CI)	sertraline 71 events† IRR (95% CI)	paroxetine 55 events† IRR (95% CI)	TCAs 118 events IRR (95% CI)
Unexposed	0.12 (0.09 - 0.17)	0.12 (0.08 - 0.17)	0.19 (0.10 - 0.35)	0.14 (0.06 - 0.31)	0.06 (0.03 - 0.15)	0.15 (0.08 - 0.30)
Pre-exposure 1 (- 4 months)	0.37 (0.22 - 0.61)	0.37 (0.19 - 0.72)	0.43 (0.15 - 1.22)	0.62 (0.20 - 1.91)	0.47 (0.12 - 1.82)	0.29 (0.08 - 1.03)
Pre-exposure 2 (- 3 months)	0.59 (0.38 - 0.90)	0.68 (0.40 - 1.15)	0.58 (0.23 - 1.48)	0.75 (0.26 - 2.18)	0.32 (0.07 - 1.52)	0.09 (0.01 - 0.71)
Pre-exposure 3 (-2 months)	0.65 (0.43 - 0.98)	0.57 (0.33 - 0.99)	0.67 (0.27 - 1.63)	0.88 (0.32 - 2.42)	0.77 (0.24 - 2.44)	0.46 (0.16 - 1.33)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	11.48 (7.93 - 16.62)	8.63 (5.13 - 14.52)	18.21 (8.69 - 38.16)	12.58 (4.72 - 33.53)	3.73 (0.77 - 17.97)	3.47 (0.97 - 12.45)
Week 1	0.69 (0.35 - 1.35)	0.60 (0.24 - 1.54)	1.41 (0.45 - 4.38)	0.57 (0.07 - 4.60)	No events	0.77 (0.17 - 3.50)
Week 2	0.96 (0.55 - 1.68)	0.63 (0.26 - 1.49)	1.53 (0.54 - 4.35)	0.91 (0.19 - 4.31)	1.02 (0.21 - 4.90)	0.33 (0.04 - 2.57)
Week 3	1.33 (0.82 - 2.19)	0.96 (0.46 - 1.99)	2.17 (0.85 - 5.51)	0.45 (0.06 - 3.63)	2.02 (0.59 - 6.93)	1.01 (0.28 - 3.61)
Week 4	1.23 (0.73 - 2.07)	0.88 (0.41 - 1.90)	1.36 (0.44 - 4.23)	0.97 (0.21 - 4.57)	1.63 (0.42 - 6.35)	0.37 (0.05 - 2.90)
Rest of AD episode	0.64 (0.45 - 0.90)	0.60 (0.38 - 0.93)	1.13 (0.56 - 2.27)	0.31 (0.12 - 0.81)	0.39 (0.12 - 1.24)	0.48 (0.18 - 1.25)
Wash-out 1 (+ 1 month)	0.28 (0.16 - 0.48)	0.39 (0.21 - 0.72)	0.47 (0.18 - 1.26)	0.13 (0.02 - 1.01)	0.27 (0.05 - 1.29)	0.09 (0.01 - 0.69)
Wash-out 2 (+ 2 months)	0.32 (0.19 - 0.55)	0.28 (0.14 - 0.56)	0.41 (0.14 - 1.17)	0.26 (0.05 - 1.21)	0.14 (0.02 - 1.13)	0.43 (0.15 - 1.25)
Wash-out 3 (+ 3 months)	0.19 (0.12 - 0.31)	0.18 (0.11 - 0.30)	0.41 (0.21 - 0.81)	0.35 (0.16 - 0.79)	0.23 (0.09 - 0.60)	0.35 (0.17 - 0.73)

†Number of events in young people taking antidepressant

eTable 3: Incidence Rate Ratios (IRRs) for suicidal ideation for different antidepressants by risk period and antidepressant type: selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)

Risk period	SSRIs 458 events† IRR (95% CI)	fluoxetine 240 events† IRR (95% CI)	citalopram 108 events† IRR (95% CI)	sertraline 36 events† IRR (95% CI)	paroxetine 41 events† IRR (95% CI)	TCAs 81 events IRR (95% CI)
Unexposed	0.07 (0.05 - 0.10)	0.06 (0.04 - 0.09)	0.14 (0.06 - 0.32)	0.13 (0.05 - 0.34)	0.06 (0.02 - 0.18)	0.09 (0.05 - 0.18)
Pre-exposure 1 (- 4 months)	0.29 (0.15 - 0.54)	0.17 (0.07 - 0.44)	0.75 (0.24 - 2.35)	0.36 (0.07 - 1.79)	0.21 (0.02 - 1.77)	0.15 (0.03 - 0.68)
Pre-exposure 2 (- 3 months)	0.45 (0.26 - 0.77)	0.31 (0.15 - 0.65)	0.87 (0.29 - 2.59)	0.55 (0.14 - 2.20)	0.40 (0.08 - 2.09)	0.30 (0.10 - 0.90)
Pre-exposure 3 (-2 months)	0.76 (0.48 - 1.19)	0.56 (0.31 - 1.02)	1.27 (0.47 - 3.41)	1.07 (0.35 - 3.33)	0.98 (0.28 - 3.38)	0.21 (0.06 - 0.74)
Pre-exposure 4 (- 1 month)	Reference	Reference	Reference	Reference	Reference	Reference
Prescription day	33.41 (23.56 - 47.39)	25.34 (16.34 - 39.31)	71.07 (31.77 - 159.01)	8.43 (2.37 - 29.93)	20.90 (6.83 - 64.01)	14.00 (6.81 - 28.75)
Week 1	0.38 (0.13 - 1.05)	0.43 (0.13 - 1.40)	0.61 (0.07 - 4.95)	No events	No events	0.59 (0.13 - 2.59)
Week 2	0.57 (0.26 - 1.27)	0.25 (0.06 - 1.03)	0.52 (0.06 - 4.23)	1.20 (0.24 - 5.96)	No events	0.25 (0.03 - 1.91)
Week 3	1.56 (0.91 - 2.68)	1.24 (0.60 - 2.53)	4.17 (1.51 - 11.51)	No events	1.49 (0.29 - 7.70)	1.03 (0.34 - 3.13)
Week 4	0.98 (0.51 - 1.91)	1.23 (0.58 - 2.59)	0.55 (0.07 - 4.50)	0.62 (0.07 - 5.16)	No events	0.84 (0.24 - 2.94)
Rest of AD episode	0.72 (0.49 - 1.08)	0.49 (0.29 - 0.82)	1.40 (0.58 - 3.37)	0.47 (0.16 - 1.35)	1.30 (0.43 - 3.90)	0.52 (0.20 - 1.35)
Wash-out 1 (+ 1 month)	0.40 (0.23 - 0.70)	0.38 (0.20 - 0.75)	0.27 (0.06 - 1.31)	0.33 (0.07 - 1.66)	0.20 (0.02 - 1.72)	0.43 (0.16 - 1.11)
Wash-out 2 (+ 2 months)	0.12 (0.06 - 0.29)	0.13 (0.04 - 0.36)	0.55 (0.16 - 1.88)	0.34 (0.07 - 1.73)	0.57 (0.14 - 2.42)	0.27 (0.09 - 0.83)
Wash-out 3 (+ 3 months)	0.20 (0.12 - 0.33)	0.15 (0.08 - 2.73)	0.50 (0.21 - 1.18)	0.07 (0.02 - 0.21)	0.08 (0.02 - 0.27)	0.13 (0.06 - 0.27)

†Number of events in young people taking antidepressant

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5-9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	n/a
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	7-9
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-9
		(b) Describe any methods used to examine subgroups and interactions	7-9
		(c) Explain how missing data were addressed	10
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	10-11

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	10
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-12
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.